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3 SUMMARY 
As part of the adaptive immune system cytotoxic, effector memory CD8+ T cells patrol through the 
body and screen cells with their T cell receptor for peptide-major histocompatibility (MHC) class I 
complexes. Upon encounter of foreign or mutated self-peptides displayed on MHC class I molecules 
they rapidly expand and trigger elimination of the target cell. Tumors can evade the immune 
surveillance by reducing immunogenicity including down-regulation of MHC class I molecule 
expression. Antibody-mediated delivery of recombinant peptide-MHC class I complexes to tumor 
cells can overcome this and induce potent tumor cell lysis after recruitment and activation of 
specific, cytotoxic CD8+ T cells. Schmittnaegel et al. successfully produced fully recombinant fusion 
proteins comprising a full length human IgG antibody and a MHC class I complex carrying an 
immunodominant epitope of the human Cytomegalovirus (CMV) and confirmed potent tumor cell 
killing capacity with pre-existing CMV-specific CD8+ T cells from human donor-derived lymphocytes 
in vitro [1, 2]. Due to the polymorphism of MHC complexes the in vivo efficacy can only be tested in 
syngeneic, immunocompetent mouse models using surrogate molecules characterized in this study. 
Fully recombinant surrogate fusion proteins containing a full length murine IgG antibody directed 
against the murine fibroblast activation protein (FAP) and a murine MHC class I complex (H-2Kb) 
carrying an immunodominant epitope of either the murine Cytomegalovirus (MCMV m38: 
“SSPPMFRV”) or ovalbumin (OVA257-264: “SIINFEKL”) were designed. For generation of MCMV m38- 
or OVA257-264-specific CD8
+ T cells in immunocompetent mice different vaccination methods were 
tested. In cytotoxicity assays with splenocytes from vaccinated mice the surrogate molecules 
mediated IFN-γ-activation of CD8+ T cells and eradication of tumor cells in vitro. Experimental lung 
metastasis in vivo studies with FAP-transfected B16 melanoma cells were performed to assess 
tumor burden after pMHCI-IgG treatment by counting of visible metastasis and real time-PCR. In a 
preventive setting pMHCI-IgG fusions mediated complete elimination of tumor cells in the 
circulation before settlement in the lung. In a therapeutic setting pMHCI-IgG molecules engaged     
T cells in a peptide-specific mode and induced delayed metastasis growth. A solid subcutaneous 
tumor model with FAP-transfected MC38 colorectal cancer cells represented a greater hurdle for 
pMHCI-IgG proteins. In this case no tumor growth inhibition under pMHCI-IgG treatment could be 
achieved. Basic prerequisites, like penetration of effector molecules and effector cells into the 
tumor and binding of pMHCI-IgG fusions to their target on the tumor cell surface, were 
accomplished as confirmed by immunohistochemisty and ultramicroscopy. Lack of tumor growth 
        Summary 18 
 
inhibition was more likely due to inactivation of cytotoxic CD8+ T cells by PD-1 / PD-L1 (programmed 
cell death protein 1 / Programmed cell death ligand 1) interactions with tumor cells and 
suppressive influences on the basis of regulatory T cells (Treg cells) as revealed by flow cytometry 
analysis of tumors. To remove those inhibitory influences on T cells, blockage of the PD-1 / PD-L1 
axis in combination with Treg depletion could be applied. The study also compared the anti-tumor 
efficacy mediated by pMHCI-IgG molecules and CD3-based T cell recruiters. The T cell bispecific 
(TCB) antibody and the pMHCI-IgG molecule showed comparable outcomes in both the 
experimental lung metastasis and the solid subcutaneous tumor model. 
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4 ZUSAMMENFASSUNG 
Zielgerichtete Eliminierung von Tumorzellen in vivo durch Rekrutierung von Vakzin-induzierten 
CD8+ T-Zellen mit Hilfe von bispezifischen Peptid-MHC Klasse I-IgG-Antikörper Fusionen 
Als Teil des adaptiven Immunsystems patrouillieren zytotoxische CD8+ T-Gedächtniszellen durch 
den Körper und überprüfen peptidbeladene MHCI-Komplexe (engl. major histocompatibility class I 
complex) anderer Zellen mit ihrem T-Zell-Rezeptor. Erkennen sie ein fremdes oder ein mutiertes 
Eigenantigen auf einem MHCI-Komplex expandieren sie clonal und eliminieren die Zielzelle. Tumore 
können der Überwachung durch das Immunsystem entgehen, indem sie ihre Immunogenität 
reduzieren, was unter anderem durch verringerte Expression von MHCI-Molekülen erreicht wird. 
Durch Antikörper-vermittelte Beladung von Tumorzellen mit rekombinanten Peptid-MHCI-
Komplexen kann dies umgangen und eine effiziente Lyse der Tumorzellen durch Rekrutierung und 
Aktivierung von spezifischen, zytotoxischen CD8+ T-Zellen ausgelöst werden. Schmittnaegel et al. 
konnten erfolgreich komplett rekombinante Fusionsproteine herstellen, die aus einem ganzen 
humanen IgG Antikörper und einem MHCI-Komplex bestehen, der mit einem immundominanten 
Epitop des humanen Zytomegalievirus (engl. Cytomegalovirus: CMV) beladen ist. In in vitro 
Zytotoxizitätsexperimenten mit CMV-spezifischen CD8+ T-Zellen von Lymphozyten, die aus 
Spenderblut isoliert wurden, konnten die Fusionsmoleküle eine potente Lyse der Tumorzellen 
induzieren [1, 2]. Aufgrund des Polymorphismus von MHC Komplexen kann die in vivo Wirksamkeit 
solcher Proteine nur in syngenen, immunkompetenten Mausmodellen mit Surrogatmolekülen, die 
in dieser Arbeit charakerisiert werden, getestet werden. Für diesen Zweck wurden komplett 
rekombinante Surrogat-Fusionsproteine hergestellt, die aus einem ganzen murinen IgG Antikörper, 
der gegen murines FAP (engl. fibroblast activation protein) gerichtet ist, und einem murinen MHCI-
Komplex (H-2Kb), der ein immundominantes Epitop des murinen Zytomegalievirus (MCMV m38: 
“SSPPMFRV”) oder von Ovalbumin (OVA257-264: “SIINFEKL”) trägt, aufgebaut sind. Zur Erzeugung von 
MCMV m38- oder OVA257-264-spezifischen CD8
+ T-Zellen in den Veruchstieren wurden verschiedene 
Vakzinierungsmethoden getestet. In in vitro Zytotoxizitätsexperimenten mit Splenozyten von 
immunisierten Mäusen konnten die Surrogatmoleküle eine IFN-γ-Aktivierung von CD8+ T-Zellen 
erzeugen und eine potente Eliminierung von Tumorzellen hervorrufen. In einem experimentellen 
Lungenmetastasenmodell mit FAP-transfizierten B16 Melanomzellen wurde die Metastasenlast 
nach Behandlung mit den Fusionsmolekülen durch RT-PCR und durch Zählen der sichtbaren 
Metastasen auf der Lungenoberfläche ermittelt. Bei präventiver Behandlung mit pMHCI-IgG 
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Molekülen konnten alle Tumorzellen im Blutkreislauf abgetötet werden, bevor sie sich in der Lunge 
ansiedeln konnten. Bei der therapeutischen Behandlung von Lungenmetastasen konnte gezeigt 
werden, dass die pMHCI-IgG Fusionen peptid-spezifisch CD8+ T-Zellen aktivieren und das 
Metastasenwachstum verzögern. Das solide subkutane Tumormodell mit FAP-transfizierten MC38 
Kolonkarzinomzellen stellte eine größere Hürde für die pMHCI-IgG Moleküle dar. Hier konnte bei 
der Behandlung mit pMHCI-IgG Fusionsproteinen keine Hemmung des Tumorwachstums erzielt 
werden. Durch Immunhistochemie und Ultramikroskopie konnte bestätigt werden, dass 
grundlegende Voraussetzungen, wie Penetration der Moleküle und der Effektorzellen in den Tumor 
und Bindung der pMHCI-IgG Moleküle an die Zielstruktur an der Oberfläche der Tumorzellen, 
gegeben waren. Mit durchflusszytometrischen Analysen der Tumore konnte schließlich gezeigt 
werden, dass die fehlende Wirksamkeit der Therapie sehr wahrscheinlich auf eine Inaktivierung der 
zytotoxischen CD8+ T-Zellen durch PD-1 / PD-L1 (engl. programmed cell death protein 1 / 
Programmed cell death ligand 1) Interaktionen mit den Tumorzellen und auf den suppressiven 
Einfluss von regulatorischen T-Zellen (Treg Zellen) zurückzuführen ist. Um diesen inhibitorischen 
Einflüssen entgegenzuwirken, könnte eine Blockade der PD-1 / PD-L1 Achse in Kombination mit der 
Depletion von regulatorischen T-Zellen angewendet werden. In dieser Arbeit wurde außerdem die 
anti-tumorale Wirksamkeit der pMHCI-IgG Fusionen mit der der CD3-basierten bispezifischen            
T-Zell-Antikörper (engl. T cell bispecific antibody: TCB) verglichen. Beide Moleküle zeigten 
vergleichbare Ergebnisse sowohl im experimentellen Lungenmetastasenmodell als auch im soliden 
subkutanen Tumormodell. 
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5 INTRODUCTION 
5.1 CHARACTERISTICS AND STRATEGIES OF CANCER DEVELOPMENT  
Tumors are not simply a homogeneous mass of cells derived from a mutated, abnormal cell, whose 
cell cycle got out of control. Instead, they consist of multiple cell types and an established tumor 
microenvironment influencing each other and can be compared with organs of high complexity. For 
development and maintenance of tumors several factors play a crucial role and there are a number 
of characteristics, which define a cell as cancerous (reviewed in [3]). Normal cells control 
production and secretion of growth-promoting signals in such a way that homeostasis of cell 
number and conservation of tissue architecture is sustained. By dysregulation of these control 
signals cancer cells are able to proliferate without control and affect other cell-biological processes 
such as cell survival and energy catabolism [3]. In addition tumor cells can produce growth factor 
ligands themselves and, by simultaneous expression of cognate receptors, trigger their own 
proliferation by autocrine proliferative stimulation [4]. Another way is to stimulate normal cells in 
the surrounding, which in the turn provide different growth factors for proliferation of cancer cells 
[5]. Alterations in number of growth factor ligand receptors expressed on the tumor cell surface 
and structure of receptor proteins enabling ligand-independent activation can make tumor cells 
hyperresponsive and contribute to enhanced proliferation of cancer cells [3]. Interruption of 
negative feedback loops, which normally attenuate proliferative signaling to avoid excessive 
proliferation, can also lead to increased proliferative signaling and is often used by tumor cells [6]. 
On the other hand tumor cells have to evade growth suppression by typical tumor suppressors, that 
decide whether a cell can proceed to another growth-and-division cycle or goes into apoptosis [7]. 
Another strategy of tumor cells is to escape programmed cell death by inactivation of transcription 
factors that induce apoptosis or senescence of cells in response to cellular stress like DNA 
(Desoxyribonucleic acid) damage, hypoxia or nutrient deprivation, which are circumstances often 
present in tumor cells [8, 9]. Necrotic cells frequently found in large tumor masses release 
proinflammatory signals into the surrounding. This recruits inflammatory cells of the immune 
system, which remove necrotic debris, but also promote tumor proliferation by enhancement of 
angiogenesis, cell proliferation and invasiveness [10]. Gaining capabilities like replicative 
immortality is also a strategy of cancer cells for enabling unlimited proliferation. The vast majority 
of tumor cells aberrantly upregulates telomerase, a DNA polymerase that fuses telomeres to the 
ends of chromosomes. Telomeres shorten over live time of a cell and in this way regulate cell aging 
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and viability by inhibiting cells from passing through a new growth-and-division cycle, if telomeres 
are too short. By overexpression of telomerase cancer cells prevent shortening of telomeres and 
consequently senescence and apoptosis of cells [11]. Genome instability and mutation in general is 
a characteristic that enables cancer cells to emerge, proliferate and adapt to new conditions. By 
enhanced sensitivity to mutagenic agents or impairment of the system that is responsible for 
genomic integrity, tumor cells increase the rates of mutations and in that way gain properties 
needed for tumorigenesis [12]. 
To continuously get access to oxygen and nutrients in a growing tumor new vessels are built in the 
process of angiogenesis. In contrast to normal tissue, where angiogenesis is turned on only 
transiently during e.g. wound healing, tumors activate an “angiogenic switch” that causes 
chronically activated angiogenesis promoting continuous sprouting and production of new, partially 
abnormal vessels [13, 14].  
One further characteristic of advanced cancer is invasive and metastatic growth. Beginning with 
local invasion of thin-walled venules and lymphatic channels of the host, tumor cells or aggregates 
of them traffic through the lymphatic and hematogenous system and arrest in capillary beds of 
distant tissues. After extravasation cancer cells form micrometastases applying similar mechanisms 
as those used for initial tissue invasion. Finally proliferation and vascularization of metastatic foci 
lead to colonization of macroscopic tumors, which in turn reinitiate the development of new 
metastases [15]. After dissemination from the primary tumor some micrometastases in distant 
tissues may also adopt a state of dormancy and resume activation long time or directly after 
removal of the primary tumor. This micrometastatic dormancy can be mediated by the primary 
tumor itself via release of systemic suppressor factors, nutrient starvation, anti-growth signals from 
normal tissue or suppression of the immune system [16-19]. When changes in the 
microenvironment occur, dormant micrometastases regain activity and start to proliferate. Certain 
tissue microenvironments also seem to provide more favorable preconditions for metastasis 
formation than others [20]. Also the site of the primary tumor is a hospitable site for colonization of 
circulating tumor cells, so that returning tumors at the site of primary tumors often originate from 
reseeding and not from classical tumor progression [21].  
Another characteristic of cancer cells is their reprogrammed energy metabolism first observed by 
Otto Warburg [3]. Even if oxygen is provided cancer cells pull the vast majority of energy from 
glycolysis. At first sight this seems surprising as glucose metabolism via glycolysis is much less 
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efficient compared to mitochondrial oxidative phosphorylation. However, glycolytic fueling is 
associated with activated oncogenes and mutant tumor suppressors [22] and provides particularly 
energy for generation of nucleosides and amino acids, which are needed for synthesis of new cells 
[23]. By upregulation of glucose transporters such as GLUT1 (glucose transporter 1) tumor cells 
compensate poor efficiency of their reprogrammed glucose metabolism [22]. In addition symbiosis 
of two cancer cell subpopulations, in which one population produces lactate via glycolysis, whereas 
the other one uses it as main energy source, can lead to maximal exploitation of resources [24]. 
The tumor has to be seen in context of its microenvironment. An assemblage of distinct cell types 
including cancer cells, cancer stem cells, immune inflammatory cells, cancer-associated fibroblasts, 
pericytes and endothelial cells constitutes most solid tumors [3]. Cancer cells build the basis of the 
disease and initiate tumors, while in the established tumor a great heterogeneity with cancer cells 
showing various degrees of differentiation, proliferation, vascularity, inflammation and invasiveness 
can be found. A special role is awarded to the cancer stem cells (CSCs), which represent a small 
population of cancer cells within the tumor that is suggested to display increased tumorigenic 
potential and possess a self-renewal capacity [15]. Endothelial cells and pericytes collaborate 
particularly in angiogenesis and maintenance of tumor vasculature, while cancer-associated 
fibroblasts contribute to cell proliferation and invasion and are involved in the formation of a 
desmoplastic stroma [3]. The tumor microenvironment consists of multiple stromal cell types and 
the extracellular matrix and interacts in complex processes with neoplastic and stromal cells within 
the tumor [3]. It enables primary, invasive and metastatic growth of tumor cells by reciprocal 
signaling interactions between cancer cells and stromal cells changing phenotype and histologic 
organization of supportive stroma during tumor progression [25]. Furthermore it is likely that also 
normal cells in the surrounding influence the character of the tumor microenvironment. 
Some tumors and their microenvironment are infiltrated by immune cells from both the innate and 
the adaptive immune system. While cells belonging mainly to the adaptive immune system like 
cytotoxic T cells, T-helper Type I cells and mature dendritic cells (DCs) induce tumor regression, 
inflammatory cells such as M2 macrophages, mast cells, neutrophils and T regulatory (Treg) cells, 
which are largely associated with the innate immune system, mediate tumor-promoting effects [10, 
26]. Inflammation in tumors can, as partly already mentioned before, contribute to tumor 
proliferation by secretion of growth, signaling, survival and proangiogenic factors and extracellular-
matrix modifying enzymes resulting in limitation of cell death, invasion, metastasis and 
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angiogenesis. In addition escape of tumor cells from the control of the immune system is achieved 
by various complex mechanisms and promotes tumor formation and progression [27]. In this sense 
the immune system plays a critical role in cancerogenesis and tumor progression and is therefore 
an interesting platform for the development of new and innovative approaches in cancer therapy. 
 
5.2 THE INNATE AND ADAPTIVE IMMUNE SYSTEM 
The immune system has the task to protect the organism from pathogens like viruses, bacteria or 
parasites. To fulfill this mission different specialized compartments of the immune system interact 
with each other (reviewed in [28]). In general the immune system can be divided into the innate 
and the adaptive arm, the latter consists of a humoral and cellular part. The innate immune system 
includes macrophages, dendritic cells (DCs), neutrophil granulocytes, and natural killer (NK) cells. 
Upon encounter of a pathogen cells of the innate immune system are rapidly and non-specifically 
activated and provide immediate effector functions. In this sense they represent the first line of 
defense in the organism. Recognition of pathogens is thereby mediated by pattern-recognition 
receptors (PRRs), which detect conserved pathogen-associated molecular patterns (PAMPs). Most 
PAMPs can be detected both by cell-extrinsic pathways and by cell-intrinsic pathways. There are 
several classes of PRRs such as Toll-like receptors (TLRs) recognizing common components of 
bacterial and fungal cell walls, like lipopolysaccharides (LPS), bacterial lipopeptides, flagellin and    
β-glucans, or nucleotide-binding domain, leucine-rich repeat–containing receptors (NLRs) and RIG-I-
like receptors (RLRs), sensing PAMPs in the cytosol like viral RNA (ribonucleic acid) or peptidoglycan 
fragments and flagellin. In addition cells of the innate immune system are capable to activate cells 
of the adaptive immune system. If professional antigen presenting cells (APCs) like DCs are 
activated via PRRs and take up pathogens, they process the foreign protein in the cytosol and 
display parts of it as immunogenic peptides on MHC (major histocompatibility) complexes, which 
activates T cells belonging to the adaptive part of the immune system. Besides presentation of 
pathogen-derived immunogenic peptides on MHC complexes, the expression of costimulatory 
molecules like CD80 and CD86 is enhanced and secretion of proinflammatory cytokines is induced. 
Pathogen-derived peptides are presented on MHC class II complexes for activation of CD4+ T cells. 
Via cross-presentation of peptides on MHC class I complexes also CD8+ T cells can be primed. This 
process takes place in secondary lymphoid organs like lymph nodes and spleen, to where DCs 
migrate after encounter of antigen. 
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The adaptive immune system includes B cells and T lymphocytes and is, in contrast to the innate 
immune system, able to specifically eliminate pathogens and build up an immunological memory. 
After priming of naïve CD8+ T cells in the secondary lymphoid organs via T cell receptor / peptide-
MHC class I complex interactions, CD8+ T cells differentiate into effector cells, which specifically 
recognize the combination of peptide and MHC class I complex that they were primed for. Once 
activated they expand and patrol through the body searching for infected cells bearing the 
appropriate peptide-MHC class I complex. By secretion of cytotoxic granules containing granzymes 
and perforin antigen-specific CD8+ T cells finally mediate killing of infected cells. In addition they 
can mediate apoptosis of target cells via Fas-ligand (FasL) / Fas-receptor (FasR) interaction and 
release pro-inflammatory cytokines like IFN-γ, IL-2 and TNF-α, which activate cells of the innate 
immune system such as macrophages. After clearance of the infection most effector cells die, but a 
small population of memory cells remains building an immunological memory that can very quickly 
mount an effective immune response upon reencounter of the same antigen. Sometimes CD8+ T 
cells are divided into two subtypes. In this case Tc1 cells represent the classical cytotoxic CD8+ T 
cells, which mediate pro-inflammatory immune responses via release of IFN-γ, and Tc2 cells 
contribute to anti-inflammatory immune reactions with IL-4 secretion [29]. 
B cells belong to the humoral part of the adaptive immune system as they produce antibodies 
against cell surface proteins and pathogens. They recognize specific antigens with their B cell 
receptor (BCR), which is a membrane bound antibody molecule. Once a B cell encounters its 
specific antigen it engulfs and digests it and displays parts of it on MHC class II complexes. This 
attracts and activates matching specific CD4+ T cells, which secrete cytokines that help the B cell to 
multiply and differentiate into an effector cell, called plasma cell. Plasma cells produce and release 
antibodies, which specifically bind to antigens and mark them as targets for phagocytosis and 
clearance by the complement cascade.  
As already partly mentioned above CD4+ T cells are most notably responsible for the help of other 
immune cells to perform their tasks. In this sense they are immune mediators, which have rare 
cytotoxic activity, but rather a managing function for the immune response. By interaction of their 
T cell receptor (TCR) with antigens bound to MHC class II complexes on the surface of APCs they get 
activated and secrete cytokines, which influence many cell types including B cells, macrophages, 
neutrophils, cytotoxic lymphocytes and also APCs, that originally activated the CD4+ T cell. In 
addition they activate other cells via direct cell-to-cell contact by CD40 / CD40 ligand-interactions. 
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There are two types of helper T cell responses. CD4+ Th1 cells release proinflammatory cytokines 
like IFN-γ, IL-2 and TNF-α and activate mainly macrophages and cytotoxic CD8+ T cells, which 
eliminate viruses and intracellular pathogens. CD4+ Th2 cells play a critical role in defense against 
extracellular pathogens and parasites and activate eosinophils and B cells via secretion of anti-
inflammatory cytokines such as IL-4, IL-5, IL-6, IL-10 and IL-13. Also CD4+ T cells can build an 
immunological memory after resolution of the infection. A special kind of CD4+ T cells are Treg cells, 
which constitutively express CD25 and are positive for FoxP3 (Forkhead box P3). They are 
immunosuppressive T cells, which reduce proinflammatory and enhance anti-inflammatory 
processes, i. a. via secretion of IL-10, and in this way control autoimmunity. Other subtypes of CD4+ 
T cells are Th9 cells, which contribute to defense against parasites and Th17 cells, which play a role 
in defense against extracellular bacteria and fungi. Both subtypes also seem to be able to activate 
CD8+ T cells via release of cytokines like IL-9 and IL-21. In addition cytotoxic CD4+ T cells (ThCTL) 
represent a small population, which can directly induce apoptosis of target cells via cytotoxic 
granules or FasL / FasR interaction [30]. 
Another subset of T cells are γδ T cells, which possess an alternative TCR that is able to recognize 
pathogens independent from MHC complexes. Those cells are involved in the epithelial and 
mucosal defense of the organism and have characteristics of both innate and adaptive immunity. 
T cells go through different stages of differentiation during their development. In the thymus, 
hematopoietic precursors from the bone-marrow, referred to as thymocytes, undergo a procedure 
of selection that eliminates autoreactive cells and conserves only functional cells, that bind strongly 
or medium to MHC complexes or peptide molecules with their TCR. This selection process 
establishes a functional and self-tolerant repertoire of naïve T cells, which patrol between 
secondary lymphoid organs searching for their specific antigen. Once the naïve T cell has 
recognized its antigen as processed peptide loaded on a MHC complex on the surface on an APC, it 
gets activated and clonal expansion and differentiation of the T cell is induced. For activation and 
priming of naïve T cells a costimulatory signal via interaction of CD28 on the T cell surface and CD80 
or CD86 on the APC is obligatory. The majority of activated T cells differentiate into effector               
T cells (TE), which provide immediate effector functions. Simultaneously a small population of 
activated T cells differentiates into long-lived memory T cells, which can be divided into central 
memory T cells (TCM), effector memory T cells (TEM) and effector memory RA T cells (TEMRA) [31, 32]. 
Memory T cells can get activated directly by TCR / peptide-MHC complex interactions without a 
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costimulatory signal via CD28. TEM cells patrol through peripheral tissues and organs and provide 
immediate protection upon reencounter with their antigen. However, their proliferation capacity is 
very poor. In contrast, TCM cells, which lack direct effector functions, reside in secondary lymphoid 
organs and mount effective recall responses following antigen stimulation by massive proliferation. 
TEMRA cells show same characteristics as TEM cells and provide immediate effector functions. After 
clearance of antigen they seem to develop from TEM cells and represent the real long-lived memory 
T cells [33]. 
 
5.3 CANCER IMMUNOEDITING AND IMMUNE ESCAPE MECHANISMS OF TUMORS 
In the last decades immuno-oncology research provided solid evidence that the immune system 
can recognize tumors and plays a critical role in cancer protection but also tumor progression. 
Those immune system - tumor interactions including host-protective and tumor shaping processes 
are called cancer immunoediting and composed of three sequential phases: Elimination, 
equilibrium and escape (reviewed in [34-37]). Unedited cancer cells express tumor-specific 
antigens, which emerge from mutations and are therefore exclusively expressed on those 
transformed cells [38]. In the elimination phase cells of the innate immune system recognize those 
specific ligands as foreign, destroy cancer cells and present tumor-derived peptides to T and B cells. 
This leads to production of tumor-specific, cytotoxic T cells and tumor-specific antibodies and finally 
the raised adaptive immune response eliminates remaining tumor cells and induces immune 
memory preventing tumor recurrence. However, if the immune system is not able to completely 
eradicate tumors cells, some cancer cells remain and the tumor enters a state of functional 
dormancy. In this phase called equilibrium repeated cycles of tumor regrowth and immune-
mediated destruction occur, whereby the tumor does not progress or metastasize [39]. However, 
during this process the adaptive immune system edits tumor cell immunogenicity resulting in a 
selection pressure, which promotes capacities of tumor cells that enable them to escape the 
control of the immune system. The escape phase represents the final phase of cancer 
immunoediting, where edited tumors of reduced immunogenicity begin to grow progressively, 
become clinically apparent and establish an immunosuppressive tumor microenvironment [27]. 
Escape from immunosurveillance can thereby occur through many different mechanisms.  
One mechanism of immune escape is loss of HLA (human leukocyte antigen) expression of tumors 
[40-43]. MHC molecules can thereby be lost during steps required for HLA synthesis, transport or 
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expression on the cell surface, by genetic mutation regarding heavy chain or beta-2-microglobulin 
(ß2M), or by alterations in glycosylation or regulatory factors (reviewed in [40]). Reduced 
presentation of tumor-associated peptides on MHC complexes leads to decreased immunogenicity 
of tumors. This altered phenotype of tumor cells can be found in many human cancers like 
melanomas, head-neck, colorectal, prostate and breast tumors [44]. 
Besides reduction of immunogenicity tumors evade control of the immune system by formation of 
an immunosuppressive tumor microenvironment. Tumors can release immunosuppressive factors 
like TGF-ß or IL-10 [45, 46], which leads among other things to reduced CD28-signaling and IL-2 
secretion of APCs and subsequently direct to decreased T cell activation. The recruitment of         
Treg cells into the tumor induces suppression of cytotoxic lymphocytes [47]. Normally those cells are 
involved in the control of autoimmunity [48], but in this case the tumor exploits them for inhibition 
of tumor-specific T cell immunity [49]. Myeloid–derived suppressor cells (MDSCs) inhibit both the 
innate and adaptive immunity and can also be attracted by the tumor [50, 51]. They are induced by 
proinflammatory mediators released by the tumor and suppress cytotoxic T lymphocytes (CTL) and 
NK cell activity. In addition cancer-associated fibroblasts can actively recruit monocytes via 
secretion of growth factors and drive their polarization to M2 macrophages. This leads to increased 
tumor cell motility resulting in dissemination from the primary tumor and metastatic spread [52].  
Furthermore cancer cells influence T cell activity via expression or down-regulation of surface 
molecules. For full activation of resting T cells a costimulatory signal by CD80/CD86 - CD28 
interaction between APC and T cell is needed. If TCR engagement occurs in the absence of the 
second signal, T cells cannot develop full effector function and become anergic. In this case T cells 
also fail to provide effector function after a second encounter with antigen, even if both signals are 
delivered then [53]. This mechanism ensures tolerance to self-antigens, which are not able to 
provide a costimulatory signal. As most tumor cells are poor APCs, levels of CD80 and CD86 
expression are low resulting in anergy of tumor-antigen-specific T cells due to absence of a 
costimulatory signal [54]. In addition CTLA-4 (cytotoxic T lymphocyte-associated protein 4), an 
inhibitory ligand on cytotoxic T cells, binds with higher affinity to CD80/CD86 than the engaging 
ligand CD28 [55, 56], which leads to further inhibition of tumor-antigen-specific T cells. Another 
strategy of tumor cells for immune escape is expression of the Programmed cell death ligand 1   
(PD-L1). In a physiological immune reaction PD-L1 suppresses T cell activity via binding to the 
programmed cell death protein 1 (PD-1) on the T cell surface and in this way controls the immune 
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response. By upregulation of PD-L1 on cancer cells tumor-antigen-specific T cells are inhibited by 
tumor cells [57-59]. Not only the cancer cells but also other cell types associated with the tumor 
can express immunosuppressive surface molecules. For example endothelial cells in the vasculature 
of tumors express FasL in response to VEGF-A (vascular endothelial growth factor A) and IL-10, 
which is a death mediator for effector CD8+ T cells [60].  
Taken together tumors exploit a plethora of mechanisms to evade the control of the immune 
system, which enables them to promote proliferation, invasion and metastatic spread without 
immunologic constraint. 
 
5.4 DIFFERENT APPROACHES IN CANCER IMMUNOTHERAPY 
In the last decades immunotherapy of cancer has become a clinically validated treatment for many 
types of tumors. In general the idea is to specifically target and eliminate tumor cells, while leaving 
healthy cells unaffected, which can be successfully accomplished by exploiting the host´s immune 
system. Several promising immunotherapeutic strategies are recently approved for the treatment 
of cancer or are in clinical trials (reviewed in [61-63]).  
For activation of the host´s innate and adaptive immune system cytokine therapies have been 
applied to enhance the patient´s anti-tumor immune response [64]. Administration of IL-2 was used 
for example for the treatment of renal cell carcinoma (RCC) and IFN-α for the treatment of 
melanoma [65, 66]. The major disadvantages of cytokine therapies are low response rates, high 
toxicity and no tumor specificity.  
A more specific approach constitute cancer vaccines, which specifically activate host T cells against 
tumor antigens (reviewed in [61, 67]). Prophylactic as well as therapeutic vaccines are in use. For 
defense against cancer-causing infectious diseases like hepatitis B virus and human papillomavirus 
preventive vaccines are approved [68, 69]. Therapeutic anti-cancer vaccines are developed to prime 
or boost tumor-specific immune responses. Thereby the identification of the most suitable antigens 
is a main hurdle. Cancer vaccines should contain a wide variety of tumor-associated antigens 
(TAAs), thus tumor lysates, purified tumor antigens, weakened whole tumor cells, tumor cells 
genetically engineered to secrete immunostimulatory cytokines as well as TAA-encoding 
recombinant DNA/RNA molecules formulated in various delivery systems were evaluated for 
treatment of established tumors [61, 67]. DC-based vaccines seem to be the most promising 
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approach in this field. For this vaccination DCs are isolated from the patient´s peripheral blood 
mononuclear cells (PBMCs), loaded with tumor antigens ex vivo, activated and then reinfused into 
the patient. Sipuleucel-T is such a cell-based vaccine and is approved for the treatment of 
metastatic prostate cancer. Unfortunately, this approach is often associated with complications in 
production and administration of antigen-loaded DCs and only moderate clinical effectiveness, 
resulting in low application rates [61]. 
Besides that, various monoclonal antibodies targeting surface proteins on cancer cells are in use 
(reviewed in [63, 70]). Rituximab, a chimeric human-mouse monoclonal antibody, targets CD20 on 
B cells and is approved for the treatment of Non-Hodgkin´s lymphoma. Herceptin (also known as 
Trastuzumab) is a recombinant humanized monoclonal antibody that is directed against HER2 
(Human epidermal growth factor receptor 2) which was found to be overexpressed in breast 
cancer. Applying monoclonal antibodies for cancer treatment, tumor cell killing is achieved by 
different mechanisms (reviewed in [70]). By binding of the antibody to its target dimerization, 
downstream signaling and kinase activation can be blocked resulting in reduced proliferation and, 
finally, apoptosis. This antagonist activity is applied for example by Herceptin. Also agonist activities 
leading directly to apoptosis of tumor cells can be mediated by antibodies. Immune-mediated 
tumor cell killing can be achieved with antibodies as well. With binding of the antibody to the 
tumor cell surface antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular 
phagocytosis (ADCP) or complement-dependent cellular cytotoxicity (CDC) can be mediated by the 
Fc (fragment crystallizable)-part of the antibody [71]. This mechanism is exploited applying 
Rituximab. Also conjugated antibodies are in use to deliver a payload, such as a drug, a toxin or a 
radioisotope, which induces tumor cell killing. 
As CD8+ T cells represent the natural defense against mutated cells in the immue system, many 
approaches are aimed at initiating, retargeting or enhancing the tumor-specific cytotoxic T cell 
response. 
Various immunomodulating antibodies, called checkpoint inhibitors, which enhance tumor-specific 
T cell activation via binding to costimulatory receptors or blockage of inhibitory receptors are 
approved or in clinical trials so far. Antibodies blocking the PD-1 receptor on T cells, like Nivolumab 
or Pembrolizumab, or its ligand PD-L1 on tumor cells, such as Atezolizumab, showed improvement 
of outcome in melanoma, RCC, non-small cell lung cancer (NSCLC), colorectal cancer, bladder 
cancer or Hodgkin´s lymphoma [72-79]. Ipilimumab or Tremelimumab, antibodies blocking CTLA-4, 
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which is an inhibitory receptor on T cells that down-regulates their activation, are approved for the 
treatment of melanoma [80]. Antagonistic antibodies targeting costimulatory receptors on T cells, 
like 4-1BB (tumor necrosis factor receptor superfamily member 9 (TNFRSF9)), are also in clinical 
trials to test anti-tumor efficacy [81, 82]. 
Adoptive cell therapy is another strategy to broaden tumor-specific T cell response in the host. For 
this approach lymphocytes are isolated from patients’ peripheral blood, tumor-draining lymph 
nodes or tumor tissue, expanded ex vivo, and reinfused back into the patient [83]. In clinical trials 
this therapy showed encouraging results in melanoma patients [84]. To enable this approach also 
for patients lacking MHC molecules on tumor cells, genetically engineered T cells, which express a 
chimeric antigen receptor (CAR) were developed. CARs consist of an IgG variable extracellular 
domain fused to a TCR constant domain. Thus the engineered T cells can directly bind to any 
potential tumor cell surface target antigen [85]. Administration of engineered T cells has been 
successful in B-cell malignancies, melanoma and synovial sarcoma and trials in other cancer types 
are ongoing [86]. 
Another approach is to redirect cytotoxic T cells independent from their specificity to eliminate 
tumor cells. This is accomplished by development of bispecific molecules consisting of a tumor 
targeting moiety and a second domain, which recruits T cells via CD3. At the moment two T cell 
engagers recruiting and activating T cells via CD3 are approved. Catumaxomab is a T cell bispecific 
(TCB) molecule that targets the epithelial cell adhesion molecule (EpCAM) for the treatment of 
malignant ascites [87, 88]. Blinatumomab targets CD19 and is approved for treatment of refractory 
B-cell acute lymphocytic leukemia [89, 90]. A novel IgG-based TCB, which targets carcinoembryonic 
antigen (CEA)-expressing solid tumors, is currently in phase I clinical trials [91]. However, 
redirection and activation of cytotoxic T cells via CD3 is often associated with toxicity due to severe 
cytokine releases and has to be handeled with care [92]. 
 
5.5 AIM OF THE STUDY 
One mechanism for immune escape of tumors is loss of HLA expression [40-43]. Antibody-mediated 
delivery of viral peptide-MHC class I complexes is an auspicious approach to enhance 
immunogenicity of tumor cells. Applying this strategy, a viral infection of target cells can be 
mimicked and thus tumor cell lysis is induced after recruitment of virus-specific, cytotoxic CD8+ T 
cells (Fig. 5.1). In contrast to classical T cell recruiters based on CD3 involvement (TCBs), the 
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engagement of T cells via MHC class I complexes activates only a peptide-specific subpopulation of 
CD8+ T cells. This may have the advantage of a lower risk of side effects due to inappropriate T cell 
activation, which may lead to a favorable safety profile. Several molecules have been developed to 
meet this strategy, but until now those bifunctional molecules could not be produced as a full 
monoclonal antibody in the IgG format, which would be associated with an improved 
pharmacokinetic profile [93-105]. Schmittnaegel et al. were the first ones to successfully produce a 
fully recombinant fusion protein comprising a full length IgG antibody and a MHC class I complex 
carrying an immunodominant epitope of the human Cytomegalovirus [1, 2]. The peptide-MHC class 
I-IgG (pMHCI-IgG) fusion proteins could successfully recruit pre-existing virus-specific CD8+ T cells 
from human donor-derived lymphocytes and effectively trigger eradication of the targeted tumor 
cells in vitro [2]. Due to the polymorphism of MHC complexes the in vivo efficacy can only be tested 
in syngeneic immunocompetent mouse models using surrogate molecules. This study pursues 
following objectives: 
 
 Design and production of functional surrogate pMHCI-IgG fusion proteins 
 
 Establishment of a tunable and reproducible vaccination method for generation of effector 
cells in mouse tumor models 
 
 In vitro evaluation of biological activity and cytotoxicity mediated by surrogate pMHCI-IgG 
fusion molecules 
 
 Anti-tumor efficacy evaluation of surrogate pMHCI-IgG fusions in an experimental lung 
metastasis model and a solid subcutaneous tumor model 
 
 Investigation of penetration profile and T cell recruitment capabilities of surrogate pMHCI-
IgG fusion proteins in the solid subcutaneous tumor model and characterization of 
redirected effector cells 
 
 Comparison of pMHCI-IgG molecules with CD3-based TCB antibodies regarding recruitment 
and activation of effector cells and mediation of tumor cell killing 
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Figure 5.1: Mechanism of action for peptide-MHC class I-IgG fusion molecules. 
PMHCI-IgG molecules selectively recruit peptide-specific, cytotoxic CD8
+
 T cells via their peptide-MHCI complex. Upon 
binding of the antibody to target-specific tumor cells cytotoxic CD8
+
 T cells mediate tumor cell lysis. 
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6 MATERIAL 
6.1 LABORATORY EQUIPMENT 
6.1.1 Devices 
Incubator Cytoperm 2      Heraeus Instruments  
Vortex-Genie 2      Scientific Industries  
Evacuator Vacusafe     INTEGRA Biosciences 
Microscope Axiovert 135    Carl Zeiss International 
Fluorescent microscope DM IL LED microscope  Leica Instruments 
Centrifuge Multifuge 4 KR    Heraeus Holding  
Rotixa 500 RS      Hettich Lab Technology 
Centrifuge 5417R     Eppendorf  
Centrifuge Megafuge 1.0 R     Thermo Fisher Scientific  
Vi-Cell XR Cell Viability Analyzer    Beckman Coulter Biomedical  
Fluorescence-Scanner Pannoramic 250 Flash III  3D Histech 
Isofluran-vaporizer      Eickenmeyer Medizintechnik  
Laboratory scale      Sartorius 
Cooling plate TES 99     MEDITE 
AutostainerPlus      Dako  
Microtome Microm HM 560    Thermo Fisher Scientific  
Microtome Microm HM 355S    Thermo Fisher Scientific 
Paraffin-deflasking station    Vogel 
Laminar flow hood     Weiss Pharmatechnik 
Tissue-Tek VIP Vacuum Infiltration Processor   Sakura Finetek  
Ultramicroscope MVX10 Fluoreszenz MacroZoom OLYMPUS CORPORATION 
3QE Kamera      LaVision BioTec 
SuperK EXTREME supercontinuum laser   NKT Photonics A/S  
Water bath Julabo 5A      Julabo 
MACSQuant Analyzer 10     Miltenyi Biotec 
BTX Electroporation device ECM 830   Harvard Apparatus  
2 Needle Array      Harvard Apparatus 
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FastPrep 24 homogenizer    MP Biomedicals 
MagNA Pure LC 1.0     Roche  
Veriti 96 Well Thermal Cycler    Applied Biosystems  
LightCycler Carousel-Based System    Roche  
LightCycler Sample Carousel     Roche  
LightCycler Carousel Centrifuge     Roche  
LightCycler instrument      Roche  
xCELLigence RTCA SP     ACEA Biosciences  
Eppendorf Thermomixer comfort    Eppendorf 
NanoDrop Spectrophotometer ND-1000   Thermo Scientific 
GelDOC-XR+System     Bio-Rad  
Pipetboy acu 2      INTEGRA Biosciences 
2.5 µl / 10 µl / 100 µl / 200 µl / 1 000 µl / 5 ml pipettes Eppendorf 
 
6.1.2 Consumables 
Cell culture flasks (T175)    Greiner-bio-one 
96-deepwell-plates      Eppendorf  
96-well-plates      Brand, R&D Systems 
E-Plate 96      ACEA Biosciences 
6-well-plates (non-tissue culture treated)  Thermo Fisher Scientific 
Erlenmeyer cell culture flasks    Corning  
0.5 / 1.5 / 2 ml Eppendorf Safe-Lock Tubes   Eppendorf  
50 ml tubes      Greiner-bio-one 
15 ml tubes      Greiner-bio-one 
250 ml tubes      Corning 
70 µm cell strainer     FALCON, a Corning Brand 
FACS tubes      FALCON, a Corning Brand 
Reservoirs      Corning  
2 ml / 5 ml / 10 ml syringes    Omnifix 
Petri dishes      Corning 
Pipette tips      Eppendorf 
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6.1.3 Chemicals 
70 / 80 / 90 / 100 % ethanol    Roche  
Isopropyl alcohol     Sigma Aldrich     
Benzyl alcohol       Sigma Aldrich  
Benzyl benzoate      Sigma Aldrich  
Formalin (10 %)      VWR International  
Histoplast Paraffin      Thermo Fisher Scientific  
Xylene       Merck  
Acetone       Merck 
Methanol       Merck 
TBST 10x      Roche  
DMSO (Dimethyl sulfoxide)    Sigma Aldrich 
Sucrose       Sigma Aldrich 
Aqua bidest      SERAG-WIESSNER  
Sodium acetate solution    Sigma Aldrich 
 
6.2 MATERIALS FOR DIFFERENT PROCEDURES 
6.2.1 Molecular biological procedures 
Restriction enzymes and corresponding buffers  New England BioLabs  
Bromophenol blue      Sigma Aldrich 
Ficoll Plaque PLUS     GE Healthcare 
EDTA       Sigma Aldrich 
Agarose      Sigma Aldrich 
TBE Buffer (Tris-borate-EDTA) (10X)    Thermo Fisher Scientific  
SYBR Safe DNA Gel Stain     Thermo Fisher Scientific  
QIAquick Gel Extraction Kit    Qiagen  
Alkaline Phosphatase     Roche  
Rapid DNA Ligation Kit     Roche  
E.coli strain NEB 5-alphaF´Iq      New England BioLabs  
SOC Outgrowth Medium     New England BioLabs  
QIAprep Spin Miniprep Kit     Qiagen  
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NucleoBond PC 2000 Kit     Macherey-Nagel 
 
6.2.2 Transfection of production cell line and protein purification 
FreeStyle F17       Gibco by Life Technologies 
Glutamax      Gibco by Life Technologies 
10 % Pluronic F-68     Gibco by Life Technologies 
PEIpro       Polyplus-transfection SA 
Valproic acid sodium     Sigma Aldrich 
D-glucose      Merck 
L-glutamine      Life Technologies 
L-asparagine      Sigma Aldrich 
Ethanolamine      Sigma Aldrich  
HyPep 1510       Kerry 
Ammonium-Fe(III)-citrate    Roche  
HiTrap MabSelect SuRe columns    GE Healthcare 
HiLoad 16/60 Superdex 200 pg columns   GE Healthcare 
Amicon Ultra – 15 Centrifugal Filter Units   Merck Millipore 
Sortase       Roche  
 
6.2.3 Cells, media, supplements and antibiotics for cell culture 
HBSS       Life Technologies 
DPBS        PAN Biotech  
FCS        PAN Biotech  
RPMI-1640       PAN Biotech  
DMEM        PAN Biotech 
CTS AIM-V Medium     Gibco by Life Technologies 
L-Glutamine       PAN Biotech  
NEAA (non-essential amino acids)    PAN Biotech  
Sodium pyruvate      PAN Biotech  
2-Mercaptoethanol     Gibco by Life Technologies 
Accutase solution     Sigma Aldrich 
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LB Broth       Sigma Aldrich 
GM-CSF       R&D Systems 
LPS       Sigma Aldrich 
Antibiotics: 
Puromycin      Gibco by Life Technologies 
Zeocin       Invitrogen 
Ampicillin      Gibco by Life Technologies 
Penicillin-Streptomycin     Gibco by Life Technologies 
Peptides: 
Peptide MCMV m38 (“SSPPMFRV”)   BIOSYNTAN  
Peptide OVA257-264 (“SIINFEKL”)    IBA  
Cell lines: 
Cell line Species Tissue Disease Growth 
properties 
Stable 
transfections 
Antibiotic H-2Kb Vendor 
B16-muFAP: 
B16-F10 
_PHOPY_LUC 
_MUSMU_FAP 
C57BL/6 
(mouse) 
Skin Melanoma adherent FAP (fibroblast 
activation 
protein) 
Puromycin 
+ 
Perkin Elmer 
 
Luciferase Zeocin 
MC38-muFAP: 
MC38 
_MUSMU _FAP 
C57BL/6 
(mouse) 
Colon Adeno-
carcinoma 
adherent FAP (fibroblast 
activation 
protein) 
Puromycin 
+ 
City of Hope 
HEK293-F Human Embryonic 
kidney 
Production 
cell line 
suspension   
- 
Invitrogen 
Table 6.1: Cell lines 
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Cell culture media: 
Cells Cell culture medium 
B16-muFAP RPMI 1640 supplemented with: 
- 10 % FCS 
- 0.75 µg/ml puromycin 
- 250 µg/ml zeocin 
MC38-muFAP Dulbecco´s Modified Eagle´s Medium (DMEM) supplemented with: 
- 10 % FCS 
- 2 mM L-Glutamine 
- 1 mM sodium pyruvate 
- 0.1 mM NEAA 
- 6 µg/ml puromycin 
HEK293-F FreeStyle F17 supplemented with: 
- 20 ml/L Glutamax  
- 2.5 ml/L Pluronic F-68  
Bone marrow-derived dendritic cells RPMI 1640 supplemented with: 
- 10 % FCS,  
- 2 mM L-Glutamine,  
- 1 mM sodium pyruvate,  
- 50 mM ß-Mercaptoethanol,  
- 100 units/ml penicillin + 100 µg/ml streptomycin 
Freshly isolated splenocytes 
(R10F
+
/ß-Me medium) 
RPMI 1640 supplemented with: 
- 10 % FCS 
- 1 mM sodium pyruvate 
- 0.1 mM NEAA 
- 50 mM ß-Mercaptoethanol 
- 100 units/ml penicillin + 100 µg/ml streptomycin 
Table 6.2: Cell culture media 
 
6.2.4 In vivo procedures 
C57BL/6NCrl mice     Charles River Laboratories 
Bedding       Ssniff  
Cages       Tecniplast 
Drink bottle      Tecniplast 
Pelleted standard diet     ProvimiKliba  
Isofluran CP (Isofluran)     CP-Pharma  
Ketavet (ketamine)     Pfizer Deutschland  
Rompun (xylazine)     Bayer Pharma  
ODN 1585 VacciGrade     InvivoGen 
Poly(I:C) HMW       InvivoGen 
Recombinant Murine IL-2    PeproTech 
Purified anti-mouse IL-2 Antibody (JES6-5H4)  BioLegend 
Shaver       Harotec  
Caliper        Mitutoyo Messgeräte  
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Surgical instruments      B. Braun Melsungen  
27 G / 25 G needles STERICAN    B. Braun Melsungen  
BD Microfine+ U100 Insulin syringes   Becton, Dickinson and Company 
SOLOFIX blood lancets     B. Braun Melsungen 
Blood capillaries     Hirschmann Laborgeräte  
Microvette tubes 100 LH    Sarstedt  
 
6.2.5 Quantitative real-time polymerase chain reaction  
RNA later      Qiagen  
Lysing matrix tubes     MP Biomedicals 
MagNA Pure LC RNA Isolation Kit III   Roche  
iScript Select cDNA Synthesis Kit   Bio-Rad  
LightCycler FastSart DNA Master SYBR Green I Kit  Roche  
LightCycler Capillaries      Roche  
Primer: 
Gene Primer sense Primer antisense Company 
TRP-2 5´-TTAGGTCCAGGACGCCCC-3´ 5´-CTGTGCCACGTGACAAAGGC-3´ Metabion International AG 
GAPDH 5´-CAATGTGTCCGTCGTGGA-3´ 5´-GATGCCTGCTTCACCACC-3´ Metabion International AG 
Table 6.3: Primer for qPCR 
 
6.2.6 Flow cytometry 
MACSQuant Running buffer    Miltenyi Biotec  
MACSQuant Washing solution    Miltenyi Biotec  
MACSQuant Storage solution    Miltenyi Biotec  
MACS Bleach solution     Miltenyi Biotec  
MACSQuant Calibration Beads    Miltenyi Biotec  
Compensation Particles Set (Anti-Mouse, Hamster, Rat) BD Biosciences 
Cell Staining Buffer     BioLegend 
Fixation Buffer      BioLegend 
Intracellular Staining Perm Wash Buffer (10x)  BioLegend 
RBC Lysis Buffer 10x     BioLegend 
TruStain fcX antibody     BioLegend 
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DAPI (4′,6-diamidin-2-phenylindol)   Roche  
DNase I solution     StemCell Technologies 
Dispase       StemCell Technologies  
Collagenase D       Roche  
Flow cytometry antibodies: 
Primary antibodies 
Antigen Fluorochrome Source Reactivity Clone Isotype Manufacturer 
CD45 PerCP Rat Mouse 30-F11 IgG2b, κ BioLegend 
CD3ε Brilliant Violet 421 Hamster Mouse 145-2C11 IgG BioLegend 
CD3ε APC-Cy7 Hamster Mouse 145-2C11 IgG BioLegend 
CD3ε FITC Hamster Mouse 145-2C11 IgG BioLegend 
CD4 FITC Rat Mouse GK1.5 IgG2b, κ BioLegend 
CD4 APC-Cy7 Rat Mouse GK1.5 IgG2b, κ BioLegend 
CD8a Brilliant Violet 510 Rat Mouse 53-6.7 IgG2a, κ BioLegend 
CD8a PerCP Rat Mouse 53-6.7 IgG2a, κ BioLegend 
CD44 PE Rat Mouse IM7 IgG2b, κ BioLegend 
CD62L PE-Cy7 Rat Mouse MEL-14 IgG2a, κ BioLegend 
CD127 PE-Cy7 Rat Mouse A7R34 IgG2a, κ BioLegend 
PD-1 PE Rat Mouse 29F.1A12 IgG2a, κ BioLegend 
PD-L1 PE Rat Mouse 10F.9G2 IgG2b, κ BioLegend 
CD25 PE-Cy7 Rat Mouse PC61 IgG1, λ BioLegend 
FoxP3 PE Rat Mouse MF-14 IgG2b, κ BioLegend 
IFN-γ PE Rat Mouse XMG1.2 IgG1, κ BioLegend 
CD40 PerCP-Cy5.5 Rat Mouse 3/23 IgG2a, κ BioLegend 
CD80 PE-Cy7 Hamster Mouse 16-10A1 IgG BioLegend 
CD86 Brilliant Violet 510 Rat Mouse GL-1 IgG2a, κ BioLegend 
I-A/I-E FITC Rat Mouse M5/114.15.2 IgG2b, κ BioLegend 
CD11c APC Hamster Mouse N418 IgG BioLegend 
“SIINFEKL” on   
H-2Kb 
PE Mouse Mouse 25-D1.16 IgG1, κ BioLegend 
Table 6.4: Primary antibodies for flow cytometry 
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Dextramers for detection of specific CD8+ T cells 
Antigen Fluorochrome Source Reactivity Manufacturer 
“SSPPMFRV” / H-2Kb APC Synthetic 
production 
MCMV m38-specific        
T cell receptor (murine) 
Immudex 
“SIINFEKL” / H-2Kb APC Synthetic 
production 
OVA257-264-specific              
T cell receptor (murine) 
Immudex 
Table 6.5: Dextramers for flow cytometry 
 
Secondary antibodies 
Antigen Fluorochrome Source Reactivity Clone Isotype Manufacturer 
Mouse IgG2c FITC Goat Mouse Polyclonal - LifeSpan BioSciences 
H-2Kb APC Mouse 
(BALB/c) 
Mouse 
(C57BL/6) 
AF6-88.5 IgG2a, κ BioLegend 
Table 6.6: Secondary antibodies for flow cytometry 
 
Isotype control antibodies 
Fluorochrome Source Clone Isotype Manufacturer 
PE-Cy7 Rat G0114F7 IgG1, λ BioLegend 
PE Rat RTK2071 IgG1, κ BioLegend 
Brilliant Violet 510 Rat RTK2758 IgG2a, κ BioLegend 
PE Rat RTK2758 IgG2a, κ BioLegend 
PerCP Rat RTK2758 IgG2a, κ BioLegend 
PerCP-Cy5.5 Rat RTK2758 IgG2a, κ BioLegend 
PE-Cy7 Rat RTK2758 IgG2a, κ BioLegend 
FITC Rat RTK4530 IgG2b, κ BioLegend 
PE Rat RTK4530 IgG2b, κ BioLegend 
PerCP Rat RTK4530 IgG2b, κ BioLegend 
APC-Cy7 Rat RTK4530 IgG2b, κ BioLegend 
Brilliant Violet 421 Hamster RTK888 IgG BioLegend 
FITC Hamster RTK888 IgG BioLegend 
APC Hamster RTK888 IgG BioLegend 
APC-Cy7 Hamster RTK888 IgG BioLegend 
PE-Cy7 Hamster RTK888 IgG BioLegend 
PE Mouse MOPC-21 IgG1, κ BioLegend 
APC Mouse MOPC-173 IgG2a, κ BioLegend 
Table 6.7: Isotype control antibodies for flow cytometry 
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6.2.7 Immunohistochemistry and ultramicroscopy 
Richard-Allan Scientific NEG 50 Frozen Section Medium  Thermo Scientific 
Microscope slides     Thermo Scientific 
Coverslips      Carl Roth 
Microtome blades A35     FEATHER Safety Razor  
Microtome blades C35     FEATHER Safety Razor 
Dako Pen      Dako  
Protein Block Serum-Free     Dako 
Antibody Diluent, Dako REAL    Dako 
Discovery Antibody Diluent    Ventana 
ProLong Gold antifade reagent with DAPI  Life Technologies 
Eukitt       Fluka 
Immunohistochemistry antibodies: 
Primary antibodies 
Antigen Conjugate Source Reactivity Clone Concentration Manufacturer 
CD8a - Rabbit Mouse Polyclonal 1 mg/ml Synaptic Systems 
FAP Alexa 647 Human Human  
Mouse 
28H1sf W(3a) 
IgG1 
0.96 mg/ml Roche Glycart  
Table 6.8: Primary antibodies for immunohistochemistry 
 
Secondary antibodies 
Antigen Conjugate Source Reactivity Clone Concentration Manufacturer 
IgG  
(H+L) 
Alexa 488 Goat Rabbit Polyclonal 2 mg/ml Thermo Fisher 
Scientific  
Table 6.9: Secondary antibodies for immunohistochemistry 
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7 METHODS 
7.1 DESIGN AND CONSTRUCTION OF SURROGATE FUSION MOLECULES AND 
ANTIBODIES 
7.1.1 DNA expression vector construction 
For production of the plasmids needed for DNA vaccination and expression of peptide-MHC class I-
IgG fusion proteins, T cell bispecific and anti-XCR1 antibodies already established standard 
protocols were used. Plasmid maps of the cloned DNA vectors with amino acid sequences were 
designed with the program Vector NTI (Invitrogen) and can be found in the appendix. Plasmids 
were cloned by inserting new sequences into already existing standard expression vectors. All 
expression vectors contained a CMV-promoter, Intron A, start codon and signal peptide for 
secretion and a bovine growth hormone polyadenylation (BGHpA). New sequences were designed 
and then purchased from GeneArt as gene synthesis. Gene synthesis were provided as lyophilisate 
and reconstituted in PCR-grade water to a concentration of 0.1 µg/µl. 
 
7.1.2 Restriction enzyme DNA fragmentation 
DNA fragments for recombinant cloning were generated with restriction enzyme cleavage. Two 
restriction enzymes were used to cut out DNA sequences. For both donor plasmid and receiving 
plasmid, identical enzymes were used to generate matching DNA ends. 2 to 3 µg DNA of each 
plasmid were digested with 20 U of each restriction enzyme in a buffer and at a temperature 
suitable for both enzymes. Afterwards DNA fragments were separated with gel electrophoresis. 
For analytical digestions two to three restriction enzymes, which cut the destination vector in 
another pattern as the new subcloned vector, were chosen. As a result destination and subcloned 
vector show different gel electrophoresis lanes. Analytical digestions were performed for one hour 
with 200 ng DNA and 5 U of each restriction enzyme in a buffer and at a temperature suitable for all 
used enzymes. 
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7.1.3 Agarose gel electrophoresis 
For gel electrophoresis DNA samples were diluted with a gel loading buffer containing 0.125 % 
(w/v) bromophenol blue, 25 % (w/v) Ficoll and 100 mM EDTA and loaded to an agarose gel (1 % 
agarose, TRIS-Borat-EDTA-buffer, 10 µg/ml SYBR Safe DNA Gel Stain (Thermo Fisher Scientific)). 
Gels were run at a constant voltage of 7 V/cm for 30 to 60 minutes. By excitation of the SYBR Safe 
DNA Gel Stain intercalated in the DNA with ultraviolet light, DNA got visible and could be recovered 
from the gel. 
 
7.1.4 Agarose gel extraction of DNA 
For extraction of DNA from the agarose gel the QIAquick Gel Extraction Kit (Qiagen) was used. DNA 
fragments of interest were cut out of the gel and transferred into a 2 ml Eppendorf tube. Then DNA 
was isolated according to the manufacturer`s instructions. Gel slides were dissolved in a buffer and 
then applied to a column which binds nucleic acids to a silica membrane at high-salt conditions. 
Finally pure DNA was eluted with water. DNA concentration was measured with a spectral 
photometer. 
 
7.1.5 Dephosphorylation of vector fragments 
In order to prevent re-ligation of the digested destination vector, phosphate groups of the 
linearized plasmid DNA were removed with Alkaline Phosphatase (Roche). Therefore up to 1 pM 
5´terminal phosphorylated DNA fragments were incubated with 1 U Alkaline Phosphatase for        
10 minutes at 37°C. Afterwards the enzyme was inactivated at 65°C for 10 minutes. 
 
7.1.6 Ligation of DNA fragments 
Ligation of insert and dephosphorylated vector fragment was performed using the Rapid DNA 
Ligation Kit (Roche). Vector fragment and insert were mixed at a molar ratio of 1:5 not exceeding 
the maximum amount of 200 ng DNA. Then DNA solution was filled up to 10 µl with DNA Dilution 
Buffer and 10 µl Ligation buffer and 1 µl T4 DNA Ligase were added. After 10 minutes of incubation 
at 25°C ligated plasmid DNA could be stored at -20°C without heat inactivation of enzyme or 
directly used for transformation of competent E.coli cells. 
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7.1.7 Bacterial transformation 
For amplification of plasmid DNA the chemically competent E.coli strain NEB 5-alphaF´Iq from NEB 
was used. 50 µl of cells were thawed on ice for 10 minutes and 100 ng of plasmid DNA was added. 
After incubation of the mixture on ice for 30 minutes a heat shock was performed placing the vial in 
a 42°C water bath for exactly 30 seconds. Then cells were put back on ice for 5 minutes and 
resuspended in 200 µl SOC Outgrowth Medium (NEB). After incubation with shaking at 350 rpm for 
30 to 60 minutes at 37°C the mixture was spread on a LB agar plate (LB medium: 5 g Trypton, 10 g 
yeast exract, 10 g sodium chloride in 1 L water) containing ampicillin (100 µg/ml) as selection 
antibiotic. Agar plates were placed into the brood chamber at 37°C overnight and the day later 
single colonies on the agar plate were picked and incubated in 3 ml LB medium containing 
ampicillin (amp+) for another 24 hours.  
Genotype NEB 5-alphaF´Iq:  fhuA2 Δ(argF-lacZ)U169 phoA glnV44 Φ80 Δ(lacZ)M15 
gyrA96 recA1 relA1 endA1 thi-1 hsdR17 
 
7.1.8 Plasmid DNA isolation and further proliferation 
To verify the right assembling of the subcloned vector, plasmid DNA was isolated from E.coli clones 
with the QIAprep Spin Miniprep Kit (Qiagen) and used for analytical restriction enzyme cleavage. 
With the kit plasmid DNA is prepared by alkaline lysis of bacterial cells and adsorption of plasmid 
DNA to silica matrices. DNA sequence of plasmids was additionally confirmed by Sanger sequence 
analysis performed by the company Sequiserve. If correct assembling of the subcloned vector was 
confirmed in one of the Mini-Preps, the same clone was picked again from the agar plate, 
propagated in 3 ml LB medium (amp+) for 12 hours and inoculated into 800 ml LB medium (amp+) in 
a ratio of 1:1 000. After 12 to 16 hours of incubation in the brood chamber with shaking at 300 rpm 
at 37°C, plasmid DNA was extracted with the NucleoBond PC 2000 Kit (Macherey-Nagel). Cells are 
lysed under alkaline conditions and plasmid DNA is isolated via anion-exchange chromatography. 
DNA extracted from Mega-Preps was used for transfection of HEK293-F cells and therefore had to 
be sterilized by ethanol precipitation. 
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7.1.9 DNA purification by ethanol precipitation 
For ethanol precipitation plasmid DNA was mixed with sodium acetate solution (3 M, pH 5.2) in a 
ratio of 1:10 and precipitated by addition of 2.5 volume ethanol. The pellet was washed with 70 % 
ethanol, centrifuged and resuspended in sterile water. Yield and concentration of DNA was 
determined with a spectral photometer. 
 
7.1.10 Transient transfection of HEK293-F cells 
Peptide-MHC class I-IgG fusion proteins, T cell bispecific and anti-XCR1 antibodies were transiently 
expressed in HEK293-F cells (Invitrogen). The transfection reagent PEIpro (Polyplus) was used. It is 
based on poly-cationic PEI polymers, which build so called polyplexes with the negative charged 
DNA. Production of antibodies and fusion molecules for in vivo use was accomplished in 2 to 6 L 
shake flasks scale to yield enough protein for this purpose. Transfection of HEK293-F cells was 
performed at a cell density of 20 to 25 x 105 cells/ml. For each liter of HEK293-F culture volume     
0.5 mg DNA was diluted with 40 ml PBS and 1.25 ml PEIpro transfection reagent was added. When 
more than one plasmid was used for transfection, the equimolar amount of DNA depending on the 
size of plasmid (bp) was calculated and accordingly used. For production of pMHCI-IgG fusion 
proteins a molar ratio of 3:2:1 for peptide-MHCI-antibody heavy chain:antibody heavy 
chain:antibody light chain was applied. For the TCB antibody a molar ratio of 1:1:1:1 for all of the 4 
plasmids was used. The normal anti-XCR1 antibody was produced with a molar ratio of 1:2 for 
antibody heavy chain:antibody light chain. For complex building the DNA/PEIpro mixture was 
incubated at room temperature for 8 to 15 minutes. Then it was added to the HEK293-F culture 
incubated in shake flasks in a humidified incubator at 120 rpm, 36.5°C temperature and 7% CO2. 
Three hours after transfection VPA (valproic acid) solution was added to a final concentration of      
4 mM in the shake flask. VPA is a histon-deacetylase inhibitor, which was used for enhancement of 
protein expression. Special attention was paid to the right dilution of VPA as it induces apoptosis 
and contributes to a premature cell death. Until harvest, cell number and viability was checked 
daily. 24 hours after transfection supplementary feeding of cells was started. Therefore a 6 ml 
glucose bolus (Stock solution: 500 g/L glucose) was added once per liter HEK293-F transfection 
culture and additionally 120 ml Feed7 (Stock solution: 6.5 g/L D-glucose, 3 g/L L-glutamine, 2 g/L     
L-asparagine, 0.3 ml/L ethanolamine, 30 g/L soy peptone (HyPep 1510), 85.5 mg/L ammonium-
Fe(III)-citrate) was administered daily per liter HEK293-F transfection culture. Harvest of 
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transfection culture was performed when viability of cells dropped to 50 % or on day 7 after 
transfection. Cell suspension was centrifuged first at 2 000 rpm for 30 minutes to deplete cells from 
the supernatant containing the protein and then at 3 500 rpm for 90 minutes for optimal removal 
of remaining cell fragments. The supernatant was pre-filtrated over a PES filter with pore size     
0.45 µm and then filtered through a 0.22 µm sterile filter. Afterwards the sterile harvest was stored 
at -20°C or directly used for purification of protein. 
 
7.1.11 Protein purification 
Protein purification was carried out by the department for Biochemistry (Large Molecule Research, 
Roche Diagnostics GmbH). Proteins were purified from supernatant by Protein A affinity 
chromatography with HiTrap MabSelect SuRe columns (GE Healthcare). After a wash step 
antibodies were eluted with 50 mM sodium citrate (pH 3.2). To remove aggregates and byproducts 
a preparative size-exclusion chromatography was performed with HiLoad 16/60 Superdex 200 pg 
columns (GE Healthcare). Purified proteins were buffered in 20 mM Histidine and 140 mM sodium 
chloride at pH 6.0. The concentration of purified proteins was determined with a calculation of the 
extinction coefficient according to the protein sequence and measurements of the optical density 
at 280 nm. Purified proteins were concentrated to 2 to 6 mg/ml with Amicon Ultra – 15 Centrifugal 
Filter Units (Merck Millipore) with a molecular cut off of 30 000. Purity of protein was assessed by 
SDS-PAGE (sodium dodecyl sulfate polyacrylamide gel electrophoresis) and western blotting and 
protein identity by mass spectroscopy. 
 
7.1.12 Protein fusion by enzymatic sortase coupling  
The anti-XCR1 antibody MARX10 used for vaccination was produced with a C-terminally fused 
sortase tag followed by a poly-histidine tag. This has the advantage that any peptide, which should 
be used as antigen for vaccination, can be fused to the antibody via enzymatic sortase coupling. The 
sortase A peptide recognition motif “LPXTG” (amino acid sequence: Leu–Pro-any-Thr-Gly) was 
added to the C-terminus of the antibody (sortase tag) and an oligo-glycine motif was fused to the   
N-terminus of the peptide. For linking the immunodominant epitope m38 of the murine 
Cytomegalovirus (MCMV) to the MARX10 antibody, an amino acid sequence consisting of the 
complete m38 peptide (“SSPPMFRV”) and the ten amino acids naturally occurring N-terminally of 
the peptide in the protein sequence was used. This ensures that the m38 epitope is normally 
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processed inside the cell after internalization and correctly presented in MHC class I complexes on 
the cell surface. The following amino acid sequences were fused to the heavy chain of the antibody            
(C-terminal) and the peptide (N-terminal): 
Antibody:  
Antibody heavy chain-GGGGSLPETGGSGSHHHHHH-COOH sortase motif poly-histidine-tag 
Peptide:  
H2N-GGGPPMPMTVTLISSPPMFRV-COOH (Gly)3 motif  10 previous AA      m38 peptide 
For enzymatic reaction 20 mg of the sortase tagged MARX10 antibody were incubated with (Gly)3-
fused peptide and sortase A in sortase buffer at a molar ratio of 0.8:1:15 (sortase 
A:antibody:peptide). After 3 hours of incubation in a 37°C water bath the peptide was C-terminally 
fused to the MARX10 antibody. 
Enzymatic reaction: 
HC of Ab-GGGGSLPETGGSGSHHHHHH-COOH + H2N-GGGPPMPMTVTLISSPPMFRV-COOH 
(Sortase tagged antibody)    ([Gly]3 linked peptide) 
 
 
HC of Ab-GGGGSLPET GGGPPMPMTVTLISSPPMFRV-COOH 
After sortase coupling affinity purification was performed with poly-histidine-tag columns to 
deplete non- or single-coupled protein. After purification antibodies were concentrated to                
2 to 6 mg/ml with Amicon Ultra – 15 Centrifugal Filter Units (Merck Millipore) with a molecular cut 
off of 30 000. Purity of protein was assessed by SDS-PAGE and western blotting. 
 
7.2 CELL CULTURE TECHNIQUES 
7.2.1 Cell culture conditions 
All adherent tumor cell lines (table 6.1: B16-muFAP and MC38-muFAP) were grown on polystyrene 
dishes in a humidified incubator at 37°C supplied with 5% CO2. Bone marrow-derived dendritic cells 
were cultured under same conditions in non-tissue culture treated 6-well-plates to avoid 
        Methods 50 
 
attachment of the cells to the dish. Production cell line HEK293-F (table 6.1: Human embryonic 
kidney 293-FreeStyle) was cultured in shake flasks in a humidified incubator at 120 rpm, 36.5°C 
temperature and 7% CO2. All cells were grown in dedicated media as specified in table 6.2. To 
maintain selective pressure, permanently transfected tumor cell lines were cultured with addition 
of the respective antibiotic. Before in vivo inoculation the absence of murine pathogens like 
Mycoplasma Genus, Mousepox (Ectromelia), Mouse parvoviruses (MPV/MVM), Mouse Hepatitis 
Virus (MHV), Reovirus (REO-3), Lymphochoriomeningitis Virus (LCMV), Mouse Rotavirus (MRV 
(EDIM)), Theiler's Murine Encephalomyelitis Virus (TMEV), Hantavirus Hantaan, Mouse 
Adenoviruses (MAV 1 and 2), Murine Cytomegalovirus (MCMV), Pneumonia Virus of Mice (PVM), 
Sendai Virus and Murine Norovirus (MNV) in tumor cell lines was confirmed by PCR. 
 
7.2.2 Thawing, subculturing and freezing of cells 
For cultivating cells stored in liquid nitrogen, cell suspension was briefly thawed in a water bath at 
37°C until a little clump of frozen cells remained and then immediately mixed with preheated cell 
culture media. To remove DMSO the cell suspension was centrifuged at 300 x g for 5 minutes at 
room temperature and the supernatant was discarded. The remaining cell pellet was resuspended 
in cell culture medium and transferred to a culture dish. 
When adherent cells (tumor cell lines) were 80 to 100 % confluent, cell culture medium was 
removed from the culture dish and the cell layer was washed with PBS and then covered with 
Accutase Solution (Sigma Aldrich) for cell detachment. After incubation with accutase at 37°C for     
2 to 5 minutes detached cells were resuspended in cell culture medium containing FCS (fetal calf 
serum) to stop the enzymatic reaction. Cells were centrifuged at 300 x g for 5 minutes and the cell 
pellet was resuspended in the required volume of cell culture medium. Cells were counted and 
subcultured into new dishes in a ratio ranging from 1:3 – 1:10 depending on the cell type. If tumor 
cell lines were used for flow cytometry analysis, cells were resuspended in an appropriate volume 
of Cell Staining Buffer (BioLegend) after centrifugation and adjusted to 10 x 106 cells/ml. 
Suspension cells (HEK293-F and dendritic cells) were subcultured by addition or replacement of 
fresh cell culture medium. When HEK293-F cells reached a viable cell density of 40 to 45 x 105 
cells/ml cells were subcultured in a ratio of 1:10. For transfection of HEK293-F cells a viable cell 
density of 20 to 25 x 105 cells/ml cells was preferred. Dendritic cells were subcultured only once in a 
ratio of 1:2 three days after cell culture start. 
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For permanent storage detached and resuspended cells were centrifuged at 300 x g for 5 minutes 
at room temperature. Then the cell pellet was resuspended in 1ml FCS containing 10% DMSO, 
frozen at - 80°C and transferred to liquid nitrogen for permanent storage the next day. 
 
7.2.3 Cell counting 
Cell number was calculated with the Vi-Cell XR Cell Viability Analyzer (Beckman Coulter Biomedical). 
The device diluted the provided cell suspension with trypan blue and analyzed 50 aliquots of the 
suspension. Cellular viability and cell number were determined.  
 
7.2.4 Development and maturation of bone marrow-derived dendritic cells 
After generating a single cell suspension, bone marrow cells were cultivated in a special medium 
(see table 6.2) supplemented with 0.05 µg/ml GM-CSF (granulocyte macrophage colony-stimulating 
factor) to induce development of dendritic cells out of bone marrow cells. After three days DCs 
were subcultured with the same medium in a ratio of 1:2. Another three days later LPS 
(Lipopolysaccharide; final concentration: 0.1 µg/ml) was added overnight for maturation of bone 
marrow-derived DCs. The day after maturation DCs could be used for peptide-loading. 
 
7.2.5 Peptide-loading of cells 
Loading of cells was always performed with the peptides of the immunodominant epitopes of 
either the murine Cytomegalovirus (MCMV m38: “SSPPMFRV”) or ovalbumin (OVA257-264: 
“SIINFEKL”). The peptides were presented on the murine MHC class I complex H-2Kb. All cells to be 
loaded were positive for expression of the murine H-2Kb MHC class I complex. 
 
7.2.5.1 Bone marrow-derived dendritic cells 
For loading of mature bone marrow-derived DCs with peptide cells were resuspended in RPMI(-) 
and cell density was adjusted to 5 x 105 cells/ml. Peptide was added in a concentration of 2 µg/ml. 
After incubation for 1 to 2 hours at 37°C in the humidified incubator supplied with 5% CO2 cells 
were washed twice with RPMI containing 10% FCS and finally resuspended in PBS for injection into 
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animals. Before administration, peptide-loading of bone marrow-derived DCs was confirmed by 
flow cytometry at least in the case of the peptide “SIINFEKL” (see chapter 7.4.2.4). 
 
7.2.5.2 Splenocytes 
Splenocytes were loaded with peptide at a cell density of 5 x 106 cells/ml in R10F+/ß-Me medium 
(see table 6.2). Cells were loaded for 1 – 2 hours at 37°C in a humidified incubator supplied with 5% 
CO2 at a molar peptide concentration of 10 µM. To remove unbound peptide, splenocytes were 
washed two times with PBS and then resuspended in PBS for injection into mice. Before 
administration, peptide-loading of splenocytes was checked by flow cytometry at least in the case 
of the peptide “SIINFEKL” (see chapter 7.4.2.4). 
 
7.2.5.3 Tumor cells 
Peptide-loaded tumor cells served as positive control in in vitro assays. Tumor cell lines B16-muFAP 
and MC38-muFAP were loaded at different molar peptide concentrations. Peptide-loading was 
performed with cells adherent at the dish or in suspension after detachment at a cell density of        
5 x 106 cells/ml. After incubation in a humidified incubator at 37°C supplied with 5% CO2 for 1 to 2 
hours, unbound peptide was removed by washing of cells with plain medium or Cell Staining Buffer 
(BioLegend). 
 
7.3 IN VIVO PROCEDURES 
7.3.1 General modalities 
7.3.1.1 Animal facility 
Animals were kept in the conventional area of the animal facility of the Roche Diagnostics GmbH in 
Penzberg. The facility is AAALAC accredited and therefore conform to the “Association for the 
Assessment and Accreditation of Laboratory Animal Care International”. Animals are tested 
quarterly for defined germs according to FELASA (Federation of Laboratory Animal Science 
Associations) guidelines. Mice were purchased from Charles River Laboratories. After an adaption 
period of one week after arrival, mice were used for experiments. A 12 hour dark/light-rhythm was 
used in the facility. Mice were housed in groups of six animals in M3 cages and fed with autoclaved 
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standard diet. As enrichment animals got hemp pads for nest-building and small pieces of wood for 
gnawing. Bedding, water bottles and food pellets were changed weekly by animal care takers. All 
animals were monitored daily for general health condition. The Veterinary Office of the 
administrative district examines the animal facility quarterly and all experiments conducted for this 
work were approved by the Government of Upper Bavaria. 
 
7.3.1.2 Laboratory animals 
Due to the polymorphism of MHC complexes in vivo efficacy, tolerability and interaction with the 
immune system of peptide-MHC class I-IgG fusion proteins could only be tested in syngeneic 
immunocompetent mouse models using surrogate molecules. In the fusion molecules the murine 
MHC class I complex H-2Kb carrying an immunodominant epitope of the murine Cytomegalovirus 
(m38: “SSPPMFRV”) or ovalbumin (OVA257-264: “SIINFEKL”) was used. Effector cells recruited by the 
fusion proteins for elimination of tumor cells were generated via vaccination. As C57BL/6N mice are 
immunocompetent and have the MHC haplotype H-2Kb this mouse strain was the most appropriate 
one for the studies. There are also several established tumor models available for that mouse 
strain. The C57BL/6N strain is a black coated inbred strain broadly used for multiple purposes. It 
was developed by C.C. Little in 1921.  
 
7.3.1.3 Anesthesia of mice 
For painful procedures such as opening of the thorax for final blood drawing from the heart mice 
were anesthetized with an intraperitoneal injection of 100 mg/kg ketamine (Ketavet) and 20 mg/kg 
xylazine (Rompun) in a total volume of 200 µl PBS. After 5 to 10 minutes surgical tolerance was 
reached, which could be proved by testing of reflexes such as the pedal withdrawal reflex of the 
hind limb. If animals were not euthanized during intervention (e.g. final blood draw from the heart) 
awakening after the procedure was monitored and heat source was provided. For short time 
anesthesia or anesthesia during less painful procedures inhalation anesthesia with Isofluran was 
used. Applying this method animals get anesthetized within a few minutes and awake easily 
without extended post-anesthetic sleep. 
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7.3.1.4 Euthanasia of mice 
Mice were sacrificed by cervical dislocation, exposure to CO2 or final blood draw from the heart 
under ketamine / xylazine anesthesia. When using CO2 for euthanasia special attention was paid to 
a laminar flow rate, slowly rising concentration in the sealed cage and maintenance of accustomed 
groups of animals. 
 
7.3.2 Vaccination methods 
7.3.2.1 Vaccination with peptide-loaded, bone marrow-derived dendritic cells 
After generation of peptide-loaded dendritic cells out of bone marrow from donor mice as 
described in chapters 7.3.4.3.4, 7.2.4 and 7.2.5.1, animals were injected with the cells for 
vaccination. Before injection into mice loading of DCs with peptide (OVA257-264: “SIINFEKL”) was 
checked with flow cytometry (see chapter 7.4.2.4). OVA257-264-loaded DCs were injected into mice in 
four different application routes (i.v., i.p., i.d. and s.c.) with different cell numbers for each 
administration route. The following table describes the classification of animals and number of cells 
injected: 
Group: Route of administration of DC: Number of cells injected: Injected volume: 
1 intravenous (i.v.) 8 x 105 100 µl 
2 Intraperitoneal (i.p.) 1.6 x 106 200 µl 
3 Intradermal (i.d.) 2 x 105 20 µl 
4 Subcutaneous (s.c.) 1.6 x 106 200 µl 
Table 7.1: Injections of peptide-loaded dendritic cells 
For intradermal injection mice were anesthetized with Isofluran, other injections were performed 
without anesthesia. Intradermal and subcutaneous injection sites were shaved and disinfected with 
alcohol prior to injection. In total animals of all groups were injected 3 times at an interval of 7 days 
with the peptide-loaded DCs. Together with the first and the second immunization 20 µg of          
CpG oligodeoxynucleotides (CpG ODN: ODN 1585 VacciGrade, InvivoGen) were administered 
subcutaneously. In bacterial DNA CpG motifs are 20 times more frequent compared to mammalian 
DNA. The motifs are recognized by TLR9, which leads to strong immunostimulatory effects on cells 
of the innate immune system [106]. After injection DCs presenting the peptide OVA257-264 prime 
CD8+ T cells and induce an OVA257-264-specific CD8
+ T cell response. Blood was drawn twice weekly 
from mice to evaluate CD8+ T cell response with flow cytometry analysis (see chapter 7.4.2.3). 
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7.3.2.2 DNA vaccination with electroporation 
Generation of standard vectors encoding for ovalbumin was described in chapters 7.1.1 to 7.1.9. 
Mice were anesthetized with Isofluran and shaved on the back or hind leg. Then 100 µg plasmid 
DNA was injected either intradermal (volume: 20 µl) on the back or intramuscular (volume: 30 µl) 
into the M. tibialis anterior. Immediately after injection of DNA the electroporation was performed 
with the BTX Electroporation device ECM 830 (Harvard Apparatus) with a 2 Needle Array (Harvard 
Apparatus; needle length: 20 mm, needle spacing: 10 mm). After intradermal injection electrodes 
were placed on the dry, shaved skin in such a way that they enclose the welt resulting from the 
intradermal injection. After intramuscular injection electrodes were inserted into the muscle to a 
depth of 5 mm so that they encompass the injection site of DNA. Following electric pulses were 
delivered for electroporation: 
Injection route of DNA: intradermal intramuscular 
Number of pulses: 2 6 
Voltage: 500 V 75 V 
Duration: 0.1 ms 20 ms 
Interval: 0.125 s 200 ms 
 followed by  
Number of pulses: 4 
Voltage: 144 V 
Duration: 10 ms 
Interval: 0.125 s 
Table 7.2: Electric pulses for electroporation 
 
Injection of DNA with subsequent electroporation was performed two times at an interval of seven 
days. Together with every immunization 20 µg of the TLR9-agonist CpG ODN (InvivoGen) were 
administered subcutaneously. Electroporation enhances the uptake of the vector into the antigen 
presenting cells. Genes encoding for the antigen are expressed and produce a xenogeneic protein. 
This protein (ovalbumin) is processed inside the cell and immunogenic peptides (including      
OVA257-264) of the protein are displayed on MHC class I molecules on the cell surface of antigen 
presenting cells. Cells presenting the peptide OVA257-264 prime CD8
+ T cells and induce an OVA257-264-
specific CD8+ T cell response. After vaccination blood was drawn twice weekly from mice to 
evaluate CD8+ T cell response with flow cytometry analysis (see chapter 7.4.2.3). 
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7.3.2.3 XCR1-targeted vaccination 
The XCR1-targeted vaccination was performed according to a modified and expanded protocol 
from Hartung et al. [107]. The anti-XCR1 antibody MARX10 was produced and recombinantly fused 
to an antigen as described in chapter 7.1. The entire ovalbumin protein or peptides of the 
immunodominant epitopes of either ovalbumin (OVA257-264: “SIINFEKL”) or the murine 
Cytomegalovirus (MCMV m38: “SSPPMFRV”) were used as antigens for fusion to the targeting 
antibody. Antibody fusion molecules OVA257-264-MARX10 and ovalbumin-MARX10 were kindly 
provided from Prof. Richard Krokzek from the Robert-Koch-Institute in Berlin, whereas the MCMV 
m38-MARX10 antibody fusion was procuced in house (see chapter 7.1). Peptide-loaded splenocytes 
were generated as described in chapters 7.3.4.3.1 and 7.2.5.2. Vaccination was performed in three 
steps as shown in table 7.3. In the first step called “Prime” mice were injected intravenously with 
the XCR1-targeting antibody MARX10, which was C-terminally fused to the antigen, and 
polyinosinic-polycytidylic acid (Poly(I:C) HMW: InvivoGen). The MARX10 antibody targets cross-
presenting DCs via binding to XCR1, which is exclusively expressed on those cells. The antigen gets 
internalized into cross-presenting DCs together with the antibody. In order to become degraded by 
the proteasome the antigenic fragments need to escape from the endosomal compartment. After 
reaching the cytoplasm the antigens become degraded at the proteasome and loaded onto MHC 
class I complexes after transport into the endoplasmatic reticulum via the TAP-transporter. Cells 
presenting the peptide OVA257-264 prime CD8
+ T cells and induce an OVA257-264-specific CD8
+ T cell 
response, cells presenting the peptide MCMV m38 prime CD8+ T cells and induce a MCMV m38-
specific CD8+ T cell response. The TLR3-agonist Poly(I:C) was applied as adjuvant to enhance 
immune activation. It is a synthetic analog of double-stranded RNA (dsRNA) present in viruses that 
activates mainly cells of the innate immune system [108]. Five days after the “Prime” step the 
“Antigen dependent amplification system” (ADAS) was applied. Peptide-loaded splenocytes 
(OVA257-264 or MCMV m38) from donor mice of the same mouse strain were administered 
intravenously together with Poly(I:C). This step was performed to boost the specific CD8+ T cell 
response elicited in the first step of vaccination. Prior to injection, peptide-loading of splenocytes 
was confirmed by flow cytometry at least in the case of OVA257-264 (see chapter 7.4.2.4). The 
following two or three days complexed IL-2 (cxIL-2) was injected intraperitoneally for further 
amplification of specific CD8+ T cells. Complexed IL-2 was prepared by adding the purified anti-
mouse IL-2 antibody JES6-5H4 (BioLegend) to Recombinant Murine IL-2 (PeproTec) the day before 
injection. Antibody and target got complexed overnight and could be further diluted with PBS and 
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administered the next day. To evaluate the contribution of every single step to the CD8+ T cell 
response, three treatment groups were built for each antigen (OVA257-264 and MCMV m38). One 
group was administered the “Prime” step only, the other group was given the “Prime” step 
followed by the “ADAS” step and the third group was treated with all three steps of the vaccination 
method. After vaccination blood was drawn twice weekly from mice to evaluate CD8+ T cell 
response with flow cytometry analysis (see chapter 7.4.2.3). 
Step: Compounds  
administered: 
Amount: Injection  
route: 
Injected  
volume: 
Injection  
time point: 
Step 1 
Prime 
MCMV m38-MARX10 or  
OVA257-264-MARX10 or  
ovalbumin-MARX10 
5 µg/animal 
5 µg/animal 
2 µg/animal 
intravenous 100 µl Day 0 
Poly(I:C) 10 µg/animal 
Step 2 
ADAS 
MCMV m38- or OVA257-264- 
loaded splenocytes 
1 x 10
7
 
cells/animal 
intravenous 100 µl Day 5 
Poly(I:C) 50 µg/animal 
Step 3 
cxIL-2 
Complexed IL-2: 
-Recombinant Murine IL-2 
-anti-mouse IL-2 Ab: JES6-5H4 
 
2.5 µg/animal 
10 µg/animal 
intraperitoneal 200 µl Day 6, 7 (and 8) 
Table 7.3: Steps of XCR1-targeted vaccination 
 
7.3.3 Tumor models 
7.3.3.1 Experimental lung metastasis model 
In order to induce experimental lung metastasis, mice were injected intravenously into the lateral 
tail vein with 2 x 105 FAP-transfected B16 melanoma cells in a total volume of 100 µl Hank´s 
Balanced Salt Solution (HBSS). For generation of effector cells, animals were immunized with the 
XCR1-targeted vaccination. In the preventive setting animals were pretreated with the therapeutic 
proteins 24 hours before tumor challenge followed by one therapeutic treatment three days later. 
In the therapeutic setting melanoma cells were allowed to grow in the lungs for nine days after 
intravenous injection. Then mice were treated twice at an interval of 3 days (see figure 8.9 and 
table 8.1). Animals were monitored daily for general health condition. When stopping criterion 
(such as bad health condition, bodyweight loss > 20 %) was reached mice were sacrificed. After 21 
days of metastasis growth animals were sacrificed by cervical dislocation under Isofluran anesthesia 
and lungs were removed for assessment of metastasis burden or confirmation of stable target 
expression in tumor cells with immunohistochemistry (IHC) staining of FAP.   
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7.3.3.2 Subcutaneous tumor model 
Mice were anesthetized with Isofluran and shaved on the right flank. After disinfection of the skin 
with alcohol 1x106 FAP-transfected MC38 colorectal cancer cells were injected subcutaneously in a 
total volume of 100 µl PBS. Tumor volume was measured weekly with a caliper. After 2 to 3 weeks 
tumors reached an average volume of 75 mm3 and animals were immunized with the                 
XCR1-targeted vaccination. Finally animals included into the study were selected based on their 
blood level of specific CD8+ T cells and tumor volume. Four different groups were treated five times 
at an interval of 3 days during the CD8+ T cell peak after vaccination (see figure 8.13 and table 8.2). 
Tumor volume and bodyweight were assessed twice weekly during study. Animals were monitored 
daily for general health condition. When stopping criterion (such as bad health condition, 
bodyweight loss > 20 % or tumor diameter > 2.0 cm) was reached mice were sacrificed. Besides 
efficacy evaluation of pMHCI-IgG and TCB treatment, tumors were used for ultramicroscopy, flow 
cytometry and IHC analyses (see chapters 7.3.4.3.3 and 7.4.2 to 7.4.4). 
Formula for calculation of ellipsoid tumor volumes: 
TV = (l · w2)/2 [mm3] 
TV = tumor volume in mm3 
l = length of tumor in mm 
w = width of tumor in mm 
 
7.3.3.3 Treatment with fusion molecules 
After assignment to treatment and control groups animals were treated with compounds or PBS as 
shown in the tables 8.1 and 8.2. Peptide-MHC class I-IgG fusion (pMHCI-IgG) molecules were 
administered in a dosage of 5 mg/kg and T cell bispecific (TCB) antibodies were given with 2 mg/kg. 
All compounds were tested for endotoxin levels before injection (reference value: < 1 EU/ml). 
Therapeutic proteins were diluted with PBS in such a way that they could be injected in a total 
volume of 100 µl into the lateral tail vein of mice. 
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7.3.4 Harvest of sample material 
7.3.4.1 Blood sampling and preparation of blood samples 
Blood samples were taken to determine blood levels of specific CD8+ T cells. For evaluation of              
CD8+ T cell response after vaccination blood was drawn twice weekly from mice over a period of 
three to four weeks. Blood sampling methods were changed for consecutive blood draws. Blood 
taking from the retrobulbar venous plexus was performed only once at every eye at an interval of 
at least two weeks and under Isofluran anesthesia. A non-heparinized glass capillary with an 
external diameter of 0.8 mm was used. Blood sampling from the tail vein and the facial vein was 
conducted without anesthesia. For drawing blood from the tail vein a 27 G needle was employed 
and the facial vein was punctured with a lancet. Maximally 7.5 % of the total blood volume was 
taken weekly, assuming that the total blood volume is about 7 % of bodyweight. When blood 
sampling was performed only once during the whole study (lung metastasis and subcutaneous 
tumor model) up to 10 % of the total blood volume was taken. For final blood drawings mice were 
anesthetized with an intraperitoneal injection of ketamine / xylazine. Thorax was opened and blood 
was drawn with a 25 G needle from the right ventricle of the heart.  
For flow cytometry analysis 50 to 100 µl blood were collected in heparinized Microvette tubes 
(Sarstedt) and diluted with 50 µl PBS. Next lysis of blood was performed with 1 ml of 1x RBC Lysis 
Buffer (BioLegend) for 15 minutes at room temperature. After blood lysis erythrocytes were 
destroyed and only leukocytes remained. To remove cell debris after blood lysis, white blood cells 
were washed twice with Cell Staining Buffer (BioLegend) and could be used for flow cytometry 
afterwards (see chapters 7.4.2.2 and 7.4.2.3). 
 
7.3.4.2 Harvest of organs and tissue 
For harvesting of organs and tissue animals were sacrificed by cervical dislocation, CO2 exposure or 
euthanasia by exsanguination under anesthesia.  
7.3.4.2.1 Harvest and processing of spleens 
Spleens were taken out for flow cytometry analysis of specific CD8+ T cells, for preparation of 
peptide-loaded splenocytes applied during vaccination and for the use in in vitro assays. Organs 
were placed into ice cold PBS up to further processing and then mashed through a 70 µm cell 
strainer with the plunge of a syringe. After rinsing the mesh with PBS cell suspension was 
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centrifuged at 380 x g for 8 minutes at room temperature. The splenocyte pellet was resuspended 
in 5 ml of 1x RBC Lysis Buffer (BioLegend) for lysis of erythrocytes. After 5 minutes of incubation on 
ice lysis was stopped by addition of 30 ml PBS and the cell suspension was filtered again through a 
70 µm cell strainer and centrifuged. For flow cytometry analysis splenocytes were resuspended in 
an appropriate volume of Cell Staining Buffer (BioLegend). For loading of splenocytes with peptide 
the cell pellet was resuspended in R10F+/ß-Me medium (see table 6.2) and for the use in in vitro 
assays splenocytes were resuspended in CTS AIM-V Medium (Life Technologies). 
 
7.3.4.2.2 Harvest and processing of lungs 
After 21 days of metastasis growth lungs were taken out for assessment of metastasis burden and 
IHC analysis. After opening of thorax lungs were taken out properly and placed into RNA later 
(Qiagen). Then visible metastases were counted by two different experimenters under a binocular 
microscope. Afterwards RNA was prepared from lung tissue for qPCR (see chapter 7.4.1). For IHC 
analyses lungs were placed into Richard-Allan Scientific NEG 50 Frozen Section Medium (Thermo 
Scientific) on dry ice and then stored at -80°C until preparation of sections (see chapter 7.4.3). 
 
7.3.4.2.3 Harvest and processing of tumors 
In the subcutaneous tumor model tumors were excised and used for flow cytometry, 
ultramicroscopy and IHC analyses. For flow cytometry analysis tumors were harvested 48 hours 
after the second treatment for characterization of T cells present in the tumor or 31 days after the 
last treatment for detection of PD-L1 expression of tumor cells. Tumors were cut into small pieces 
and digested in 5 ml RPMI (-) with 1 mg/ml Dispase (StemCell Technologies), 0.8 mg/ml Collagenase 
D (Roche) and 0.01 mg/ml DNase (StemCell Technologies). After 20 minutes of incubation under 
rotation in a humidified incubator at 37°C supplied with 5% CO2, the digest was transferred over a 
70 µm cell strainer by gently pressing the tumor pieces through the mesh with the plunge of a 
syringe. The mesh was rinsed with PBS and the tumor cell suspension was then centrifuged at      
300 x g for 5 minutes at room temperature. After centrifugation the cell pellet was resuspended in 
an appropriate volume of Cell Staining Buffer (BioLegend) for flow cytometry analysis (see chapter 
7.4.2). For IHC analyses of stable target expression of tumor cells, tumors were excised 18 days 
after the last treatment. For IHC staining of CD8+ T cells recruited into the tumor, tumors were 
harvested 24 hours after the first treatment. After excision tumors were put immediately in liquid 
        Methods 61 
 
nitrogen and then stored at -80°C until preparation of sections (see chapter 7.4.3). Explanting of 
tumors for ultramicroscopy analysis is described in chapter 7.4.4.1. 
 
7.3.4.2.4 Harvest and processing of bone marrow 
For generation of peptide-loaded DCs bone marrow from femur and tibia of mice was isolated. 
Therefore animals’ fur was disinfected with 70 % ethanol and bones were prepared as clean as 
possible. Both hind limbs were cut off by cutting through the hip joint and placed into sterile PBS. 
Special care was taken not to open the bone cavity. Bones were washed with ethanol and placed in 
a new petri dish containing sterile PBS. Remnants of muscle tissue were removed by rubbing the 
bones in gauze. Then femur and tibia were separated by cutting through the knee joint. After 
another disinfection step with ethanol, single bones were placed in a new petri dish with sterile 
PBS. Then each bone was cut at both ends and the bone cavity was flushed with medium (see table 
6.2) using a 27 G needle. Bone marrow of two femurs and two tibias each was collected in one tube 
and centrifuged at 400 x g for 4 minutes at room temperature. The cell pellet was resuspended in   
6 ml of 1x RBC lysis buffer (BioLegend) and incubated at room temperature for two minutes to lyse 
erythrocytes. Reaction was stopped by filling up to 50 ml with sterile PBS and bone marrow cell 
suspension was filtered through a 70 µm cell strainer by mashing the cells through the sieve using 
the plunge of a syringe. After a second centrifugation step bone marrow cells were resuspended in 
medium (see table 6.2) supplemented with 0.05 µg/ml GM-CSF and cultivated in non-tissue culture 
treated 6-well-plates to differentiate into DCs. 
 
7.4 EX VIVO PROCEDURES 
7.4.1 Quantitative real-time polymerase chain reaction for evaluation of lung 
metastasis burden 
Quantitative real-time polymerase chain reaction (qPCR) for quantification of tyrosinase-related 
protein 2 (TRP-2) expression in lungs was performed according to a modified protocol from 
Sorensen et al. [109]. 
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7.4.1.1 RNA isolation 
RNA isolation from lungs was performed with the MagNA Pure LC RNA Isolation Kit III (Roche). 
Harvested lungs were fixed in RNA later (Qiagen) until processing. For tissue disruption and 
homogenization lungs were transferred to Lysing Matrix Tubes (MP Biomedicals) containing garnet 
matrix and a ceramic sphere and 1 ml Tissue Lysis Buffer (bottle 8) was added. Then tubes were 
placed into the FastPrep 24 homogenizer and 2 cycles of tissue disruption and homogenization 
were carried out at 6.5 M/S for 2 x 50 seconds. After every run samples were put on ice for a few 
minutes to avoid degradation of RNA by heat stress. After incubation for 30 minutes at room 
temperature samples were centrifuged at room temperature for 3 minutes at 13 000 x g and 350 µl 
of the lysate supernatant were used for RNA isolation with the MagNA Pure LC 1.0 instrument. 
Therefore all reagents provided with the kit (bottle 1 to 7) were filled into the reagent tubs in an 
appropriate volume as listed in the information screen of the instrument. Then RNA isolation 
procedure was started. In the first step Binding Buffer (bottle 3) and Proteinase K (bottle 6a 
reconstituted with buffer from bottle 6b) are added to the samples for complete cell lysis, digestion 
of proteins and release of RNA. Then Magnetic Glass Particles (bottle 5) are added and RNA binds 
to the silica surface of the particles. By incubation with DNase I (bottle 4a reconstituted with buffer 
from bottle 4b) genomic DNA is removed. Magnetic Glass Particles with bound RNA are 
magnetically separated from the residual lysed sample and washed with Wash Buffer I (bottle 1) 
several times to purify RNA from unbound substances. Then a second wash step is carried out with 
Wash Buffer II (bottle 2) to remove residual salts and cellular debris. Finally purified RNA is eluted 
from the Magnetic Glass Particles with 50 µl Elution Buffer (bottle 7). The whole procedure is run 
and monitored by the MagNA Pure LC Software V3.0. After isolation of RNA, concentration was 
determined with a spectral photometer and adjusted to 25 ng/µl with PCR-grade water. 
 
7.4.1.2 Reverse transcription of RNA 
For synthesis of first-strand complementary DNA (cDNA) from RNA the iScript Select cDNA Synthesis 
Kit (Bio-Rad) was used. 200 ng of RNA were mixed with following components of the kit and 
incubated in the Veriti 96 Well Thermal Cycler (Applied Biosystems) as follows: 
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Component: Volume (µl):  Temperature: Incubation time: 
RNA sample (25 ng/µl) 8  25°C 5 min. 
5x iScript select reaction mix 4  42°C 30 min. 
Random primer 2  85°C 5 min. 
iScript reverse transcriptase 1  Table 7.4: Reverse transcription protocol 
Nuclease-free water 5    
Total: 20    
Table 7.5: Reverse transcription reaction mix 
 
Using this method about 1 µg/µl cDNA was yielded. One-tenth (2 µl) of the reaction volume was 
used for quantitative real-time polymerase chain reaction. 
 
7.4.1.3 Quantitative real-time polymerase chain reaction (qPCR) 
For qPCR the LightCycler FastSart DNA Master SYBR Green I Kit (Roche) and the LightCycler 
Carousel-Based System (Roche) was used. PCR primers for TRP-2 (tyrosinase-related protein 2) and 
GAPDH (glycerinaldehyd-3-phosphat-dehydrogenase) were purchased from Metabion and 
reconstituted with PCR-grade water to 200 µM. The melanocyte-specific gene TRP-2 was used as 
target gene and the housekeeping gene GAPDH served as reference gene. Tyrosinase-related 
protein 2 is involved in the synthesis of melanin and therefore specifically expressed in 
melanocytes. The detection of melanocyte-specific cDNA, or mRNA (messenger ribonucleic acid) 
respectively, encoding TRP-2 in lung tissue indicates the presence of B16-muFAP melanoma cells in 
the lung. During qPCR the desired PCR products are amplified and detected by measurement of a 
fluorescence signal. The fluorescent dye SYBR Green I intercalates into double stranded DNA. If 
SYBR Green I is in solution, it exhibits only very little fluorescence. Bound to DNA its fluorescence is 
greatly enhanced. Therefore the amount of intercalated dye is directly proportional to the amount 
of PCR product generated during PCR. 2 µg of cDNA produced by reverse transcription as described 
above were used as template for quantitative real time PCR. LightCycler FastStart DNA Master SYBR 
Green I (10x conc.) was prepared by pipetting 10 µl from vial 1a (LightCycler FastStart Enzyme) into 
one vial 1b (LightCycler FastStart Reaction Mix SYBR Green I, 10 x conc.) containing FastSart Taq 
DNA Polymerase, reaction buffer, dNTP mix, SYBR Green I dye and 10 mM MgCl2. Total MgCl2 
concentration in the reaction mix was raised to 1.5 mM by adding additional MgCl2 to ensure 
specific and efficient amplification of target DNA. Primer stock solutions (200 µM) were diluted 1:40 
to 5 µM with PCR-grade water prior to use. All solutions were prepared and stored on ice during 
procedure and mixed gently by pipetting up and down before use. Components were mixed 
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together in pre-cooled LightCycler Capillaries as described in table 7.6 below. Then capillaries were 
put into the LightCycler Sample Carousel, centrifuged with the LC Carousel Centrifuge and 
transferred into the LightCycler instrument for qPCR applying the following protocol (see table 7.7): 
Component: Volume (µl):  Segment:  Temperature: Time: Cycles: 
cDNA sample (1 µg/µl) 2  Pre-Incubation 
LightCycler FastStart 
DNA Master SYBR  
Green I (10x conc.) 
2  Enzyme activation 95°C 5 min. 1 
 Amplification 
 Denaturation 95°C 1 sec.  
50 MgCl2 (25 nM) 0.4  Annealing 58°C 9 sec. 
Primer sense (5 µM) 2  Elongation 72°C 9 sec. 
Primer antisense (5 µM) 2  Melting Curve 
PCR-grade water 11.6  Denaturation 95°C 0 sec.  
1 Total: 20  Annealing 65°C 15 sec. 
Table 7.6: qPCR reaction mix   Melting 97°C 0 sec. 
   Cooling 
   Cooling 40°C 30 sec. 1 
   Table 7.7: qPCR protocol 
 
   
For confirmation of specificity of PCR product a melting curve was applied. qPCR was monitored 
and recorded with the LightCycler Software 3.5. 
 
7.4.1.4 Evaluation of qPCR 
For relative quantification of gene expression the crossing point (CP) values of samples were used. 
The CP values correspond to the number of PCR cycles needed for reaching a defined fluorescence 
signal. The more cycles are required to reach the defined fluorescence signal, the less amount of 
cDNA, or mRNA respectively, encoding the target gene was present in the sample at the beginning 
of PCR. Using relative quantification, not the absolute copy number of the target gene was defined, 
but the expression of the target gene was referred to a second gene, which is expressed 
ubiquitously and homogenously. In this case expression of the target gene TRP-2 was normalized to 
expression of the housekeeping gene GAPDH. As TRP-2 is specifically expressed in melanocytes, 
detection of cDNA, or mRNA respectively, encoding TRP-2 in lung tissue indicates the presence of 
B16-muFAP melanoma cells in lungs. By relative quantification of TRP-2 expression, metastasis 
burden in treatment and control groups can be quantified and compared, assuming that TRP-2 was 
expressed equally in treatment and control groups. All lung samples were measured as duplicates 
and the average value of CP was applied for relative quantification. As control samples lungs from 
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naïve mice were used. Relative expression of TRP-2 was calculated with the following formula 
[110]: 
Normalized TRP-2 expression = 2-ΔΔCP 
ΔΔCP = ΔCPsample – ΔCPcontrol 
ΔCP = CPTRP-2 – CPGAPDH 
 
7.4.2 Flow cytometry analyses 
7.4.2.1 Settings of flow cytometry 
Flow cytometry analyses were carried out with the MACSQuant Analyzer 10 (Miltenyi Biotec). The 
device is equipped with three lasers: A violet one (405 nm) with two filters (450/50 nm and 525/50 
nm), a blue one (488 nm) with four filters (525/50 nm, 585/40 nm, 655-730 nm and 750 nm LP) and 
a red one (635 nm) with two filters (655-730 nm and 750 nm LP). Consequently eight fluorescent 
channels and the forward scatter for size of cells as well as the side scatter for granularity of cells 
can be used for multi-color flow cytometry analysis. Cell surface antigens and intracellular antigens 
of cells can be detected by fluorescent dye-labeled antibodies binding to the antigen. For analysis 
the cell suspension is carried by a sheath fluid, which singularizes the cells and aligns them so that 
they pass the laser stream one after another. Thus every single cell can be analyzed by size and 
granularity as well as fluorescent pattern. For evaluation of flow cytometry analysis cells can be 
categorized into different populations according to their characters. Therefore the FlowJo Software 
(TreeStar) was used. Categorization into positive or negative populations was performed by 
reference to isotype controls of specific antibodies. 
 
7.4.2.2 Preparation of samples for flow cytometry 
For flow cytometry analyses a single cell suspension was generated and cells were adjusted to         
1 x 106 cells/well. After a wash step with Cell Staining Buffer (BioLegend), cells were resuspended in 
100 µl Cell Staining Buffer containing 1.0 µg of TruStain fcX antibody (BioLegend) and incubated on 
ice for 5 to 10 minutes. This procedure was carried out for blockage of Fcγ receptors IIa and III 
(CD32 and CD16) on the cell surface to avoid antigen independent binding of detection antibodies 
to Fc-receptors. After Fc-receptor block, fluorescent dye-conjugated detection antibodies or 
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purified primary antibodies (if a secondary antibody staining is necessary) were added at 
concentrations according to the manufacturer’s instructions. Cells were incubated on ice in the 
dark for 20 minutes. If specific CD8+ T cells should be detected, cells were pre-incubated with 10 µl 
of the appropriate Dextramer (Immudex) for 10 minutes at room temperature in the dark prior to 
cell surface staining with antibodies. After incubation cells were washed with 1 ml Cell Staining 
Buffer and centrifuged at 300 x g for 5 minutes at 4°C. If a purified primary antibody was used, cells 
were resuspended in 100 µl Cell Staining Buffer containing the appropriate amount of 
fluorochrome-conjugated secondary antibody, incubated on ice in the dark for 20 minutes and 
washed again with 1 ml Cell Staining Buffer. After washing cells were resuspended in 100 µl Cell 
Staining Buffer and analyzed with the flow cytometer. For exclusion of dead cells DAPI                 
(4′,6-diamidin-2-phenylindol), which binds to double stranded DNA in the nucleus and is therefore 
suitable for staining of dead cells, was used at a final concentration of 0.02 µg/ml. As DAPI 
penetration into the nucleus is time dependent and after longer time periods even live cells can be 
DAPI-positive, every sample on the 96-well-plate was incubated with DAPI for only a few minutes 
prior to measurement. This was accomplished by automated DAPI-labelling of every sample by the 
MACSQuant Analyzer 10 prior to measurement.  
If an intracellular target should be detected, cells were fixed and permeabilized with 1x Fixation 
Buffer (BioLegend) and 1x Intracellular Staining Perm Wash Buffer (BioLegend) after cell surface 
antigen staining. Then intracellular staining was performed with a fluorophore-conjugated antibody 
binding to the intracellular target. Cells were incubated at room temperature for 20 minutes in the 
dark and then washed two times with 1 ml of 1x Intracellular Staining Perm Wash Buffer. Finally 
cells were resuspended in 100 µl Cell Staining Buffer and analyzed with the flow cytometer. Using 
an intracellular staining no exclusion of dead cells was performed. 
 
7.4.2.3 Detection, quantification and characterization of specific CD8+ T cells 
For detection and quantification of specific CD8+ T cells in blood, spleen and tumors, cells were pre-
stained with the appropriate Dextramer (OVA257-264: “SIINFEKL” on H-2K
b or MCMV m38: 
“SSPPMFRV” on H-2Kb) and afterwards labelled with fluorochrome-conjugated antibodies specific 
for murine CD8a, CD4, CD3ε and CD45. To characterize the phenotype of specific T cells 
fluorochrome-conjugated antibodies directed against murine PD-1, CD44, CD62L, CD127, CD25 and 
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FoxP3 were used in different combinations. For staining of FoxP3 an intracellular staining was 
performed. 
 
7.4.2.4 Confirmation of peptide-loading of cells 
For confirmation of peptide-loading of bone marrow-derived DCs, splenocytes or tumor cells a 
commercially available fluorochrome-conjugated antibody recognizing the peptide “SIINFEKL” on   
H-2Kb was used. As only for this combination of peptide and MHC class I complex a detection 
antibody is available, the MCMV-derived m38 peptide “SSPPMFRV” on H-2Kb could not be checked 
for proper loading. In the case of bone marrow-derived DCs a costaining with fluorochrome-
conjugated antibodies detecting murine CD40, CD80, CD86, I-A/I-E and CD11c was performed to 
determine activation status of DCs. 
 
7.4.2.5 IFN-γ activation of CD8+ T cells 
For analysis of in vitro IFN-γ activation of CD8+ T cells an intracellular staining for IFN-γ of 
splenocytes applied in the activation assay was performed. Prior to the intracellular staining 
splenocytes were stained with fluorochrome-conjugated antibodies recognizing murine CD8a, CD4, 
CD3ε and CD45. 
 
7.4.2.6 Internalization and binding of fusion molecules to the target FAP 
For analysis of binding and internalization of peptide-MHC class I-IgG fusion proteins on the cell 
surface of tumor cell lines, a staining with secondary antibodies was carried out. Therefore tumor 
cell lines B16-muFAP and MC38-muFAP were pre-incubated with fusion molecules functioning as 
primary antibodies at different concentrations. For confirmation of molecule binding, incubation 
was carried out for 1 hour at 4°C at a cell density of 2 x 106 cells/ml. To check internalization of 
molecules, tumor cells were coincubated with the fusion molecules for 1, 6 or 24 hours at 4°C or 
37°C at a cell density of 2 x 106 cells/ml. After incubation cells were washed two times with 1 ml Cell 
Staining Buffer and incubated with a FITC-conjugated secondary antibody against murine IgG2c to 
detect the antibody part of the fusion molecule and an APC-conjugated secondary antibody 
recognizing H-2Kb to detect the MHC class I complex of the fusion molecule. At least in the case of 
the OVA257-264-H-2K
b-IgG fusion protein the APC-conjugated antibody recognizing “SIINFEKL” on       
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H-2Kb could be used to detect the peptide-MHC class I part of the fusion construct on the cell 
surface. “SIINFEKL” peptide-loaded tumor cells served as a positive control. 
 
7.4.2.7 Confirmation of binding of fusion molecules after labelling 
In order to confirm that peptide-MHC class I-IgG fusion proteins still bind to their target FAP on the 
cell surface of tumor cell lines after in house Alexa 647-conjugation for ultramicroscopy, flow 
cytometry was applied. MC38-muFAP tumor cells were incubated with Alexa 647-labeled fusion 
molecules at a concentration of 2.0 µg/ml for 1 hour at 4°C at a cell density of 2 x 106 cells/ml. Then 
cells were washed with 1 ml Cell Staining Buffer and analyzed with the flow cytometer. In the 
channel detecting APC (red laser [635 nm], 655-730nm filter) cells carrying the Alexa 647-
conjugated fusion molecule could be detected. 
 
7.4.2.8 Detection of PD-L1 expression in tumors 
For detection of PD-L1 upregulation in tumors, cells of digested tumors were stained with 
fluorochrome-conjugated antibodies specific for murine CD45 and PD-L1. 
 
7.4.3 Immunohistochemistry 
7.4.3.1 Sample preparation 
Frozen tumors or lungs embedded in Richard-Allan Scientific NEG 50 Frozen Section Medium 
(Thermo Scientific) were used for immunohistochemical analysis. Therefore 10 to 14 µm frozen 
sections of tissues were prepared using a pre-cooled cryostat. Before sectioning, tissue stored at     
-80°C was equilibrated to -20°C for approximately 15 minutes to prevent cracking of the tissue 
block while cutting. Then frozen sections were cut and mounted to adhesive glass slides. After 
drying of sections for a few minutes at room temperature, slides were stored at -80°C or directly 
used for staining.  
First tissue was fixed for 10 minutes in 4 % paraformaldehyde (PFA) containing 5 mM sucrose at 
room temperature. Then slides were washed twice with deionized water for five minutes. 
Afterwards samples were blocked with Protein Block Serum-Free (Dako) for 10 minutes to avoid 
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non-specific binding of detection antibodies. After blocking of reactive sites, staining with detection 
antibodies was performed.  
 
7.4.3.2 Target expression of tumor cells in vivo 
To confirm maintenance of target expression of tumor cells in subcutaneous tumors and lung 
metastasis in vivo, IHC was applied. Sections of tumors and lung tissue containing metastases were 
stained with an antibody detecting the target FAP. Therefore the antibody 28H1sf W(3a) (Roche 
Glycart), which is directly labeled with Alexa 647, was applied to the tissue section slides in a 
dilution of 1:900 for 60 minutes (see table 6.8 for concentration of antibody stock solution). 
Afterwards slides were washed two times with TBST for two minutes. After sealing of slides by 
mounting a coverslip with ProLong Gold antifade reagent with DAPI (Life Technologies), samples 
could be evaluated under the fluorescent microscope. 
 
7.4.3.3 Quantification of CD8+ T cells in the tumor 
For illustration and quantification of CD8+ T cell recruitment into the tumor after treatment, tumor 
sections were stained with an antibody specific for CD8a. Therefore slides were incubated with an 
unlabeled polyclonal rabbit anti-mouse CD8a antibody (Synaptic Systems) for 60 minutes at a 
dilution of 1:200 (see table 6.8 for concentration of antibody stock solution). Slides were washed 
three times with TBST for two minutes and then incubated with a secondary antibody. An          
Alexa 488-labelled goat anti-rabbit antibody (Invitrogen) was applied for 30 minutes in a dilution of 
1:400 (see table 6.9 for concentration of antibody stock solution). After washing of slides with TBST 
for two minutes for three times, slides were mounted with a coverslip with ProLong Gold antifade 
reagent with DAPI (Life Technologies) and finally evaluated under the fluorescent microscope. For 
quantification of CD8+ T cells present in the tumor, the average signal for each slide was quantified 
as positive stained area per five randomly selected tumor areas of 2 000 x 1 000 µm by automated 
analysis with the Image Intensity Threshold Tool (Roche).  
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7.4.4 Ultramicroscopy 
7.4.4.1 Treatment of animals and processing of tumors 
To analyze molecule penetration into solid subcutaneous tumors fluorescence ultramicroscopy was 
applied as described in Dobosz et al. [111]. Mice were injected intravenously into the lateral tail 
vein with Alexa 647-labelled MCMV m38-MHCI-IgG fusion protein (5 mg/kg) in a volume of 100 µl 
PBS. Alexa 647-labelling of fusion molecules was carried out by the department for Protein 
Chemistry (Roche Diagnostics GmbH). Prior to injection Alexa 647-labeled fusion proteins were 
checked for maintenance of binding capacity by flow cytometry analysis (see chapter 7.2.4.7).               
12, 24 or 48 hours after administration of Alexa 647-labeled molecules, animals were injected 
intravenously with Alexa 750-labeled Bandeiraea simplicifolia lectin (4 mg/kg) in a total volume of 
100 µl PBS to stain vessels. After five minutes of lectin circulation mice were sacrificed. Tumors 
were explanted immediately and incubated overnight in 4% PFA at room temperature in the dark. 
Afterwards tumors were dehydrated in a graded ethanol series (3 x 70 %, 2 x 95 % and 2 x 100 % for 
30 minutes each) using the Tissue-Tek VIP Vacuum Infiltration Processor (Sakura Finetek) and 
placed into a clearing solution consisting of one volume part benzylalcohol and two volume parts 
benzylbenzoate. After incubation for two days at 4°C in the dark the specimen became optically 
transparent and tumors could be scanned with the ultra-microscope.  
 
7.4.4.2 Acquisition and quantification of labelled molecule in the tumors 
Optically transparent tumors with a diameter up to 5 mm were analyzed with the ultramicroscope 
MVX10 Fluoreszenz MacroZoom (OLYMPUS CORPORATION), which is equipped with a 3QE Kamera 
(LaVision BioTec). A magnification of x0.63 in combination with a x2 objective lens was applied. This 
resulted in a final xy resolution of 5.1 µm, to which step size was adjusted. Tumors were scanned 
with the integrated SuperK EXTREME supercontinuum white light laser (NKT Photonics A/S), which 
is able to excite every fluorophore used in this experiment. First autofluorescence of tissue was 
measured to illustrate tumor morphology (excitation range: 543/22 nm; emission range:              
593/40 nm; Exposure time per slice: 300 ms). Then Alexa 647 (excitation range: 655/15 nm; 
emission range: 680/30 nm; Exposure time per slice: 200 ms) and Alexa 750 (excitation range: 
747/33 nm; emission range: 786/22 nm; Exposure time per slice: 500 ms) signals were measured to 
assess molecule penetration into the tumor and visualize vessels. Depending on tumor size 
acquisition took about 1 to 1.5 hours. During acquisition a tagged image file format (TIFF) is created 
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for every slice. Those were converted into Digital Imaging and Communications in Medicine 
(DICOM) files and visualized with the OsiriX Software (Pixmeo) for further editing. After processing 
of images with the software to exclude minimal residual fat tissue or other components not 
belonging to the tumor, data sets of each tumor were quantified with a set of custom-developed 
image analysis algorithms to define molecule penetration into the tumor and vascularization. 
 
7.4.4.3 Immunohistochemistry of ultramicroscopy samples 
Following 3D scanning with the ultramicroscope tumor samples were shortly incubated first in    
100 % xylene to remove clearing solution and then in paraffin (3 x 1 hour). Tumors were embedded 
in paraffin blocks and tissue slices with a thickness of 2 µm were cut randomly from the middle of 
the tumors and mounted to glass slides. Sections were incubated at 37°C overnight and then stored 
at 4°C until further processing. After deparaffination and rehydration (xylene: 3 x 5 minutes, 
ethanol series two minutes each: 2 x 100 %, 1 x 90 %, 1 x 80 %, 2 x 70 %, deionized water: 2 x 20 
seconds) of tissue sections using the Tissue-Tek VIP Vacuum Infiltration Processor (Sakura Finetek), 
slides were sealed by mounting a coverslip with ProLong Gold antifade reagent with DAPI (Life 
Technologies). Then slides were scanned with the Fluorescence scanner Pannoramic 250 Flash III 
(3D Histech), detecting Alexa 647, Alexa 750 and DAPI signals, and fluorescent images from sections 
were taken. 
 
7.5 IN VITRO PROCEDURES 
7.5.1 Cytotoxicity analysis 
7.5.1.1 xCELLigence assay 
For in vitro cytotoxicity analysis the xCELLigence system (Roche) was applied. The system is based 
on measurement of electrical impedance. For this purpose interdigitated microelectrodes are 
integrated on the bottom of special flat bottom E-Plate 96 well-plates (ACEA Biosciences) used for 
the assay. If contact between electrodes and medium is isolated by the cell layer of adherent cells 
on the well bottom, electrical impedance is high. When cells die, contact between electrodes and 
medium rises and therefore electrical impedance is reduced. The xCELLigence system measures 
electrical impedance every 5 to 15 minutes according to the settings. In this way cell growth or 
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elimination of cells can be displayed as variation of electrical impedance over time. For growing 
phase of tumor cells after inoculation into the plate, cell culture medium was used. During 
cytotoxicity assay serum free CTS AIM-V Medium (Gibco by Life Technologies) was applied to avoid 
loading of effector cells with foreign antigen from serum and potential mutual killing. 
 
7.5.1.2 Evaluation of cytotoxicity mediated by fusion molecules in the xCELLigence 
system 
At the beginning 50 µl of cell culture medium was added to the wells and background 
measurement was performed. Then 20 000 adherent MC38-muFAP tumor cells in a volume of 50 µl 
cell culture medium were added per well. One day after cell inoculation medium was changed. 
Another 24 hours later, when cell index exceeded 1, the assay was started. First of all tumor cells in 
the positive control wells were loaded with peptide. Therefore medium was removed from the 
wells and 100 µl cell culture medium containing peptide in different concentrations was added. 
After one to two hours in the incubator at 37°C peptide-loaded tumor cells were washed with      
100 µl CTS AIM-V Medium. Then all wells were washed with 180 µl CTS AIM-V Medium and 50 µl 
CTS AIM-V Medium was pipetted in each well. Afterwards 50 µl CTS AIM-V Medium containing 
effector molecules in different concentrations (pMHCI-IgG fusion proteins or TCB antibodies) were 
administered. Then 50 µl CTS AIM-V Medium with 300 000 freshly isolated splenocytes from 
vaccinated mice were added. Splenocytes from vaccinated mice varied in their percentage of 
specific CD8+ T cells from 2.5 to 3.0 % (percentage of all lymphocytes), so that effector cell:target 
cell ratio was about 0.25:1 (specific CD8+ T cells:tumor cells). Control wells containing peptide-
loaded tumor cells or tumor cells without effector molecules and/or effector cells were filled up to 
150 µl with CTS AIM-V Medium. 100 units/ml penicillin and 100 µg/ml streptomycin were added to 
all wells to avoid contamination from animal-derived splenocytes. After 40 to 55 hours of 
incubation under cell culture conditions cytotoxicity was analyzed. For determination of 
spontaneous lysis of tumor cells mediated by splenocytes without effector molecules, wells 
containing only tumor cells and splenocytes were analyzed. Evaluation of specific tumor cell lysis in 
percent was calculated with the following formula: 
Specific tumor cell lysis [%] =  
([cell index spontaneous lysis – cell index sample] / [cell index spontaneous lysis]) x 100 
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7.5.2 IFN-γ activation of CD8+ T cells 
For analysis of in vitro IFN-γ activation of CD8+ T cells normal flat bottom 96-well-plates were 
prepared in the same manner as used for the xCELLigence cytotoxicity assay (see chapter 7.5.1.2). 
However, starting cell number was raised to 30 000 MC38-muFAP tumor cells per well to ensure a 
dense cell layer when starting the assay. In this assay splenocytes from vaccinated mice varied in 
their percentage of specific CD8+ T cells from 5.5 to 13.5 % (percentage of all lymphocytes), so that 
effector cell:target cell ratio was about 0.33 to 1:1 (specific CD8+ T cells:tumor cells). After six hours 
of incubation under cell culture conditions, splenocytes were taken out of the wells, centrifuged, 
resuspended in Cell Staining Buffer (BioLegend) and used for flow cytometry analysis after 
intracellular staining for IFN-γ (see chapter 7.4.2.5). 
 
7.6 STATISTICAL ANALYSES 
All graphs were generated with GraphPad Prism 6 (Graphpad Software, Inc.). For statistical analysis 
the JMP Software (SAS Institute) was used applying the two-sided t-test for significance evaluation 
in the in vitro cytotoxicity analyses and the Wilcoxon-test for significance evaluation in the in vivo 
efficacy analyses. P-values from 0.01 to 0.05 were considered as significant (*), p-values from             
0.001 to < 0.01 were considered as very significant (**) and p-values < 0.001 were considered as 
extremely significant (***).  
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8 RESULTS 
8.1 CHARACTERIZATION OF SURROGATE FUSION MOLECULES AND ANTIBODIES 
For generation of surrogate peptide-MHC class I-IgG fusion proteins, T cell bispecific and anti-XCR1 
antibodies standard expression vectors encoding for amino acid sequences of light chains, heavy 
chains and modified heavy chains were cloned (see appendix for plasmid card and amino acid 
sequences). HEK293-F cells were transiently transfected with expression plasmids and the protein 
secreted into the supernatant was purified by Protein A affinity chromatography. 
8.1.1 Structure of peptide-MHC class I-antibody (pMHCI-IgG) fusion proteins 
8.1.1.1 Design of the molecule and transfection vectors  
For production of surrogate peptide-MHC class I-antibody fusion molecules three expression 
plasmids were cloned. All expression vectors contained a CMV-promoter, Intron A, start codon and 
signal peptide for secretion and BGHpA. The first plasmid [1] encoded for the antibody heavy chain 
with N-terminal fusion of the peptide-MHC class I complex and was about 6400 bp. The second 
vector [2] encoded for the normal antibody heavy chain with approximately 5100 bp and the third 
plasmid [3] for the antibody light chain was about 4400 bp. Vectors were applied at a molar ratio of 
3:2:1 (plasmid [1]:plasmid [2]:plasmid [3]) for transient transfection. Consequently the fusion 
protein consisted of an entire murine IgG antibody, of which one heavy chain was fused to a 
peptide-MHC class I complex (Fig. 8.1 A). The heavy chain fused to the peptide-MHC class I complex 
was composed of following components in N- to C-terminal direction (Fig. 8.1 B): The antigenic 
peptide was fused to the murine beta-2-microglobulin (ß2M) with a GS-linker ([G4S]3). The ß2M was 
linked to the α1 domain of the murine MHC class I complex with a second GS-linker ([G4S]4). The 
murine MHC class I complex lacked the transmembrane domain and ended after the α3 domain. 
The N-terminus of the variable domain (VH) of the antibody heavy chain was fused to the C-
terminus of the α3 domain of the MHC class I complex with a short GS-linker (GS). The variable 
domain is followed by the constant part of the heavy chain consisting of CH1 and the Fc-part of the 
antibody (hinge, CH2 and CH3). The normal heavy chain of the antibody was composed of the 
variable domain (VH) and constant regions CH1, hinge, CH2 and CH3. The antibody light chain 
comprised a variable domain (VL) and a constant domain Cκ.  
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8.1.1.2 Disulfide-stabilization of the peptide-MHC class I complex in the fusion molecule 
The GS-linkers used in the peptide-MHC class I complex linked to the heavy chain consisted of 
[G4S]n sequences. The linkers should have the effect of proper assembling of the MHC class I 
complex, stabilizing the peptide in the groove of the MHC class I complex. This should result in 
higher stability of the entire molecule and higher production yield. Additional stabilization of the 
peptide-MHC class I complex could be achieved by introduction of a disulfide bond connecting the 
linker between peptide and ß2M with the α1 domain of the MHC class I complex. Therefore the 
second glycine in the linker and the tyrosine at position 84 in the MHC class I complex (N- to C-
terminal direction) was mutated to cysteine [1, 112]. 
 
8.1.1.3 Modifications of the molecule for increased harvest of protein 
As surrogate pMHCI-IgG fusions were designed in a hetero-dimerized format only one of the heavy 
chains was fused to a peptide-MHC class I complex and the other one remained unfused. To avoid 
assembling of two unfused heavy chains the knob-into-hole-modification was introduced in the           
Fc-part of the antibody [113]. Therefore defined amino acids in the CH3 domain of the heavy chains 
were mutated, which leads to a structural formation in that region that promotes the assembling of 
unfused heavy chains together with peptide-MHC class I complex fused heavy chains. The hole-
modification was introduced in the peptide-MHC class I complex fused heavy chain. Threonine was 
mutated to serine at position 366 (EU-Index Kabat numbering scheme [114]), methionine to alanine 
at position 368 and tyrosine to valine at position 407. To implement the knob-modification in the 
CH3 domain of the unfused heavy chain threonine was exchanged to tryptophan at position 366. 
For enhanced stabilization of the heterodimer an additional artificial disulfide bond was inserted in 
the CH3 domain of the heavy chains. Therefore tyrosine was mutated to cysteine at position 349 on 
the hole-side and proline was exchanged to cysteine at position 354 on the knob-side. Despite the 
introduction of the knob-into-hole-modification a certain proportion of knob-knob-side products 
can be present after purification. As formats consisting of the normal antibody without peptide-
MHC class I complex should be excluded after purification, another mutation in the CH3 domain of 
the knob-antibody heavy chain (normal antibody heavy chain without peptide-MHC class I complex) 
was implemented. The histidine at position 435 was exchanged to arginine and the leucine at 
position 436 to phenylalanine (HL->RF mutation). The result of this mutation is that the knob-
antibody heavy chain can no longer bind to Protein A. Consequently unwanted knob-knob-side 
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products do not bind to the Protein A column during purification process, while desired knob-hole-
products (antibody fused to one peptide-MHC class I complex) can still bind to the column with the 
hole-antibody heavy chain. Hole-hole-side products (antibody fused to two peptide-MHC class I 
complexes) were expressed so poorly that they were negligible as side product. 
 
8.1.1.4 Introduction of a silent Fc-part 
The constant domain of the antibody fusion molecules was the murine isotype IgG2c. To abrogate 
binding to Fc-gamma receptors (FcγR) and complement components (C1q) modifications in the                      
CH2 domains of the antibody were introduced. At position 270 (Kabat numbering scheme [114]) 
aspartic acid was exchanged to alanine and at position 329 proline was mutated to glycine (DAPG 
mutation). In addition the leucine amino acids at positions 234 and 235 were mutated to alanine 
amino acids (LALA mutation) [115]. The mutations led to loss of binding capacity to FcγRI, FcγRII 
and FcγRIII, whereas FcRn (neonatal Fc-receptor) binding was unchanged. The antibody fusions 
have IgG-like half-life and pharmacokinetic properties. Also binding to C1q was inhibited so that 
CDC and FcγR-mediated co-activation of innate immune effector cells such as ADCC or ADCP were 
prevented. 
 
8.1.1.5 Specifications of the molecules 
The target on the mouse tumor cells was murine FAP (fibroblast activation protein). The 
monoclonal antibody 28H1 was used to target murine FAP. It binds to murine and human FAP with 
high bivalent affinity (muFAP: < 1 pM, huFAP: 268 pM) [116, 117]. The non-binding control 
molecule contained an antibody based on the antibody germline sequence DP47 [118] with a 
modified complementarity-determining region 3 (CDR3). Lack of binding to any murine target 
structure and normal antibody pharmacokinetic properties in vivo were confirmed previous in 
various experiments (Roche unpublished). For the peptide-MHC class I part of the molecule 
peptides of the immunodominant epitopes of the murine Cytomegalovirus (MCMV m38: 
“SSPPMFRV” or MCMV IE3: “RALEYKNL”) or ovalbumin (OVA257-264: “SIINFEKL”) were applied. 
Peptides derived from both MCMV and ovalbumin are presented on the murine MHC class I 
complex H-2Kb so that this MHC class I allotype was chosen for the fusion proteins. 
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Figure 8.1: Schematic illustration of the peptide-MHC class I-IgG fusion molecules. 
(A) pMHCI-IgGs comprise of a full murine monoclonal IgG2c antibody with two binding moieties for the target fibroblast 
activation protein (FAP). The N-terminus of one heavy chain is fused with the murine MHC class I complex H-2K
b
 is via a 
linker. The MHC class I complex carries a covalently fused, antigenic peptide. (B) N- to C-terminal drawing of antibody 
chains: pMHCI fused antibody heavy chain (1): Antigenic peptide (red), Linker 1: (G4S)3 (orange), beta-2-microglobulin 
(dark purple), Linker 2: (G4S)4 (orange), extracellular domain of H-2K
b
 α1-α3 (light purple), Linker 3: GS (orange), variable 
(VH) (green) and constant (CH1) (blue) domain of murine IgG2c antibody heavy chain, hinge (black), effector-function free 
CH2 domain and CH3 domain with hole mutation of IgG2c antibody heavy chain (grey). Unfused antibody heavy chain (2): 
Variable (VH) (green) and constant (CH1) (blue) domain of murine IgG2c antibody heavy chain, hinge (black), effector-
function free CH2 domain and CH3 domain with knob mutation of IgG2c antibody heavy chain (grey). Antibody light chain 
(3): Variable (VL) (green) and constant Ckappa (Cκ) (blue) domain of antibody light chain. 
 
8.1.2 Structure of the T cell bispecific (TCB) antibody 
8.1.2.1 Design and modifications of the molecule 
Basis of the surrogate TCB antibody was the 2+1 format (Fig. 8.2 A). It comprised a full IgG with two 
binding moieties for the target and to the N-terminus of one of the antibody heavy chains a CD3ε-
binding Fab (Fragment antigen binding) was fused. Consequently the molecule could bind bivalently 
to the antibody target on the tumor cell and monovalently to CD3ε on the T cell. The Fc-part of the 
heavy chains was engineered to promote heterodimerization. Proper assembling of light chains was 
forced by introducing a CH1-Cκ crossover in the CD3ε binding Fab in the CrossMAb format [119]. As 
CH1 and CH1 domains as well as Cκ and Cκ are repulsive and only CH1 and Cκ can form a 
heteromeric complex, light chains of CD3ε binding Fab and target binding Fab could only assemble 
to their corresponding part of the heavy chain (Fig. 8.2 B). The antibody was murine IgG1-based and 
the Fc-part was also silenced with the DAPG mutation as described in chapter 8.1.1.4. 
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8.1.2.2 Design of transfection vectors 
To generate the surrogate TCB antibody 4 expression vectors were designed (Fig. 8.2 B). The first 
plasmid [1] was about 4400 bp and encoded for the variable region of the light chain (VL) of the 
CD3ε binding domain followed by the CH1 domain crossed from the heavy chain. The second [2] 
vector encoded for the antibody heavy chain with both CD3ε binding and target binding domain 
and was about 5800 bp. The third vector [3] encoded with about 5100 bp for the normal antibody 
heavy chain containing only the target binding domain (VH-CH1-hinge-CH2-CH3) and the fourth 
plasmid [4] encoded with about 4400 bp for the normal antibody light chain with the variable 
region (VL) of the target binding domain and the constant region (Cκ). The heavy chain containing 
two binding domains (third vector) was composed of following components in N- to C-terminal 
direction: The VH domain binding to CD3ε was followed by the Cκ domain crossed from the light 
chain. Next the VH domain binding to the target followed by the CH1 domain was attached and 
fused to hinge and CH2 and CH3 domain of the Fc-part. For transient transfection of HEK293-F cells 
vectors were applied at a molar ratio of 1:1:1:1. 
 
8.1.2.3 Specifications of the molecule 
The target binding variable domains of the surrogate TCB antibody were derived from the 
monoclonal antibody 28H1 which binds to murine FAP (see chapter 8.1.1.5).The CD3ε binding Fab 
was derived from the monoclonal antibody 145-2C11 and targeted the epsilon chain of murine CD3 
[120]. 
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Figure 8.2: Schematic illustration of the T cell bispecific IgG. 
(A) The T cell bispecific antibody (TCB) consists of a full murine monoclonal IgG1 antibody in a CrossMAb format with two 
binding moieties for the target FAP and one binding site for CD3ε, linked to the N-terminus of one of the heavy chains. (B) 
N- to C-terminal drawing of antibody chains: Antibody light chain with CD3ε binding domain (1): Variable (VL) (dark 
purple) and crossed constant (CH1) (bronze) domain of antibody light chain. Antibody heavy chain with one CD3ε and one 
target binding domain (2): Variable (VH) (dark purple) and crossed constant Ckappa (Cκ) (bronze) domain of the CD3ε 
binding Fab, (G4S)2 linker (orange), variable (VH) (green) and constant (CH1) (blue) domain of the target binding Fab, 
hinge (black), effector-function free CH2 domain and CH3 domain engineered for heterodimerization of IgG1 antibody 
heavy chain (grey). Antibody heavy chain with target binding domain (3): Variable domain (VH) (green) and constant 
domain (CH1) (blue), hinge (black), effector-function free CH2 domain and CH3 domain engineered for 
heterodimerization of IgG1 antibody heavy chain (grey). Antibody light chain with target binding domain (4): Variable (VL) 
(green) and constant Ckappa (Cκ) (blue) domain of antibody light chain. 
 
8.1.3 Structure of the anti-mouse XCR1 antibody 
8.1.3.1 Design of the molecule and transfection vectors 
For generation of the monoclonal murine anti-XCR1 antibody two transfection vectors were cloned 
(Fig. 8.3). The first plasmid [1] encoded with about 5100 bp for the heavy chain of the antibody and 
the second vector [2] encoded for the antibody light chain with about 4400 bp. For transient 
transfection vectors were applied at a molar ratio of 1:2 (plasmid [1]:plasmid [2]). In N- to C-
terminal direction the heavy chain of the antibody was composed of the variable domain (VH) 
followed by constant regions CH1, hinge, CH2 and CH3. The antibody light chain consisted of the 
variable domain (VL) and the constant domain Cκ. A sortase tag was fused to the C-terminus of the 
antibody to have the option to link an antigen to the protein. Therefore the sortase A recognition 
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motif “LPXTG” (amino acid sequence: Leu–Pro-any-Thr-Gly) followed by a poly-histidine–tag was 
added C-terminally to both antibody heavy chains of the molecule. The Fc-part of the antibody was 
the murine isotype IgG2c and lacked effector functions (described in chapter 8.1.1.4). 
 
8.1.3.2 Specification of molecules 
The anti-mouse XCR1 antibody was derived from the monoclonal antibody MARX10 and targeted 
the XCR1 receptor on cross-presenting DCs [121, 122]. 
 
Figure 8.3: Schematic illustration of the sortase-tagged anti-XCR1 antibody. 
(A) The antibody targeting the murine XCR1 receptor consists of a full murine monoclonal IgG2c antibody with two 
binding sites for the target. A sortase tag is fused to the C-terminus of each heavy chain. (B) N- to C-terminal drawing of 
antibody chains: Antibody heavy chain (1): Variable (VH) (green) and constant (CH1) (blue) domain of murine IgG2c 
antibody heavy chain, hinge (black), effector-function free CH2 domain and CH3 domain of IgG2c antibody heavy chain 
(grey), sortase tag (yellow). Antibody light chain (2): Variable (VL) (green) and constant Ckappa (Cκ) (blue) domain of 
antibody light chain. 
 
8.1.4 Yield and purity of recombinant proteins 
After purification by Protein A affinity chromatography yield and purity of molecules was 
determined. Peptide–MHC class I-IgG fusions, which had a molecular weight of about 190 kDa, 
were produced in a yield of 10 to 15 mg/l transfection culture. In some cases production yields up 
to 30 mg/l transfection culture could be achieved. After preparative size-exclusion chromatography 
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aggregates and byproducts could be removed so that the purified protein could be obtained in a 
purity of about 97 %. The surrogate TCB antibody had a molecular weight of about 170 kDa and was 
produced in a yield of about 10 mg/l transfection culture. The normal anti-XCR1 antibody with a 
molecular weight of 150 kDa reached about 100 mg/l transfection culture. After sortase coupling of 
the MCMV m38 peptide to the anti-XCR1 antibody, protein was purified again with poly-histidine-
tag columns to remove non- or single-coupled protein. Thus protein yield was reduced by half, but 
finally 100 % of double-coupled antibody could be obtained. 
 
8.2 IN VITRO EVALUATION OF SURROGATE PEPTIDE–MHC CLASS I-ANTIBODY 
FUSION MOLECULES 
8.2.1 Binding of molecules to their target FAP 
Both the peptide-MHC class I-IgG fusion molecule (pMHCI-IgG) and the T cell bispecific (TCB) 
antibody targeted the murine fibroblast activation protein (FAP). FAP is a 170 kDa membrane-
bound glycoprotein, which is expressed on activated stromal fibroblasts and therefore involved in 
epithelial-mesenchymal interactions during development and tissue repair, but also in epithelial 
carcinogenesis [NCBI Gene ID: 14089]. Binding of the engineered pMHCI-IgG fusion and TCB 
antibody to their target was tested by an extracellular staining of tumor cell lines expressing FAP in 
flow cytometry analysis with a secondary antibody. 
Figure 8.4 A shows the detection of the antibody-part of the pMHCI-IgG molecules on the cell 
surface of B16-muFAP melanoma cells by staining of the Fc-part of the antibody with a secondary 
antibody directed against murine IgG2c. The Fc-part of the TCB antibody was detected with a 
secondary antibody specific for murine IgG1. Binding patterns of both molecules were similar and 
confirmed binding of molecules in a concentration dependent manner. With a molecule 
concentration of 5 nM saturation of FAP binding sites on the tumor cell surface was reached and a 
maximum binding signal could be detected with secondary antibodies. With decreasing compound 
concentrations reduction of the binding signal was found. At a molecule concentration of 0.005 nM 
nearly no binding could be detected anymore. The pMHCI-IgG molecule containing the non-binding 
IgG DP47 showed no binding to tumor cells independent of compound concentration. In figure                
8.4 A binding of molecules to FAP-transfected B16 melanoma cells is exemplarily shown. Same 
results could be found for FAP-transfected MC38 colorectal cancer cells (data not shown).  
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In figure 8.4 B internalization of pMHCI-IgG molecules into MC38-muFAP tumor cells is depicted. 
After one, six and 24 hours same amounts of molecules binding to FAP on the tumor cell surface 
could be detected at 4°C and 37°C. No internalization of pMHCI-IgG molecules could be shown at 
concentrations of 5 and 0.5 nM. The slight shifts of signals after six and 24 hours of incubation at 
37°C at a molecule concentration of 0.5 nM indicate a minimal degree of internalization, which can 
be attributed to the normal turnover of surface proteins. 
In figure 8.4 C the detection of the MHC class I-part of the pMHCI-IgG molecules with a secondary 
antibody against murine H-2Kb is illustrated. Data are shown exemplarily for the B16-muFAP tumor 
cell line, but results also apply for the MC38-muFAP tumor cell line (data not shown). With binding 
of pMHCI-IgG molecules to their target FAP the murine MHC class I complex H-2Kb could be 
delivered to the cell surface of the target cells. The red signals in the histograms show amounts of 
native H-2Kb complexes present on the cell surface of syngeneic tumor cell lines. With binding of 
pMHCI-IgG molecules to tumor cells additional H-2Kb complexes included in the fusion molecules 
were brought onto the cell surface, which is demonstrated by the green signals in the histograms. 
As green signals shift to the left and approach red signals with decreasing compound concentration, 
concentration dependent binding of molecules was confirmed in this experiment. The pMHCI-IgG 
molecule containing the non-binding IgG DP47 did not bring any additional H-2Kb complexes onto 
the cell surface of the target cells indicating that there is no binding of those molecules.  
In figure 8.4 D density of FAP surface proteins and H-2Kb complexes on FAP-transfected B16 
melanoma cells and MC38 colorectal cancer cells are compared. The red signals in histograms show 
that the MC38-muFAP tumor cell line has more native H-2Kb complexes on the cell surface than the 
B16-muFAP tumor cell line. Upon binding of pMHCI-IgG molecules to tumor cells additional H-2Kb 
complexes were delivered onto the cell surface (green signal). The shift of the green signal to the 
right found in the FAP-transfected B16-F10 melanoma cells is bigger than the one detected in FAP-
transfected MC38 colorectal cancer cells, which demonstrates that B16-muFAP tumor cells have 
more FAP binding sites on the cell surface than the MC38-muFAP tumor cells. This is also confirmed 
in figure 8.4 E, where the detection of the OVA257-264 peptide in the pMHCI-IgG molecule binding to 
the cell surface by a specific monoclonal antibody is shown. In this experiment the peptide in the 
groove of the MHC class I complex of the fusion molecule is detected. Such an antibody specific for 
the peptide within the MHC class I complex is only available for the immunodomiant epitope of 
ovalbumin (OVA257-264 “SIINFEKL” in the H-2K
b complex). The light green signals show the native     
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H-2Kb complexes of tumor cells loaded with the Ova-derived peptide “SIINFEKL” and the dark green 
signals show the “SIINFEKL”- H-2Kb complexes delivered to the cell surface exclusively by the 
pMHCI-IgG molecule. This experiment showed again that MC38-muFAP tumor cells have more 
native H-2Kb complexes, but less expression of FAP on the cell surface than B16-muFAP tumor cells. 
 
Figure 8.4: Binding of pMHCI-IgG and TCB molecules and delivery of pMHCI complexes to the tumor cell surface 
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(A) Flow cytometry analysis of binding of pMHCI-IgG and TCB molecules to the target FAP on the cell surface of the tumor 
cell line B16-muFAP at different concentrations (indicated on the left): MCMV m38-MHCI-28H1 (column 1), MCMV IE3-
MHCI-28H1 (column 2), OVA257-264-MHCI-28H1 (column 3), OVA257-264-MHCI-DP47 (column 4) and TCB (column 5). Color 
code: Autofluorescence of cells (blue), isotype control antibody (orange), secondary antibody alone (red), pMHCI-IgG or 
TCB and secondary antibody (light green). (B) Flow cytometry analysis of internalization of pMHCI-IgG molecules into 
MC38-muFAP cells at 4°C (left column) or 37°C (right column) at different concentrations (indicated on the left). Color 
code: Autofluorescence of cells (blue), secondary antibody alone (red), secondary antibody after one hour of incubation 
with pMHCI-IgGs (orange), secondary antibody after six hours of incubation with pMHCI-IgGs (light green), secondary 
antibody after 24 hours of incubation with pMHCI-IgGs (dark green). (C) Flow cytometry analysis of delivery of pMHCI 
complexes to the cell surface of B16-muFAP cells with pMHCI-IgG molecules at different concentrations (indicated on the 
left): MCMV m38-MHCI-28H1 (column 1), MCMV IE3-MHCI-28H1 (column 2), OVA257-264-MHCI-28H1 (column 3) and 
OVA257-264-MHCI-DP47 (column 4). Color code: Autofluorescence of cells (blue), isotype control antibody (orange), 
secondary antibody alone (red), pMHCI-IgG and secondary antibody (light green). (D) Flow cytometry analysis of FAP and 
H-2K
b
 density on the cell surface of B16-muFAP (left column) and MC38-muFAP (right column) cells. Color code: 
Autofluorescence of cells (blue), isotype control antibody (orange), secondary antibody alone (red), pMHCI-IgG and 
secondary antibody (light green). (E) Flow cytometry analysis of OVA257-264-H-2K
b
 delivery to B16-muFAP (left column) and 
MC38-muFAP (right column) cells. Color code: Autofluorescence of cells (blue), isotype control antibody (orange), 
secondary antibody alone (red), peptide-loaded tumor cells and secondary antibody (light green), pMHCI-IgG and 
secondary antibody (dark green). 
 
8.2.2 In vitro IFN-γ activation of CD8+ T cells mediated by compounds 
The biological activity of pMHCI-IgG fusions and the TCB antibody was tested in vitro in an IFN-γ 
activation assay. FAP-transfected MC38 colorectal cancer cells were coincubated with splenocytes 
from MCMV m38- or OVA257-264-vaccinated mice in the presence of effector molecules at various 
concentrations. After six hours of incubation splenocytes were analyzed with flow cytometry for 
IFN-γ production. 
Splenocytes applied in the IFN-γ activation assay contained about 60 % lymphocytes, of which 25 to 
33 % of lymphocytes were CD3+ T cells. Splenocytes from mice vaccinated for MCMV m38 included 
13.5 % MCMV m38-specific CD8+ T cells out of all lymphocytes, which represented 62 % of MCMV 
m38-specific CD8+ T cells out of all CD8+ T cells. Splenocytes from mice vaccinated for OVA257-264 
contained 5.5 % OVA257-264-specific CD8
+ T cells out of all lymphocytes, which represented 42 % of 
OVA257-264-specific CD8
+ T cells out of all CD8+ T cells. The TCB antibody activates effector cells via 
CD3 and the pMHCI-IgG molecule via peptide-MHC class I / T cell receptor interactions. In this 
respect 100 % of CD8+ T cells could theoretically be activated by the TCB. 62 % for MCMV m38 and 
42 % for OVA257-264 of CD8
+ T cells could theoretically be activated by pMHCI-IgG molecules. 
Figure 8.5 A shows the percentage of CD8+ T cells activated by effector molecules in different 
concentrations when splenocytes derived from MCMV m38-vaccinated mice were used. With the 
TCB antibody (Fig. 8.5 A green) 4.9 % of CD8+ T cells could be activated at a compound 
concentration of 0.1 nM. At a compound concentration of 1 nM, when nearly all FAP molecules on 
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the tumor cell surface are covered with a TCB molecule, 10.3 % of CD8+ T cells produced IFN-γ. With 
rising concentrations of the TCB antibody IFN-γ activation of CD8+ T cells slightly decreased to 7.5 % 
activated CD8+ T cells at a molecule concentration of 100 nM. The pMHCI-IgG molecule (Fig. 8.5 A 
red) could mediate activation of 2.5 % of CD8+ T cells at a compound concentration of 0.1 nM. At 
molecule concentrations ranging from 1 to 100 nM, when saturation is reached, between 5.3 and 
6.4 % of CD8+ T cells produced IFN-γ. IFN-γ activation induced by peptide (MCMV m38)-loading of 
target cells (Fig. 8.5 A blue) led to 4.7 % activated CD8+ T cells at a peptide-loading concentration of 
1 nM and 10.3 to 12.4 % activated CD8+ T cells at peptide-loading concentrations of 5 to 1 000 nM. 
The pMHCI-IgG molecule containing the control peptide MCMV IE3 (Fig. 8.5 A pink) mediated 
almost no IFN-γ activation of CD8+ T cells. 0.6 to 1.5 % of CD8+ T cells produced IFN-γ upon exposure 
to molecule concentrations of 0.1 to 100 nM. By coincubation of splenocytes together with tumor 
cells in absence of effector molecules no IFN-γ activation of CD8+ T cells could be found (Fig. 8.5 A 
cyan). In summary the pMHCI-IgG molecule could activate 6.4 % of all CD8+ T cells in maximum, 
which represents 10 % of the MCMV m38-specific CD8+ T cell population. The TCB antibody could 
activate 10 % of all CD8+ T cells. Peptide (MCMV m38)-loaded target cells mediated activation of 
12.4 % of the entire CD8+ T cell population, which represents 20 % of the MCMV m38-specific CD8+ 
T cells. The pMHCI-IgG molecule containing the control peptide MCMV IE3 induced no activation of 
CD8+ T cells indicating that IFN-γ activation of CD8+ T cells mediated by pMHCI-IgG molecules is 
specific. 
Figure 8.5 B depicts the results of the IFN-γ activation assay using splenocytes from OVA257-264-
vaccinated mice. Here the TCB antibody (Fig. 8.5 B green) could induce IFN-γ production in 7.8 % of 
CD8+ T cells at a compound concentration of 0.1 nM. Increased concentrations of the molecule led 
to a peak of IFN-γ activation with 17.2 % activated CD8+ T cells at a compound concentration of       
1 nM and slowly decreasing percentages (15.2 to 10.4 %) of activated CD8+ T cells at molecule 
concentrations ranging from 5 to 100 nM. In comparison the pMHCI-IgG molecule (Fig. 8.5 B red) 
could only activate very few CD8+ T cells with 1.6 to 2.4 % at compound concentrations of 0.1 to 
100 nM. However, OVA257-264 peptide-loaded tumor cells (Fig. 8.5 B blue) mediated IFN-γ activation 
of 11.1 % of CD8+ T cells at a peptide-loading concentration of 1 nM. With rising concentrations of 
peptide-loading more CD8+ T cells get activated with about 16.0 % of CD8+ T cells producing IFN-γ at 
concentrations of 100 to 1 000 nM. Percentages of CD8+ T cells activated by the pMHCI-IgG 
molecule containing the control peptide MCMV IE3 (Fig. 8.5 B pink) remained low with 0.8 to 1.7 % 
of activated CD8+ T cells at compound concentrations ranging from 0.1 to 100 nM. Coincubation of 
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splenocytes together with tumor cells in the absence of effector molecules (Fig. 8.5 B cyan) showed 
no IFN-γ activation of CD8+ T cells. Using the pMHCI-IgG molecule containing the immunodominant 
epitope of ovalbumin (OVA257-264) nearly no activation of CD8
+ T cells could be found, whereas 
about 40 % of the MCMV m38-specific CD8+ T cell population could be activated by loading of 
target cells with the OVA257-264 peptide. The TCB antibody mediated IFN-γ activation in about 20 % 
of CD8+ T cells. 
In addition it could be found that peptide-loading of tumor cells achieved only at higher 
concentrations (5 nM) the maximum of IFN-γ activation compared to pMHCI-IgG coated tumor 
cells, which reached maximal IFN-γ activation at lower concentrations (1 nM). 
 
 
Figure 8.5: In vitro IFN-γ activation of CD8
+
 T cells mediated by pMHCI-IgG and TCB molecules. 
Flow cytometry analysis of frequency of IFN-γ expressing cells of all CD8
+
 T cells after exposure to target cells loaded with 
different molecules. (A) Incubation of MC38-muFAP tumor cells loaded with MCMV m38 peptide (blue), TCB (green), 
MCMV m38-MHCI-IgG (red) or MCMV IE3-MHCI-IgG (pink) and unloaded tumor cells (cyan) together with freshly isolated 
splenocytes from MCMV m38-vaccinated mice. (B) Incubation of MC38-muFAP tumor cells loaded with OVA257-264 peptide 
(blue), TCB (green), OVA257-264-MHCI-IgG (red) or MCMV IE3-MHCI-IgG (pink) and unloaded tumor cells (cyan) together 
with freshly isolated splenocytes from OVA257-264-vaccinated mice. (A, B) Compounds were added in different 
concentrations (0.1, 1.0, 5.0, 25.0, 100 and 1 000 nM) and after 6 hours of incubation flow cytometry analysis of 
splenocytes with intracellular staining for IFN-γ was performed. Percentage of specific CD8
+
 T cells out of lymphocytes 
and effector cell:target cell ratio are annotated below graphs. All graphs show mean of replicates (n=2) with error bars 
indicating standard deviation. 
 
8.2.3 In vitro cytotoxicity mediated by compounds 
Functionality of the pMHCI-IgG fusion and the TCB antibody was tested in an in vitro cytotoxicity 
assay based on the xCELLigence technology. FAP-transfected MC38 colorectal cancer cells were 
incubated together with splenocytes from vaccinated mice containing either MCMV m38- or 
OVA257-264-specific CD8
+ T effector cells. After addition of effector molecules in different 
concentrations, kinetics of target cell lysis were displayed over time and specific tumor cell 
elimination mediated by pMHCI-IgG molecules or TCB antibodies was analyzed.  
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Splenocytes applied in the cytotoxicity assay contained 60 to 70 % lymphocytes. 25 to 30 % of 
lymphocytes were CD3+ T cells and 2.5 to 3.0 % of lymphocytes were specific CD8+ T cells. Thus the 
amount of cells activated by the TCB antibody via CD3 is tenfold higher than the number of cells 
engaged by the pMHCI-IgG molecule via peptide-MHC class I / T cell receptor interaction.  
In the assay using splenocytes containing MCMV m38-specific CD8+ T cells a tumor cell lysis of 93 % 
could be achieved with the TCB antibody after 40 hours of incubation at a compound concentration 
of 25 or 5 nM as shown in figure 8.6 A on the right. 63 % of tumor cells could be eliminated with the 
pMHCI-IgG molecule under same conditions. At lower molecule concentrations of 1 and 0.1 nM 
target cell killing mediated by pMHCI-IgG molecules decreased to 52 and 30 %. Tumor cell 
elimination by means of TCB antibodies stayed at a high level of 95 % at a compound concentration 
of 1 nM and slightly decreased to 86 % only at a molecule concentration of 0.1 nM. Target cell 
death induced by pMHCI-IgG molecules containing the control peptide MCMV IE3 was very small 
with about 10 % at nearly all concentrations. Looking the positive control 86 % of peptide-loaded 
tumor cells were eliminated by MCMV m38-specific CD8+ T cells at a peptide-loading concentration 
of 25 nM. When peptide-loading concentration was reduced, cell killing of peptide-loaded tumor 
cells decreased. Controls showed that tumor cell killing mediated by pMHCI-IgG molecules was 
specific. 
The TCB antibody led to an immediate reduction of target cells measured with the xCELLigence 
system in figure 8.6 A on the left. Peptide-loaded tumor cells were eliminated with similar kinetics. 
The results with the peptide-MHCI-IgG-loaded target cells showed a delayed onset of cell killing. 
After 10 hours of incubation cell killing started and continued to the end of the experiment. This 
indicated that tumor cells lysis induced by TCB antibodies happened more rapidly than the one 
mediated by pMHCI-IgG molecules. Control samples (tumor cells only, tumor cells with splenocytes 
and tumor cells loaded with the pMHCI-IgG molecule containing the control peptide MCMV IE3) 
were very similar to each other and increased constantly until viability of cells decreased due to 
lack of nutrients and space. pMHCI-IgG molecules containing the control peptide MCMV IE3 
induced only weak target cell lysis showing that tumor cell killing is specifically mediated by 
molecules. 
Figure 8.6 B shows the same assay with splenocytes containing OVA257-264-specific CD8
+ T cells. In 
this case both the pMHCI-IgG molecule and the TCB antibody induced efficacious tumor cell killing 
within 55 hours. At compound concentrations of 1 to 25 nM about 80 % target cell lysis could be 
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induced with the pMHCI-IgG fusion and about 94 % with the TCB antibody. However the 
percentage of target cells lysed with the pMHCI-IgG fusion containing the control peptide MCMV 
IE3 was very high with about 35 to 45 % at compound concentrations from 0.1 to 25 nM. 77 to 94 % 
of peptide-loaded tumor cells were eliminated in the assay. 
Looking at the kinetics of target cell lysis displayed with the xCELLigence technology the pMHCI-IgG 
molecule was clearly inferior to the TCB antibody. Tumor cell lysis induced by pMHCI-IgG molecules 
began after 10 hours but could not control tumor cell growth completely as the slowly rising curve 
indicates. Only when curves of control samples containing exclusively tumor cells started to go 
down due to decreased cell viability, killing of tumor cells mediated by pMHCI-IgG fusions also 
became prevalent and the signals went down. Curves of peptide-loaded tumor cells and TCB 
antibodies overlapped and showed efficacious tumor cell killing within a few hours. Target cell 
death induced by pMHCI-IgG molecules containing the control peptide MCMV IE3 was relatively 
high so that results showing the MHC class I-IgG fusion molecules containing the right peptide 
(OVA257-264) and the control peptide lied close together. No lysis of target cells was induced without 
effector molecules. 
Another aspect of the vitro cytotoxicity assay was to check functionality of specific CD8+ T cells 
generated by vaccination. In this experiment splenocytes from mice immunized with the XCR1-
targeted vaccination (see chapter 8.3.3) were applied. Figure 8.6 A and B show that tumor cells 
loaded with the peptide corresponding to vaccination (OVA257-264 or MCMV m38) were nearly 
completely eliminated indicating that specific CD8+ T cells generated by vaccination were 
functional. If splenocytes were applied to wells containing only tumor cells without effector 
molecules or peptide-loading, no target cell lysis was induced showing that target cell killing was 
exclusively mediated by specific CD8+ T cells generated by vaccination. 
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Figure 8.6: In vitro cytotoxicity mediated by pMHCI-IgG and TBC molecules. 
Induction of specific tumor cell lysis mediated by pMHCI-IgGs or TCB IgGs after incubation with freshly isolated 
splenocytes from vaccinated mice. (A) Analysis of target cells with the xCELLigence system: MC38-muFAP cells loaded 
with MCMV IE3-MHCI-IgG (purple), MCMV m38 peptide (blue), TCB IgG (green) or MCMV m38-MHCI-IgG (red) together 
with freshly isolated splenocytes from MCMV m38-vaccinated mice. (B) Analysis of target cells with the xCELLigence 
system: MC38-muFAP cells loaded with MCMV IE3-MHCI-IgG (purple), OVA257-264 peptide (blue), TCB IgG (green) or 
OVA257-264-MHCI-IgG (red) together with freshly isolated splenocytes from OVA257-264-vaccinated mice. (A, B) Compounds 
were added in different concentrations (0.1, 1.0, 5.0 and 25.0 nM) and induced lysis of tumor cells was evaluated after 40 
(A) or 55 hours (B) (right column). Lysis of target cells was displayed over time with the xCELLigence system and kinetics of 
cell lysis at a compound concentration of 25 nM is shown exemplarily (left column). Growing curves of tumor cells 
without compounds or splenocytes (dark purple) and spontaneous release by incubation of tumor cells with splenocytes 
but without compound (light blue) are depicted as reference. Percentage of specific CD8
+
 T cells out of lymphocytes and 
effector cell:target cell ratio are annotated below xCELLigence curves. All graphs show mean of replicates (n=3) with error 
bars indicating standard deviation. 
 
8.3 COMPARISON OF DIFFERENT VACCINATION METHODS FOR GENERATION OF 
EFFECTOR CELLS IN MICE 
To evaluate pMHCI-IgG molecules in vivo, effector cells had to be generated in mice. Therefore 
three different vaccination methods were tested. All immunizations were performed with the 
immunodominant epitope of ovalbumin (OVA257-264) as antigen. After vaccination blood was drawn 
twice weekly from mice and OVA257-264-specific CD8
+ T cells were quantified with flow cytometry 
analysis. Figure 8.7 shows exemplarily the gating strategy of flow cytometry analysis for detection 
of specific CD8+ T cells. OVA257-264-specific CD8
+ T cells were quantified as percentage of all CD8+ T 
cells. The CD8+ T cell response of the different vaccination methods was compared and the method 
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of choice for vaccination in further experiments was then also tested for the immunodominant 
epitope of the murine Cytomegalovirus (MCMV m38). 
 
 
8.3.1 Vaccination with peptide-loaded, bone marrow-derived dendritic cells 
Figure 8.8 A shows the CD8+ T cell response after vaccination with peptide-loaded DCs for four 
different application routes. The first group was injected intravenously with 8 x 105 OVA257-264 
peptide-loaded DCs for three times at an interval of seven days (red curve). The CD8+ T cell 
response constantly increased until a peak on day 13 after start of vaccination. At the peak levels of 
1.9 to 6.0 % of OVA257-264-specific CD8
+ T cells could be detected. Then the curve decreased again to 
0.7 to 1.9 % on day 20 and finally leveled out at an average percentage of 0.4 % OVA257-264-specific 
Figure 8.7: Flow cytometry analysis 
of blood for detection and 
quantification of specific CD8
+
 T 
cells. 
Figure 8.7 shows the gating strategy 
for detection and quantification of 
specific CD8
+
 T cells in blood 
samples. (A) Blood sample of a 
mouse immunized with the XCR1-
targeted vaccination (B) Blood 
sample of a naïve mouse. (A, B) 
Based on size (FSC: Forward scatter) 
and granularity (SSC: Side scatter) 
lymphocytes were selected. After 
discrimination of duplets applying 
FSC-Area versus FSC-Height, DAPI
+
 
dead cells were excluded (top row). 
Then cells were gated on CD3ε
+
 and 
CD4
-
 cells to exclude B cells and CD4
+
 
T cells. Afterwards CD8a
+
 cells were 
selected and OVA257-264- or MCMV 
m38-Dextramer
+
 cells as specific 
CD8
+
 T cells out of all CD8
+
 T cells 
were detected (bottom row).  
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CD8+ T cells from the 25th day of vaccination. The second group was immunized intraperitoneally 
with 1.6 x 106 OVA257-264-loaded DCs for three times at an interval of seven days (green curve). 
Applying this administration route for vaccination only a weak CD8+ T cell response could be 
elicited. After a small increase to 0.3 to 3.8 % OVA257-264-specific CD8
+ T cells on day 13 it constantly 
dropped again. After day 25 an average basis level of 0.3 % OVA257-264-specific CD8
+ T cells was 
found. The third group was administered intradermaly three times at an interval of seven days with 
2 x 105 OVA257-264-loaded DCs (blue curve). Here the CD8
+ T cell response showed two peaks on day 
13 and day 20. On day 13 OVA257-264-specific CD8
+ T cell levels ranged from 0.2 to 8.3 %, on day 20 
from 0.7 to 5.7 %. Afterwards the number rapidly decreased to a constant level of 0.3 % from day 
25 on. The fourth group was injected subcutaneously three times at an interval of seven days with          
1.6 x 106 OVA257-264-loaded DCs (yellow curve). This application route of peptide-loaded DCs showed 
a CD8+ T cell response with two peaks. The first peak on day 13 included OVA257-264-specific CD8
+ T 
cell levels in a range from 0.4 to 12.0 %. The second peak on day 20 was weaker with about 0.2 to 
4.5 % of OVA257-264-specific CD8
+ T cells. After day 25 an average percentage of 0.2 % OVA257-264-
specific CD8+ T cells could be detected. 
The i.d. and the s.c. injection of peptide-loaded DCs generated two CD8+ T cell peaks whereas the 
systemic administration routes (i.v. and i.p.) only elicited one peak. After the first application CD8+ T 
cell responses went up and the second injection further enhanced OVA257-264-specific CD8
+ T cell 
levels. The third administration of peptide-loaded DCs was applied without the TLR9-agonist CpG 
ODN and produced only in the i.d. and in the s.c. group a second augmentation of OVA257-264-
specific CD8+ T cells. In total the intradermal application of peptide-loaded DCs was clearly superior 
to the other administration routes, because it generated the highest specific CD8+ T cell levels and 
only a fourth or an eighth of the cells used for i.v. or s.c./i.p. injection, respectively, was needed.  
 
8.3.2 DNA vaccination with electroporation 
Figure 8.8 B depicts the CD8+ T cell response after i.m. or i.d. DNA vaccination with subsequent 
electroporation. Only low frequencies of OVA257-264-specific CD8
+ T cells could be generated after 
intramuscular injection of plasmid vectors followed by electroporation. After two immunizations 
the number of specific CD8+ T cells rose until day 15 and then decreased again to a constant level of 
0.2 % OVA257-264-specific CD8
+ T cells from day 28 on. At the peak on day 15 0.14 to 2.76 % specific 
CD8+ T cells could be detected. The intradermal injection of DNA with subsequent electroporation 
        Results 92 
 
elicited higher CD8+ T cell responses with a range of 0.7 to 3.9 % of OVA257-264-specific CD8
+ T cells at 
the peak on day 15. Here the number also increased until day 15 and then dropped down to an 
average level of 0.2 % OVA257-264-specific CD8
+ T cells from day 28 on. Comparing the application 
routes of DNA vectors, the i.d. administration was marked superior to i.m. injection. 
 
8.3.3 XCR1-targeted vaccination 
XCR1 is a chemokine receptor exclusively expressed on murine and human cross-presenting DCs 
[121]. Delivery of antigen via the XCR1-specific monoclonal antibody MARX10 (see chapter 8.1.3) 
elicited specific CD8+ T cell responses, which could be further boosted by two amplification steps. 
Table 7.3 shows the three different steps of the vaccination method.  
Figure 8.8 shows the frequencies of OVA257-264-specific CD8
+ T cells after vaccination. All groups 
generated a CD8+ T cell response with a peak on day 9 of vaccination. The first group only treated 
with the “Prime” step had only 0.5 to 1.0 % OVA257-264-specific CD8
+ T cells on day 9. Afterwards 
frequencies of OVA257-264-specific CD8
+ T cells decreased to 0.15 %. Specific CD8+ T cell levels of the 
group given the “Prime” and the “ADAS” step rose to 3.0 to 12.8 % on day 9 and then slowly 
decreased to a minimum of 1.5 % on day 44. The curve of the group treated with all steps (“Prime” 
+ “ADAS” + “cxIL-2”) increased tremendously to a CD8+ T cell peak of 19.6 to 48.7 % of OVA257-264-
specific CD8+ T cells on day 9. Then the amount of specific CD8+ T cells slowly decreased to about    
4 % between day 20 and 37 and finally went down to about 2.5 % on day 44. 
The combination of all steps of the vaccination method generated the most potent CD8+ T cell 
response, whereby the biggest part was contributed by the complexed IL-2, which was injected 
three times. Reduction of complexed IL-2 administration to two applications resulted in lower 
frequencies of OVA257-264-specific CD8
+ T cells on day 9, but still higher then combination of only 
“Prime” and “ADAS” step (data not shown). The “ADAS” step potentiated the CD8+ T cell response 
elicited with the “Prime” step by ten.  
 
8.3.4 Comparison of vaccination methods 
Figure 8.8 D shows the comparison of CD8+ T cell responses of all tested vaccination methods. DNA 
vaccination with electroporation resulted in OVA257-264-specific CD8
+ T cell frequencies that 
remained always below 4.0 %. Vaccination with peptide-loaded DCs elicited CD8+ T cell responses 
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up to 12 % in individual cases, but most of the time under 10 % depending on the administration 
route. Obviously targeting of antigen to the XCR1-receptor combined with further amplification 
steps generated the most potent CD8+ T cell response with an average level of 34.0 % OVA257-264-
specific CD8+ T cells. By addition or omission of amplification steps the intended percentage of 
specific CD8+ T cells was reasonably well controlled, so that this was the method of choice for 
generating effector cells in further efficacy studies. Keeping in mind that the vaccination method 
had to be applied in a large number of animals in the following experiments, other advantages of 
the immunization method were the simple technical implementation and the low number of 
animals needed as donors compared to the vaccination with peptide-loaded, bone marrow-derived 
DCs. To evaluate the potency of the vaccination method for other antigens, immunization for the 
immunodominant epitope m38 of the murine Cytomegalovirus was tested as shown in figure 8.8 E. 
Using the m38 peptide of MCMV as antigen, the XCR1-targeted vaccination generated less specific 
CD8+ T cells than using OVA257-264 as antigen. However, frequencies of MCMV m38-specific CD8
+ T 
cells ranged in a double-digit percentage when applying all steps of the vaccination, so that the 
method was considered the best one for further experiments. Functionality of specific CD8+ T cells 
generated with the XCR1-targeted vaccination was tested in in vitro cytotoxicity assays before 
further application in in vivo efficacy studies (see chapter 8.2.3).  
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Figure 8.8: CD8
+
 T cell responses in the blood after application of different vaccination methods. 
Frequencies of specific CD8
+
 T cells in the blood over time after different vaccination methods. Specific CD8
+
 T cells in 
blood samples were quantified by flow cytometry analysis as percentage of all CD8
+
 T cells. Time points of injections of 
compounds/cells are indicated below time axes. (A) CD8
+
 T cell response after intravenous (red), intraperitoneal (green), 
intradermal (blue), subcutaneous (yellow) or no (grey) injection of OVA257-264-loaded DCs. (B) CD8
+
 T cell response after 
intramuscular (red), intradermal (green) or no (grey) injection of DNA vectors encoding for ovalbumin with subsequent 
electroporation. (C) CD8
+
 T cell response after the XCR1-targeted vaccination. Evaluation of three different steps of the 
vaccination method: “Prime” (red), “Prime” + “ADAS” (green), “Prime” + “ADAS” + “cxIL-2” [3 days] (blue), no vaccination 
(grey). (D) Comparison of the vaccination methods: XCR1-targeted vaccination (red panel), OVA257-264-loaded DCs (blue 
panel), DNA vaccination with electroporation (green panel), not vaccinated control (grey). (E) Comparison of XCR1-
targeted vaccination for different antigens: Targeting of ovalbumin to the XCR1-receptor (red panel), Targeting of MCMV 
m38 to the XCR1-receptor (green panel). All graphs show mean of different animals per group (n=6-12) with error bars 
indicating standard deviation. 
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8.4 IN VIVO EFFICACY EVALUATION OF SURROGATE PEPTIDE–MHC CLASS I-
ANTIBODY FUSION MOLECULES 
8.4.1 Experimental lung metastasis model  
8.4.1.1 Anti-tumor efficacy of molecules in the experimental lung metastasis model 
To evaluate anti-tumor efficacy of pMHCI-IgG molecules on single tumor cells or bigger tumor cell 
agglomerates in vivo an experimental lung metastasis model with FAP-transfected B16 melanoma 
cells was carried out. First a preventive treatment setting was used to examine, if the molecule 
could mediate elimination of single tumor cells in the circulation before they could settle down in 
the lung and cause lung metastasis. Second, the ability of the molecules to induce eradication of 
already established lung metastasis was tested in a therapeutic treatment setting. Lung metastasis 
burden was assessed by counting of visible metastasis on the lung surface and qPCR for TRP-2.  
TRP-2 is involved in the synthesis of melanin and therefore specifically expressed in melanocytes. In 
the healthy lung melanin is not produced. The detection of melanocyte-specific mRNA encoding 
TRP-2 indicated the presence of B16 melanoma cells in the lung. Counting of metastasis on the lung 
surface was carried out by two different experimenters under a binocular microscope, whereby 
treatment and control groups were blinded.  
8.4.1.1.1 Preventive treatment setting 
Figure 8.9 depicts the time line of the preventive setting of the B16 lung metastasis model in 
purple. For generation of MCMV m38- or OVA257-264-specific CD8
+ T cells, animals were immunized 
with the XCR1-targeted vaccination as described in chapter 7.3.2.3. After vaccination blood was 
drawn from mice and analyzed with flow cytometry for detection and quantification of specific 
CD8+ T cells. Based on their blood level of specific CD8+ T cells animals were assigned to treatment 
or control groups with the aim of having an equal average blood level of specific CD8+ T cells in 
every group at start of treatment. Mice which were vaccinated for MCMV m38 had an average 
blood level of 3.2 % specific CD8+ T cells in every group at start of treatment, whereby the highest 
value included into the study was 5.7 % and the lowest one was 1.4 % (data not shown). Blood 
levels of animals vaccinated for OVA257-264 averaged 5.7 % specific CD8
+ T cells with 12.9% for 
maximum and 2.3 % for minimum (data not shown). Table 8.1 A shows the different groups of the 
study and the treatment schedule. Groups 1 to 3 were vaccinated for MCMV m38 and treated with 
either the pMHCI-IgG molecule containing the MCMV m38 peptide, the TCB antibody or PBS. 
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Groups 4 and 5 were not vaccinated and treated with the TCB antibody or PBS. Groups 6 to 8 were 
vaccinated for OVA257-264 and treated with the pMHCI-IgG molecule containing the OVA257-264 
peptide, with the pMHCI-IgG molecule containing the control peptide MCMV IE3 or with PBS. As 
the TCB recruits effector cells via CD3, it should show efficacy both with and without vaccination. 
The pMHCI-IgG molecule recruits only specific CD8+ T cells and can therefore only work in 
combination with previous vaccination. After assignment to treatment and control groups animals 
were treated prophylactically with the molecules (see time line in figure 8.9). One day after 
treatment mice were challenged with the B16-muFAP tumor cells. Two days after i.v. injection of 
tumor cells animals were given a second treatment with the molecules. The pMHCI-IgG molecule 
was dosed with 5 mg/kg and the TCB antibody with 2 mg/kg. On day 21 of metastasis growth lungs 
were taken out and tumor burden was assessed by counting of visible metastasis on the lung 
surface and quantifying expression of TRP-2 by qPCR.  
Figure 8.10 shows the results of the preventive treatment of B16 lung metastases. In figure 8.10 A 
the number of visible lung metastases in the MCMV m38-vaccinated groups is depicted in green. In 
the MCMV m38-vaccinated vehicle group all of the seven lungs showed metastasis with a range of 
17 to 125 and a median value of 58 counted spots per lung. Six MCMV m38-vaccinated animals 
were treated with the TCB antibody and had no metastasis after treatment except for two mice 
which had one single spot on the lung. Here the median metastasis load was 0. In the MCMV m38-
vaccinated group treated with the pMHCI-IgG molecule three out of seven animals were metastasis 
free and the other ones showed metastases in a range of 1 to 8 spots per lung, which resulted in a 
median value of 1 metastasis per lung. Representative example pictures of lungs are shown in 
figure 8.10 C. In the lung of the MCMV m38-vaccinated vehicle group a lot of metastasis could be 
recognized, whereas lungs of pMHCI-IgG and TCB treatment groups showed no metastases. Data 
from counting of lung metastases correlated well with the data of qPCR for TRP-2 expression in 
lungs depicted in figure 8.10 B in green. TRP-2 expression in lungs of the MCMV m38-vaccinated 
vehicle group was very high with values up to 3 000 and a median TRP-2 expression level of 1571. 
Treatment groups had very low levels of TRP-2 expression. In the vaccinated TCB treatment group 
levels stayed below 2 with one exception with a value of 12. Median TRP-2 expression level was 1. 
The peptide-MHCI-IgG treatment group included four lungs with a value below 3, two lungs in the 
double digit range and one outlier with a value of 605, which resulted in a median TRP-2 expression 
level of 2. Data of metastases counting and qPCR suggested that preventive treatment with the 
        Results 97 
 
pMHCI-IgG molecule or the TCB antibody could prevent metastasis growth in lungs with a slightly 
better outcome for the TCB antibody. 
Figure 8.10 A shows also the number of lung metastases counted in lungs of the not-vaccinated 
groups in blue. Those groups included ten animals per group. In the vehicle group six animals had 
over 230 lung metastasis, two animals showed only 7 spots on the lung surface and another two 
animals lied in-between. A median metastasis count of 254 spots per lung could be found. In the 
treatment group with the TCB all animals except two ones which had a single spot on the lung were 
free of metastasis, which resulted in a median metastasis count of 0 spots per lung. TRP-2 
expression levels in lungs of the not-vaccinated vehicle group ranged from 6 to about 6600 with a 
median TRP-2 expression level of 6506, whereby all lungs except two had a level over 1 000         
(Fig. 8.10 B in blue). In the not-vaccinated TCB treatment group TRP-2 expression levels stayed in 
the one-digit range except one outlier with a value of 41. Here the median TRP-2 expression level 
was 2.5. Figure 8.10 C shows also example pictures of the not-vaccinated groups, which visualize 
the results of metastasis counting and quantification for TRP-2. The TCB antibody could mediate 
nearly complete protection of mice from lung metastasis in a preventive setting also without 
vaccination. 
Counting of lung metastases in groups vaccinated for OVA257-264 is illustrated in figure 8.10 D in red. 
In the OVA257-264-vaccinated vehicle group containing six animals between 8 and 104 spots per lung 
could be found with a median value of 31 metastases per lung. The OVA257-264-vaccinated group 
treated with the pMHCI-IgG molecule containing the control peptide MCMV IE3 consisted of seven 
animals and showed lung metastasis in a range from 30 to 124 spots per lung. In this group 59 
metastases could be detected in median. In the vaccinated group treated with the OVA257-264-MHCI-
IgG four out of six animals had no metastasis, one animal had one and another one counted 28. 
This resulted in a median value of 0 metastases per lung. Expression of TRP-2 in lungs showed in 
figure 8.10 E correlated well with the data of counting the lung metastases. The OVA257-264-
vaccinated vehicle group included two lungs with values over 2 500 and two lungs with levels about 
66. One lung of the group was between them with a value of 714 and one lung had a level of 4. The 
median TRP-2 expression level of the group was 393. All lungs of the MCMV IE3-MHCI-IgG-treated 
group showed TRP-2 expression levels over 1 000 except one with a value of 744. Here the median 
TRP-2 expression level was 1911. The TRP-2 expression levels of the OVA257-264-MHCI-IgG-treated 
group were all below 3 except one lung with a value of 23 and another one with a value of 164. The 
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median TRP-2 expression level of the group was 1.5. Figure 8.10 F depicts representative example 
pictures of lungs where lung metastases in vehicle and control groups can be perceived and the 
lung of the treatment group shows no metastases. Also when the OVA257-264 peptide is applied for 
vaccination mice could be protected from lung metastases by treatment with pMHCI-IgG fusion 
molecules. 
Figures 8.10 A, B, D and E contain graphs of the not-vaccinated vehicle group in blue and graphs of 
the vaccinated vehicle groups in green (MCMV m38) or red (OVA257-264). Compared to each other a 
big influence of vaccination on metastasis growth can be noticed. This is also obvious in the 
example pictures of lungs in figures 8.10 C and F. 
In summary the experimental set up showed that both pMHCI-IgG fusion molecules and TCB 
antibody induced efficacious and specific elimination of B16 tumor cells in the circulation before 
settlement in the lung and could protect mice from lung metastasis. Antitumor efficacy of the 
pMHCI-IgG fusion molecule was thereby successful for both peptides (MCMV m38 or OVA257-264). 
 
8.4.1.1.2 Therapeutic treatment setting 
Figure 8.9 shows the time line of the therapeutic setting of the B16 lung metastasis model in green. 
Vaccination, determination of blood levels of specific CD8+ T cells and assignment of animals to 
treatment or control groups were performed in the same way as in the preventive setting of the 
lung metastasis model (see chapter 8.4.1.1.1). In this experiment MCMV m38-vaccinated mice had 
an average blood level of 11.8 % specific CD8+ T cells in every group at start of treatment, whereby 
the highest frequency included into the study was 20.5 % and the lowest one was 5.0 %. Blood 
levels of animals vaccinated for OVA257-264 averaged 16.6 % specific CD8
+ T cells with 27.1 % for 
maximum and 9.8 % for minimum (data not shown). Table 8.1 B shows the different groups and the 
treatment schedule of the lung metastasis study with the therapeutic setting. Groups in the 
therapeutic setting were similar to those in the preventive setting (see chapter 8.4.1.1.1) except 
two alterations. One control group treated with the pMHCI-IgG molecule containing the control 
peptide MCMV IE3 was added to the MCMV m38-vaccinated groups and the control peptide group 
in the OVA257-264-vaccinated groups was replaced by a group treated with the pMHCI-IgG molecule 
containing the non-binding IgG DP47. In the therapeutic setting mice were injected with the         
B16-muFAP tumor cells nine days before treatment so that tumor cells could migrate to the lung, 
settle down there and cause lung metastases (see time line in figure 8.9). Established lung 
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metastases were treated two times at an interval of three days with the test molecules. Molecules 
were dosed in the same manner as in the preventive setting with 5 mg/kg for the pMHCI-IgG 
molecule and 2 mg/kg for the TCB antibody. On day 21 after injection of tumor cells lungs were 
taken out and tumor burden was assessed by counting of visible metastases on the lung surface 
and quantification of TRP-2 expression by qPCR. 
Figure 8.11 depicts the results of the therapeutic treatment of experimental lung metastasis. In 
green counting of lung metastases (Fig. 8.11 A) and TRP-2 expression levels (Fig. 8.11 B) of the 
MCMV m38-vaccinated groups are shown. The MCMV m38-vaccinated vehicle group was very 
heterogeneous with 4 counted spots on the lung surface as minimum and 122 counted spots as 
maximum as shown in figure 8.11 A. The group included ten animals and 43 metastases per lung 
were counted in median. In the MCMV m38-vaccinated group treated with the TCB one out of eight 
animals was metastasis free and the other ones had lung metastases in a range of 3 to 32 spots per 
lung. Here the median value of counted lung metastases was 13. The MCMV m38-vaccinated group 
treated with the pMHCI-IgG molecule containing the control peptide MCMV IE3 consisted of ten 
animals per group and had a median lung metastasis burden of 45 spots per lung. Minimum count 
of lung metastasis was 1 and maximum count of lung metastasis was 157. The MCMV m38-MHCI-
IgG-treated group had 16 lung metastases in median, whereby seven out of ten animals showed 
less than 20 spots per lung. Results of metastases counting can be verified with example pictures of 
lungs shown in figure 8.11 C. On the left lungs of MCMV m38-vaccinated groups can be found 
showing multiple metastases in the control groups (vehicle and MCMV IE3-MHCI-IgG) and reduced 
metastasis burden in the treatment groups (TCB and MCMV m38-MHCI-IgG). Data of qPCR for    
TRP-2 expression in lungs is depicted in figure 8.11 B. TRP-2 expression in lungs of the MCMV m38-
vaccinated vehicle group ranged from 2 to 700, whereby half of the group had a value over 140 and 
the median value was 103. The MCMV m38-vaccinated group treated with the TCB had a median 
TRP-2 expression level of 26. Four animals were in the single-digit range, three ones in the double-
digit range and one outlier showed a value of 347. TRP-2 expression levels of the MCMV m38-
vaccinated group treated with the pMHCI-IgG molecule containing the control peptide MCMV IE3 
were in a range of 225 to 2102 except two lungs with only a value of 4 and 6. In this group the 
median TRP-2 expression level was 439. The MCMV m38-MHCI-IgG-treated group showed TRP-2 
expression levels in a double-digit range except two lungs with a value of 1 and 5 and one lung with 
a value of 100. The median TRP-2 expression level was 43. Comparing median values of metastasis 
counting and qPCR, metastasis burden of the vaccinated vehicle group and the vaccinated control 
        Results 100 
 
group (MCMV IE3-MHCI-IgG) was 2.5-fold higher than tumor burden of vaccinated groups treated 
with pMHCI-IgG molecules or the TCB antibody. 
Figures 8.11 A and B show also blue graphs, which depict results of the therapeutic treatment of 
experimental lung metastasis in the not-vaccinated groups. Here the vehicle group counted                 
463 metastases per lung in median with a range of 60 to 676 spots per lung. The TCB-treated group 
had 19 to 80 spots per lung with a median count of 55 metastases per lung. TRP-2 expression levels 
in the vehicle group ranged from 125 to 8379 with a median value of 3049. In the TCB-treated 
group the median TRP-2 expression level was 150 and values ranged from 35 to 338. Figure 8.11 C 
shows corresponding example pictures of the not vaccinated groups on the right with reduced 
metastasis burden in the treatment group (TCB) compared to the vehicle group. In not-vaccinated 
animals the TCB antibody could reduce metastases burden tenfold. Still tumor burden in the not-
vaccinated, TCB-treated group was higher than in the MCMV m38-vaccinated vehicle group. 
Figure 8.11 D depicts counts of metastases in lungs of OVA257-264-vaccinated groups in red. The 
vaccinated vehicle group consisted of ten animals and had 58 metastases per lung in median. 
Counted spots on the lung surface ranged from 4 to 124. The OVA257-264-vaccinated control group 
treated with the pMHCI-IgG molecule containing the non-binding IgG DP47 showed lung metastasis 
in a range of 2 to 178 with a median count of 41 spots per lung. The group also included ten 
animals. Lung metastasis numbers of the group treated with the OVA257-264-MHCI-IgG fusion 
molecule fell all below 57 counts with one out of nine metastasis free animal and a median count of 
12 spots per lung. Figure 8.11 F shows representative example pictures of lungs from the study, 
where lung metastasis can be found in all groups, but overall metastasis burden was slightly 
reduced in the treatment group. Expression of TRP-2 in lungs of OVA257-264-vaccinated groups is 
shown in figure 8.11 E in red. The OVA257-264-vaccinated vehicle group had TRP-2 expression levels in 
a range of 3 to 531 with a median value of 156. Seven lungs lied over a value of 100, the other three 
ones were below 30. TRP-2 expression levels of the control group treated with the pMHCI-IgG 
molecule containing the non-binding IgG DP47 showed a median value of 131 with a huge range 
from 1 to 1302. The same applied to the group treated with the OVA257-264-MHCI-IgG fusion 
molecule. Here TRP-2 expression levels were between 0.5 and 905 with a median of 62. Comparing 
all OVA257-264-vaccinated groups, treatment with the pMHCI-IgG molecule showed a trend towards 
reduction of metastasis load, but no significant difference between control and treatment groups 
could be found. 
        Results 101 
 
Besides green graphs for the MCMV m38-vaccinated groups and red graphs for the OVA257-264-
vaccinated groups, figures 8.11 A, B, D and E show also blue graphs with the results of the not-
vaccinated groups. Compared to each other metastasis burden of vehicle groups was already 
reduced by vaccination. This is also visible, when example pictures of vehicle lungs of the 
vaccinated and not-vaccinated group in figures 8.11 C and F are compared. 
When tumor cells have already settled in the lung metastasis growth can be delayed with both 
pMHCI-IgG molecules and TCB antibodies. In this case the MCMV m38 peptide was more potent 
than the OVA257-264 peptide. 
 
Figure 8.9: Time line for the experimental lung metastasis model. 
Experimental setting: Time line for the preventive treatment in the experimental lung metastasis model in purple and 
timeline for the therapeutic treatment setting in the experimental lung metastasis model in green. The blue bar shows 
time in single days. Duration of the XCR1-targeted vaccination is depicted with a red arrow. One day after vaccination 
blood sampling from mice is illustrated with a red drop and time window of CD8
+
 T cell peak after vaccination is outlined 
with a grey curve. Orange points indicate intravenous injection of 2 x 10
5
 B16-muFAP melanoma cells. Purple or green 
stars show time points of treatments in each setting. Orange crosses demonstrate euthanasia of mice and harvest of 
lungs for assessment of metastasis burden. 
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A: Preventive setting 
Group 
Number of 
animals 
Vaccination Compound 
Dosage 
(mg/kg) 
Preventive 
treatment 
Therapeutic 
treatment 
1 6 MCMV m38 PBS - x x 
2 6 MCMV m38 T cell bispecific IgG 2 x x 
3 7 MCMV m38 MCMV m38-MHCI-IgG 5 x x 
4 10 - PBS - x x 
5 10 - T cell bispecific IgG 2 x x 
6 6 OVA257-264 PBS - x x 
7 7 OVA257-264 MCMV IE3-MHCI-IgG 5 x x 
8 6 OVA257-264 OVA257-264-MHCI-IgG 5 x x 
B: Therapeutic setting 
Group 
Number of 
animals 
Vaccination Compound 
Dosage 
(mg/kg) 
Therapeutic 
treatment 1 
Therapeutic 
treatment 2 
1 10 MCMV m38 PBS - x x 
2 8 MCMV m38 T cell bispecific IgG 2 x x 
3 10 MCMV m38 MCMV IE3-MHCI-IgG 5 x x 
4 10 MCMV m38 MCMV m38-MHCI-IgG 5 x x 
5 10 - PBS - x x 
6 8 - T cell bispecific IgG 2 x x 
7 10 OVA257-264 PBS - x x 
8 10 OVA257-264 OVA257-264-MHCI-DP47 5 x x 
9 9 OVA257-264 OVA257-264-MHCI-IgG 5 x x 
Table 8.1: Classification of groups and treatment schedule in the experimental lung metastasis model. 
Classification of treatment and control groups in the experimental lung metastasis model and the treatment schedule of 
each group. (A) Classification of groups and treatment schedule in the preventive treatment setting of experimental lung 
metastasis with B16-muFAP melanoma cells. (B) Classification of groups and treatment schedule in the therapeutic 
treatment setting of experimental lung metastasis with B16-muFAP melanoma cells. (A, B) In the column “Group” the 
number of each group in the study is listed. In the following column the number of animals included in each group is 
noted. The column “Vaccination” indicates if the group was vaccinated and which epitope was used for vaccination. In the 
fourth column compounds for treatment of each group are listed and in the fifth column dosage of molecules is shown in 
mg/kg. The last two columns in the table indicate the time points and number of treatments given. 
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Figure 8.10: Assessment of metastasis burden after preventive treatment of experimental lung metastases. 
(A) Visible lung metastases were counted under a binocular after harvest of lungs on day 21 of metastasis growth. MCMV 
m38-vaccinated (green) and non-vaccinated (blue) mice were either treated with PBS (green triangles/blue hashes), TCB 
(green squares/blue inverted triangles) or MCMV m38-MHCI-IgG (green dots) 24 hours before i.v. injection of 2 x 10
5
 B16-
muFAP melanoma cells and two days after tumor challenge. All graphs show median of different animals per group (n=6-
10) with error bars indicating interquartile range. (B) Assessment of TRP-2 expression with qPCR in lungs harvested on day 
21 of metastasis growth. MCMV m38-vaccinated (green bars) and non-vaccinated (blue bars) mice were either treated 
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with PBS, TCB or MCMV m38-MHCI-IgG 24 hours before i.v. injection of 2 x 10
5
 B16-muFAP melanoma cells and two days 
after tumor challenge. All graphs show box plots with median of different animals per group (n=6-10) with whiskers 
indicating maximum and minimum value. (C) Representative example pictures of lungs taken out on day 21 of metastasis 
growth. MCMV m38-vaccinated mice were treated with PBS (first picture in the left section), TCB (second picture in the 
left section) or MCMV m38-MHCI-IgG (third picture in the left section) and non-vaccinated mice were treated with PBS 
(first picture in the right section) or TCB (second picture in the right section) 24 hours before i.v. injection of 2 x 10
5
 B16-
muFAP melanoma cells and two days after tumor challenge. (D) Visible lung metastases were counted under a binocular 
after harvest of lungs on day 21 of metastasis growth. OVA257-264-vaccinated (red) and non-vaccinated (blue) mice were 
either treated with PBS (red triangles/blue hashes), MCMV IE3-MHCI-IgG (red squares) or OVA257-264-MHCI-IgG (red dots) 
24 hours before i.v. injection of 2 x 10
5
 B16-muFAP melanoma cells and two days after tumor challenge. All graphs show 
median of different animals per group (n=6-10) with error bars indicating interquartile range. (E) Assessment of TRP-2 
expression with qPCR in lungs harvested on day 21 of metastasis growth. OVA257-264-vaccinated (red bars) and non-
vaccinated (blue bars) mice were either treated with PBS, MCMV IE3-MHCI-IgG or OVA257-264-MHCI-IgG 24 hours before 
i.v. injection of 2 x 10
5
 B16-muFAP melanoma cells and two days after tumor challenge. All graphs show box plots with 
median of different animals per group (n=6-10) with whiskers indicating maximum and minimum value. (F) 
Representative example pictures of lungs taken out on day 21 of metastasis growth. OVA257-264-vaccinated mice were 
treated with PBS (first picture in the left section), MCMV IE3-MHCI-IgG (second picture in the left section) or OVA257-264-
MHCI-IgG (third picture in the left section) and non-vaccinated mice were treated with PBS (picture in the right section) 
24 hours before i.v. injection of 2 x 10
5
 B16-muFAP melanoma cells and two days after tumor challenge. 
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Figure 8.11: Assessment of metastasis burden after therapeutic treatment of experimental lung metastases. 
(A) Visible lung metastases were counted under a binocular after harvest of lungs on day 21 of metastasis growth. MCMV 
m38-vaccinated (green) and non-vaccinated (blue) mice were either treated with PBS (green triangles/blue hashes), TCB 
(green squares/blue inverted triangles), MCMV IE3-MHCI-IgG (green hexagons) or MCMV m38-MHCI-IgG (green dots) for 
two times at an interval of three days starting nine days after i.v. injection of 2 x 10
5
 B16-muFAP melanoma cells. All 
graphs show median of different animals per group (n=8-10) with error bars indicating interquartile range. (B) Assessment 
of TRP-2 expression with qPCR in lungs harvested on day 21 of metastasis growth. MCMV m38-vaccinated (green bars) 
and non-vaccinated (blue bars) mice were either treated with PBS, TCB, MCMV IE3-MHCI-IgG or MCMV m38-MHCI-IgG for 
two times at an interval of three days starting nine days after i.v. injection of 2 x 10
5
 B16-muFAP melanoma cells. All 
graphs show box plots with median of different animals per group (n=8-10) with whiskers indicating maximum and 
minimum value. (C) Representative example pictures of lungs taken out on day 21 of metastasis growth. MCMV m38-
vaccinated mice were treated with PBS (picture in the left section, top row left), TCB (picture in the left section, top row 
right), MCMV IE3-MHCI-IgG (picture in the left section, bottom row left) or MCMV m38-MHCI-IgG (picture in the left 
section, bottom row right) and non-vaccinated mice were treated with PBS (picture in the right section, top row) or TCB 
(picture in the right section, bottom row) for two times at an interval of three days starting nine days after i.v. injection of 
2 x 10
5
 B16-muFAP melanoma cells. (D) Visible lung metastases were counted under a binocular after harvest of lungs on 
day 21 of metastasis growth. OVA257-264-vaccinated (red) and non-vaccinated (blue) mice were either treated with PBS 
(red triangles/blue hashes), OVA257-264-MHCI-DP47 (red squares) or OVA257-264-MHCI-IgG (red dots) for two times at an 
interval of three days starting nine days after i.v. injection of 2 x 10
5
 B16-muFAP melanoma cells. All graphs show median 
of different animals per group (n=9-10) with error bars indicating interquartile range. (E) Assessment of TRP-2 expression 
with qPCR in lungs harvested on day 21 of metastasis growth. OVA257-264-vaccinated (red bars) and non-vaccinated (blue 
bars) mice were either treated with PBS, OVA257-264-MHCI-DP47 or OVA257-264-MHCI-IgG for two times at an interval of 
three days starting nine days after i.v. injection of 2 x 10
5
 B16-muFAP melanoma cells. All graphs show box plots with 
median of different animals per group (n=9-10) with whiskers indicating maximum and minimum value. (F) 
Representative example pictures of lungs taken out on day 21 of metastasis growth. OVA257-264-vaccinated mice were 
treated with PBS (first picture in the left section), OVA257-264-MHCI-DP47 (second picture in the left section) or OVA257-264-
MHCI-IgG (third picture in the left section) and non-vaccinated mice were treated with PBS (picture in the right section) 
for two times at an interval of three days starting nine days after i.v. injection of 2 x 10
5
 B16-muFAP melanoma cells. 
 
8.4.1.2 FAP expression in B16 lung metastases 
Maintenance of a stable target expression of tumor cells in vivo is a prerequisite for successful 
treatment of lung metastases. To address this question, the FAP-transfected B16 melanoma cell 
line was tested for stable FAP expression in vivo. Therefore mice were injected intravenously with  
2 x 105 tumor cells and lung metastasis could grow for 21 days. Three animals were injected with 
FAP-transfected B16 melanoma cells, another three ones with non-transfected B16 melanoma cells. 
On day 21 lungs were taken out and used for IHC staining for detection of FAP-transfected B16 lung 
metastases. Figure 8.12 shows the IHC staining of a lung from a mouse injected with non-
transfected B16 melanoma cells on the left and the IHC staining of a lung from a mouse injected 
with FAP-transfected B16 melanoma cells on the right. Cell nuclei of normal lung tissue and lung 
metastases were stained with DAPI and are depicted in blue. Cell nuclei of tumor cells are bigger 
and less bright than cell nuclei of normal lung tissue. This is due to a higher mitotic rate of tumor 
cells and to the fact that B16 melanoma cells contain melanin, which quenches the DAPI 
fluorescence signal. Taking advantage of this, lung metastases can be detected in normal lung 
tissue without an additional marker for B16 tumor cells. In addition metastases in lung sections can 
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be localized by matching the tissue section with the end of the cut cryo-section tissue block. B16 
lung metastases on the right show FAP expression of tumor cells in cyan. Control lungs containing 
metastases with non-transfected B16 melanoma cells show no cyan signal confirming the absence 
of FAP expression. Even after 21 days of tumor cell growth in vivo FAP-transfected B16 melanoma 
cells still express their recombinant target FAP so that effector molecules applied in the in vivo 
efficacy study can bind to their target in lung metastases.  
 
Figure 8.12: FAP expression of experimental lung metastases. 
Immunofluorescence staining for murine FAP expression in lungs containing metastases of either murine FAP-transfected 
(right) or non-transfected (left) B16 melanoma cells. In the top row cut ends of cryo-section tissue blocks are depicted so 
that metastases can be localized in the corresponding stained cryo-sections below (middle row). The close-up images 
(bottom row) show normal lung tissue and parts of metastases. Cell nuclei are stained with DAPI and depicted in blue. 
Murine FAP located on the cell surface is depicted in cyan. Red arrows indicate borders of metastases.  
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8.4.2 Solid subcutaneous tumor model 
8.4.2.1 Anti-tumor efficacy of molecules in the solid subcutaneous tumor model 
To evaluate anti-tumor efficacy of pMHCI-IgG molecules on solid tumors in vivo a subcutaneous 
tumor model with FAP-transfected MC38 colorectal cancer cells was carried out. In figure 8.13 the 
time line of the study is depicted. When solid subcutaneous tumors were established 2 to 3 weeks 
after subcutaneous inoculation of tumor cells, XCR1-targeted vaccination for MCMV m38 as 
described in chapter 7.3.2.3 was started. After vaccination blood was drawn from mice and 
analyzed with flow cytometry for detection and quantification of specific CD8+ T cells. Based on 
their blood level of MCMV m38-specific CD8+ T cells and tumor volume animals were assigned to 
treatment or control groups with the aim of having an equal average blood level of specific        
CD8+ T cells and an equal average tumor volume in every group at start of treatment. Mice had an 
average blood level of 4.8 % MCMV m38-specific CD8+ T cells and an average tumor volume of      
97 mm3 in every group at start of treatment. Frequencies of MCMV m38-specific CD8+ T cells 
ranged from 1.4 to 15.3 % and tumor volume from 55 to 142 mm3 (data not shown). Table 8.2 
shows the different groups of the study and the treatment schedule. All groups consisted of eight 
animals and were treated with either the MCMV m38-MHCI-IgG fusion molecule, the MCMV IE3-
MHCI-IgG fusion control molecule, the TCB antibody or PBS. Animals were treated five times at an 
interval of three days with the compounds. Molecules were dosed with 5 mg/kg for the pMHCI-IgG 
molecule and 2 mg/kg for the TCB antibody. During and after treatment tumor volume was 
measured with a caliper. 
Figure 8.14 shows the results of the treatment of solid subcutaneous FAP-transfected MC38 tumors 
with pMHCI-IgG molecules or the TCB antibody. The red curve in figure 8.14 A depicts the growth 
kinetics of the MCMV m38-MHCI-IgG fusion molecule-treated group. Three out of eight animals 
were tumor free nine days after start of treatment, whereas tumor volumes of the other ones 
increased constantly and reached 380 to 1063 mm3 on day 26 after start of treatment. This resulted 
in a median tumor volume of 428 mm3 at the end of study. In the group treated with the TCB      
(Fig. 8.14 A green curve) two out of eight animals were tumor free 13 days after start of treatment. 
The other ones had tumor volumes in a range of 550 to 1882 mm3 on day 26 after start of 
treatment. In the end median tumor volume of the group was 789 mm3. The group treated with the 
pMHCI-IgG molecule containing the control peptide MCMV IE3 is depicted in pink and showed two 
tumor free animals on day nine after start of treatment. Tumor volumes of the other ones 
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constantly rose to 534 to 1660 mm3, which resulted in a median tumor volume of 598 mm3 on day 
26. Also in the vehicle group (Fig. 8.14 A blue curve) two tumor free animals could be found on day 
nine and remaining animals reached tumor volumes of 431 to 1294 mm3. The median tumor 
volume of the group was 437 mm3 on day 26. In total there was one more tumor free animal in the 
MCMV m38-MHCI-IgG fusion molecule-treated group than in the others, but in the end median 
tumor volumes in all groups increased constantly to high values with no significant difference 
between groups. 
Figure 8.14 B shows the results of the time-to-event analysis of the study, when the event is 
defined as a tumor volume > 500 mm3. In the vehicle group (Fig. 8.14 B blue line) some animals 
successively reached the event, but others showed complete tumor regression. Those animals 
never reached the event. Same results could be found in treatment groups. At the beginning MCMV 
m38-MHCI-IgG-treated animals (Fig. 8.14 B red line) needed more time to reach a tumor volume of 
500 mm3, but finally on day 26 the same number of animals in the treatment group as in the vehicle 
group (Fig. 8.14 B blue line) reached the event. Animals in the MCMV IE3-MHCI-IgG- or TCB-treated 
group (Fig. 8.14 B pink and green lines) reached the event as quickly as mice in the vehicle group. In 
the end in those two groups more animals had a tumor volume > 500 mm3 than in the vehicle or 
MCMV m38-MHCI-IgG fusion molecule-treated groups. Ultimately none of the effector molecules 
could induce reduction or stasis of tumor growth and prevent tumors from reaching the event. 
In summary, neither the pMHCI-IgG molecule nor the TCB antibody could induce tumor growth 
inhibition. No significant difference between treatment and control groups and no specific tumor 
cell killing could be found. 
 
Figure 8.13: Time line for the solid subcutaneous tumor model. 
Experimental setting for the solid subcutaneous tumor model. The blue bar shows the time. The purple dot indicates the 
subcutaneous inoculation of 1 x 10
6
 MC38-muFAP colorectal cancer cells. Duration of the XCR1-targeted vaccination is 
depicted with a red arrow. One day after vaccination blood sampling from mice is illustrated with a red drop and time 
window of CD8
+
 T cell peak after vaccination is outlined with a grey curve. Green stars show time points of treatments 
during the CD8
+
 T cell peak. The orange cross demonstrates euthanasia of mice and harvest of tumors for further 
investigations. 
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Group 
Number of 
animals 
Vaccination Compound 
Dosage 
(mg/kg) 
Treatments 
d 0 d 3 d 6 d 9 d 12 
1 8 MCMV m38 PBS - x x x x x 
2 8 MCMV m38 T cell bispecific IgG 2 x x x x x 
3 8 MCMV m38 MCMV IE3-MHCI-IgG 5 x x x x x 
4 8 MCMV m38 MCMV m38-MHCI-IgG 5 x x x x x 
Table 8.2: Classification of groups and treatment schedule in the solid subcutaneous tumor model. 
Classification of treatment and control groups in the solid subcutaneous tumor model and the treatment schedule of each 
group. In the column “Group” the number of each group in the study is listed. In the following column the number of 
animals included in each group is noted. The column “Vaccination” indicates which epitope was used for vaccination. In 
the fourth column compounds for treatment of each group are listed and in the fifth column dosage of molecules is 
shown in mg/kg. The last five columns in the table indicate the time points and number of treatments given. 
 
 
Figure 8.14: Growth kinetics of solid subcutaneous tumors after treatment with pMHCI-IgG or TCB molecules. 
(A) Growing curves of tumors after treatment with TCB (green), MCMV IE3-MHCI-IgG (pink), MCMV m38-MHCI-IgG (pink) 
or without treatment (blue). On day 0 treatments were started at an average tumor volume of 97 mm
3
 in every group. 
Time points of treatments are indicated with arrows below time axis. All graphs show median of different animals per 
group (n=8) with error bars indicating interquartile range. (B) Time-to-event analysis of groups treated with TCB (green), 
MCMV IE3-MHCI-IgG (pink), MCMV m38-MHCI-IgG (pink) or without treatment (blue) starting with an average tumor 
volume of 97 mm
3
. A tumor volume > 500 mm
3
 was defined as event. Time points of treatments are indicated with 
arrows below time axis. 
 
8.4.2.2 FAP expression in MC38 tumors 
Also in the case of a solid subcutaneous tumor maintenance of stable target expression of tumor 
cells in vivo is a prerequisite for successful treatment of tumors with effector molecules. Tumor 
cells can lose their target expression when growing in vivo, which in this case leads to inability of 
effector molecules to bind to tumor cells and mediate tumor cell killing. MC38 tumors were 
harvested after several weeks of in vivo growth with or without treatment and checked for stable 
expression of their target FAP. Figure 8.15 depicts representative pictures of IHC stainings of MC38 
tumors for detection of FAP expression. The illustration at top left shows the IHC staining for FAP of 
a tumor with non-transfected MC38 colorectal cancer cells. The other three pictures show tumors 
with FAP-transfected MC38 colorectal cancer cells after treatment with effector molecules or PBS. 
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Cell nuclei of tumor cells are depicted in blue. The cyan signal shows that tumors with FAP-
transfected MC38 colorectal cancer cells maintain their FAP expression, when grown for several 
weeks in vivo. 
 
Figure 8.15: FAP expression of solid subcutaneous tumors. 
Immunofluorescence staining for murine FAP of solid tumors derived from either murine FAP-transfected (upper right, 
lower left, lower right) or non-transfected (upper left) MC38 colorectal cancer cells. Murine FAP-transfected tumors were 
treated with the TCB (lower left), the pMHCI-IgG (lower right) or untreated (upper right). Cell nuclei are stained with DAPI 
and depicted in blue. Murine FAP located on the cell surface is depicted in cyan.  
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8.4.2.3 Penetration of the MCMV m38-MHCI-IgG fusion molecule into tumors 
For successful treatment of solid tumors, it is a requirement that effector molecules penetrate into 
the tumor tissue and bind to their target on the surface of tumor cells. To confirm penetration of 
the test molecules ultramicroscopy analyses of tumors treated with Alexa 647-labelled pMHCI-IgG 
molecules were carried out.  
Figure 8.16 A shows the penetration profile of the Alexa 647-labelled MCMV m38-MHCI-IgG fusion 
molecule. The bigger the distance to the vessels got, the less fusion molecule could be found in the 
tumor tissue. This applies to tumors excised 12, 24 and 48 hours after application. 12 and 24 hours 
after injection the highest amount of molecule could be found at a distance of about 50 µm around 
the vessels. With increasing distance from the vessel the amount of molecule quickly decreased 
almost by half. In distances to vessels exceeding 50 µm amounts of molecule present in the tumor 
tissue remained constant 12 and 24 hours after application. 48 hours after injection much less of 
the molecule could be found in the tumor regardless of distance to vessels. However in larger 
distances to vessels curves go up again indicating increasing quantities of the molecule in the 
tumor. This finding might be due to accumulation of molecule in non-vascularized, necrotic areas of 
the tumor with no possibility of clearance. 
In figure 8.16 B the accumulation of the Alexa 647-labelled MCMV m38-MHCI-IgG fusion molecule 
is depicted. The highest amount of molecule could be detected 12 hours after injection. Clearance 
was obvious after 24 hours and the bulk was cleared after 48 hours. This is also reflected by images 
in figure 8.16 C, which depict representative sections of tumors used for ultramicroscopy analysis. 
Overview images in the top row show that after 12 hours the Alexa 647-labelled MCMV m38-MHCI-
IgG fusion molecule penetrated into the tumor. Distribution pattern was spotty with areas 
containing more and areas containing less labelled molecule, whereby particularly in marginal 
regions and in areas, where vessel density was high, the highest amount of labelled fusion molecule 
could be found. As also shown in figure 8.16 B most of the molecule could be detected 12 hours 
after application. After 24 and 48 hours decreasing quantities of the molecule were visible in the 
tissue due to clearance from tumor. The close-up image of a section in the bottom row on the right 
shows that the Alexa 647-labelled MCMV m38-MHCI-IgG fusion molecule can be found especially 
near the vessels (as also demonstrated in the penetration profile in figure 8.16 A) and that the 
labelled molecule binds to its target on the tumor cell surface. In the bottom row on the left an 
overview image of a non-treated control tumor is depicted, showing no Alexa 647 signal. 
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Figure 8.16: Tumor penetration and accumulation of pMHCI-IgG molecules. 
(A) Penetration profile of Alexa 647-labelled MCMV m38-MHCI-IgG molecule. Tumors were excised 12 (green), 24 (blue) 
and 48 (red) hours after injection of molecule or without injection of labelled molecule (grey). Amount of MCMV m38-
MHCI-IgG molecule present in the tumor is depicted in relation to distance to vessel borders. All graphs show mean of 
different animals per group (n=4) with error bars indicating standard deviation. (B) Accumulation of Alexa 647-labelled 
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MCMV m38-MHCI-IgG molecule in the tumor. Total amounts of MCMV m38-MHCI-IgG molecule present in the tumor 12 
(green), 24 (blue) and 48 (red) hours after injection of molecule or without injection of labelled molecule (grey) are 
shown. All graphs show mean of different animals per group (n=4) with error bars indicating standard deviation. (C) 
Sections of in vivo stained tumors excised 12 (upper left), 24 (upper middle) and 48 (upper right) hours after injection of 
Alexa 647-labelled MCMV m38-MHCI-IgG molecule or without injection of labelled molecule (lower left). Close-up image 
of tumor tissue with high penetration of Alexa 647-labelled MCMV m38-MHCI-IgG molecule shows binding of labelled 
molecule to tumor cells (lower middle). Color code: Cell nuclei (blue), vessels (red), MCMV m38-MHCI-IgG (green). 
 
8.4.2.4 Infiltration of tumors with CD8+ T cells 
Another prerequisite for successful treatment of solid subcutaneous tumors with T cell recruiters is 
the penetration of effector cells into the tumor mass. To check this, tumor bearing mice were 
vaccinated and treated with effector molecules as depicted in figure 8.13. 24 hours after the first 
treatment with pMHCI-IgG or TCB molecules tumors were excised and used for IHC staining 
detecting CD8+ T cells.  
Figure 8.17 shows representative example pictures of tumor cryo-sections stained for CD8a          
(Fig 8.17 A) and a quantification analysis of CD8+ T cells infiltrating the tumor (Fig. 8.17 B). The 
tumor samples from not vaccinated animals showed only poor CD8+ T cell infiltration, while in 
tumors from MCMV m38-vaccinated mice markedly more CD8+ T cells could be detected. The 
amount of tumor infiltrating CD8+ T cells could be even slightly increased by treatment with        
pMHCI-IgGs or TCBs. The molecules function as CD8+ T cell recruiters and attract effector cells via 
the pMHC class I complex (pMHCI-IgG) or via CD3 (TCB). With this staining it could only be proven 
that CD8+ T cells are recruited into the tumor after treatment with CD8+ T cell recruiters, but not 
that MCMV m38-specific CD8+ T cells are attracted, as needed for the anti-tumor activity of            
pMHCI-IgGs. It is however not unreasonable to assume that the proportion of MCMV m38-specific 
CD8+ T cells present in the pMHCI-IgG-treated tumors correlates with or even exceeds the amount 
of MCMV m38-specific CD8+ T cells found in the blood.  
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Figure 8.17: CD8
+
 T cell infiltration in the tumors. 
(A) Immunofluorescence staining for murine CD8a of tumors without vaccination and without treatment (lower left) or 
MCMV m38 vaccination and TCB (upper right), MCMV IE3-MHCI-IgG (middle left), MCMV m38-MHCI-IgG (middle right) 
treatment or without treatment (upper left). Cell nuclei are stained with DAPI and depicted in blue. Murine CD8a
+
 cells 
are depicted in green. (B) Quantification of CD8
+
 T cells in the tumor. Area covered by CD8
+
T cells in relation to tumor 
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area is depicted for MCMV m38-vaccinated/untreated, MCMV m38-vaccinated/TCB-treated, MCMV m38-
vaccinated/MCMV IE3-MHCI-IgG-treated, MCMV m38-vaccinated/MCMV m38-MHCI-IgG-treated and not 
vaccinated/untreated tumors. All graphs show mean of different animals per group (n=4) with error bars indicating 
standard deviation. 
 
8.4.2.5 Characterization of T cells in tumors and blood 
To determine the phenotype of T cells recruited into the tumor and in the blood flow cytometry 
analyses were applied. Tumor bearing mice were vaccinated and treated with effector molecules as 
depicted in figure 8.13 and 48 hours after the second treatment tumors were taken out and blood 
was drawn.  
Figure 8.18 A shows the characterization of MCMV m38-specific and unspecific CD8+ T cells in the 
tumor and in the blood. CD8+ T cells were checked for expression of CD44 (bottom left), CD62L 
(bottom middle), CD127 (bottom right) and PD-1 (top left). As can be seen in the left histograms for 
each marker MCMV m38-specific CD8+ T cells were CD44+/CD62L-/CD127+ both in the tumor and in 
the blood. Unspecific CD8+ T cells depicted in the right histograms for each marker were 
CD44+/CD62L-/CD127+ in the tumor and CD44+ or -/CD62L+/CD127+ in the blood. Those phenotypes 
were independent from treatment except from CD44 expression in pMHCI-IgG- or TCB-treated 
tumors, where CD44 expression was slightly higher. Evaluating the marker expression MCMV m38-
specific CD8+ T cells generated by vaccination could be characterized as effector cells (CD44+/CD62L-
/CD127+) both in the tumor and in the blood. Unspecific CD8+ T cells in the tumor were effector 
cells as well and unspecific CD8+ T cells in the blood could be divided into naïve (CD44-
/CD62L+/CD127+) or memory (CD44+/CD62L+/CD127+) cells, whereby also cells in the transition state 
could be found. In not vaccinated vehicle mice nearly no CD8+ T cells could be found in the tumor 
so that characterization of CD8+ T cells was only possible in the blood. They were also characterized 
as naïve or memory cells. 
MCMV m38-specific CD8+ T cells in the tumor and in the blood expressed PD-1. With pMHCI-IgG or 
TCB treatment PD-1 expression was a little bit higher. In the tumor expression of PD-1 could be 
found on all CD8+ T cells, regardless of whether they were MCMV m38-specific or unspecific. 
Unspecific CD8+ T cells in the blood showed no PD-1 expression. 
Figure 8.18 B shows the detection of regulatory T cells (Treg cells: CD4
+/CD25+/FoxP3+) in the tumor. 
In the left histogram the detection of CD25+ and CD25- CD4+ T cells in tumors independent from 
treatment is shown. The same applied to the marker FoxP3 analyzed in the right histogram. A 
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FoxP3+ and a FoxP3- population of CD4+ T cells could be found in the tumors of every treatment or 
control group. 
 
Figure 8.18: Characterization of T cells in tumors and blood. 
(A) Flow cytometry analysis for PD-1 (top row), CD44 (bottom row left), CD62L (bottom row middle) and CD127 (bottom 
row right) of MCMV m38-specific (left column each marker) and unspecific (right column each marker) CD8
+
 T cells in 
tumor (top row each marker) and blood (bottom row each marker) samples 48 hours after the second treatment. Color 
code for treatment: Not vaccinated/vehicle (markers only detectable for unspecific CD8
+
T cells in the blood) (purple), 
MCMV m38-vaccinated/vehicle (dark green), MCMV m38-vaccinated/TCB (light green), MCMV m38-vaccinated/MCMV 
IE3-MHCI-IgG (orange), MCMV m38-vaccinated/MCMV m38-MHCI-IgG (blue), Isotype control antibody (red). (B) Flow 
cytometry analysis for CD25 (left) and FoxP3 (right) of CD4
+
 T cells in tumor samples 48 hours after the second treatment. 
Color code for treatment: MCMV m38-vaccinated/vehicle (dark green), MCMV m38-vaccinated/TCB (light green), MCMV 
m38-vaccinated/MCMV IE3-MHCI-IgG (orange), MCMV m38-vaccinated/MCMV m38-MHCI-IgG (blue), Isotype control 
antibody (red). 
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8.4.2.6 PD-L1 expression in tumors 
PD-L1 expression is often found in human and murine tumors and influences effector functions of 
cytotoxic T cells via binding to PD-1 on those cells. To determine whether this is the case in the 
present tumor model, tumors which escaped pMHCI-IgG or TCB therapy were excised 31 days after 
the last treatment and used for flow cytometry analysis of PD-L1 expression. 
Figure 8.19 shows the flow cytometry analysis of tumors for PD-L1. While tumors of the vehicle 
group showed only little PD-L1 expression with 4.9 to 5.9 % PD-L1+ tumor cells out of all tumor 
cells, upregulation of PD-L1 could be found in treatment groups. In tumors of the TCB-treated 
group 24.2 to 30.5 % PD-L1+ tumor cells out of all tumor cells could be detected and in the pMHCI-
IgG-treated group about 20.8 % of all tumor cells were positive for PD-L1.  
 
 
 
 
 
 
 
 
  
Figure 8.19: PD-L1 expression in 
tumors escaping therapy. 
Flow cytometry analysis of tumors, 
which escaped pMHCI-IgG or TCB 
therapy. Tumors of the untreated 
(left), TCB treated (middle), MCMV 
m38-MHCI-IgG treated (right) groups 
were analyzed for PD-L1 expression 
on the cell surface. Color code: 
Autofluorescence of cells (blue), 
isotype control antibody (orange), 
anti-PD-L1 antibody (red). 
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9 DISCUSSION 
9.1 COMPARISON OF DIFFERENT VACCINATION METHODS FOR GENERATION OF 
EFFECTOR CELLS IN MICE 
For in vivo characterization of pMHCI-IgG molecules a surrogate mouse model with endogenous     
T cell recruitment should be applied. Generation of effector cells should be accomplished by 
vaccination of mice. Therefore three different vaccination methods were tested. The aim was to 
establish a reproducable immunization, which is tunable, predictable and also flexible regarding 
level of effector cells generated. For proof of concept relatively high levels and for final efficacy 
studies considerable low levels of effector cells, reflecting frequencies of effector cells in patients, 
should be elicited. 
In the adaptive immune response naïve CD8+ T cells get primed upon encounter of their antigen on 
DCs. In the following primary response primed CD8+ T cells differentiate into effector CD8+ T cells 
and expand up to 50 000-fold to complete killing of infected cells [123, 124]. After the peak of the 
primary CD8+ T cell response most of the effector cells die and only few continue to differentiate 
into memory CD8+ T cells [125]. Upon rechallenge with the same pathogen the long lived memory 
CD8+ T cells can mount very quickly and effectively a secondary immune response against the 
previously encountered antigen [124].  
In the present experiments the primary response of effector CD8+ T cells after vaccination should 
be used for endogenous T cell recruitment. The magnitude of the primary CD8+ T cell response is 
dependent on the duration of the TCR stimulus during initial antigen encounter [126] and therefore 
influenced by availability and amount of antigen at first contact with precursor cells [125]. Thus 
delivery of antigen via different vaccination methods and application routes results in different 
frequencies of effector CD8+ T cells during the primary response. Three different vaccination 
methods, resulting in presentation of antigen on MHC complexes of DCs, were tested. First, 
differentiated and activated DCs, already loaded with antigen in vitro, were injected into mice via 
different administration routes. Second, DNA vectors encoding for the antigen were introduced 
into DCs of animals with DNA injection and following in vivo electroporation. As a third method 
antigen was targeted to DCs in mice via antibody-delivery of antigen to the XCR1-receptor of DCs 
with following internalization and cross-presentation of antigen.  
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For the vaccination with peptide-loaded DCs (see chapter 8.3.1), maturated bone marrow-derived 
DCs were loaded with the OVA-derived peptide “SIINFEKL” and injected into mice to induce a 
“SIINFEKL”-specific CD8+ T cell response. As “SIINFEKL”-pulsed DCs showed superior efficacy 
compared to OVA-protein pulsed DCs [127], the decision was made in favour of the peptide-pulsed 
DCs. With this strategy no CD4+ T cell response is expected, but priming of CD8+ T cells for 
expansion and development of effector functions like cytotoxicity or cytokine secretion during 
primary response is feasible in the absence of CD4+ T cell help [128]. Indeed, secondary immune 
response is impaired as no second round of clonal expansion is possible upon restimulation [128]. It 
was found that vaccination with mature DCs is superior regarding migration, accumulation in lymph 
nodes and expansion of CD8+ T cells [129]. Hence vaccination was performed with LPS-treated DCs. 
LPS-activated DCs are able to secrete MHC class I-bearing exosomes, which can be uptaken by 
autochthonus DCs in secondary lymphoid organs [130, 131]. Those DCs can then present the 
antigen themselves without having got in touch with the original antigen source. Thereby exosomes 
bearing antigen / MHC class I complexes can get to secondary lymphoid organs via migration of 
peptide-loaded, injected DCs or via transport of exosomes with the lymphatic fluid or blood stream 
[130, 131]. This exosomal way of antigen distribution results in an increase of antigen presentation 
and therefore augments antigen-specific CD8+ T cell response (discussed in [132]). 
Depending on how good preconditions like migration and accumulation of APCs in lymph nodes and 
availability and amount of antigen during initial antigen encounter are satisfied, antigen-specific 
CD8+ T cell response will turn out correspondingly. In the present experiment with peptide-loaded 
DCs the i.d. and the s.c. administration of cells seemed to fulfill those requirements best. Peptide-
loaded DCs provided with those injection routes elicited antigen-specific CD8+ T cell responses of 
about 3 to 4 % after two administrations at interval of one week. After a third injection a second 
peak could be triggered, which was marked higher with i.d. administration of cells. By contrast i.p. 
or i.v. injection of peptide-loaded DCs was clearly inferior to i.d. or s.c. administration with the i.p. 
administration route only inducing very low levels of antigen-specific CD8+ T cells in general and the 
i.v. injection missing the second peak after the third administration of DCs.  
The normal localisation of DCs is the skin or other surface tissues, where the primary contact with 
pathogens takes place. Antigens are taken up by DCs via endocytosis and DCs migrate to draining 
secondary lymphatic organs. If antigen uptake took place in the periphery DCs migrate to draining 
lymph nodes, if pathogens entered blood stream antigens are trapped in the spleen and uptaken by 
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DCs there. In the secondary lymphatic organs DCs present peptides of the antigen on MHC 
complexes and prime naïve CD8+ T cells. With injection of already peptide-loaded DCs this 
procedure is mimicked. By i.p. or i.v. injection of DCs a very broad distribution pattern in various 
organic systems can be found [133, 134]. It is likely that many peptide-loaded DCs die or get stuck 
after i.p. or i.v. injection before they can enter the spleen or a lymph node and induce CD8+ T cell 
priming there. The final amount of antigen presented during initial antigen encounter may be 
strongly reduced compared to the amount injected at the beginning. As the physiological 
localisation of DCs is the skin, it is probably argumentative that i.d. and s.c. injection of peptide-
loaded DCs worked better. The exosomal way of antigen distribution as described before with 
secretion of peptide-MHC class I-bearing exosomes, which can be uptaken by other DCs located in 
the skin, is likely to contribute to the success of those application routes. The amount of antigen 
presented during initial antigen encounter in the lymph nodes is probably higher than the one in 
the spleen after i.p. or i.v. injection. The amount of peptide-loaded DCs which can be injected also 
depends on the volume, that can be administered using a certain application route. Applying i.d. 
injection only 20 µl are allowed to be administered, so that only 2 x 105 cells could be injected, 
which is a fourth or an eighth of the cells used for i.v. or s.c./i.p. injection, respectively. In this 
respect, the i.d. injection of peptide-loaded DCs was the most effective one in inducing a antigen-
specific CD8+ T cell response, which can be due to the “most physiological” introduction of peptide-
loaded DCs into the organism. In the past years also others compared different administration 
routes of peptide-loaded DCs for generation of an antigen-specific CD8+ T cell response. However, 
in most cases indirect parameters such as outgrowth of tumor cells were used for efficacy 
evaluation of induced antigen-specific  CD8+ T cell responses. Challenge of mice with tumor cells 
after immunization with peptide-loaded DCs led to better tumor rejection after i.d. or s.c. injection 
of cells than systemic administration of peptide-loaded DC [129, 135, 136], whereby Okada et al. 
also showed a superior efficacy of i.d. administration in an in vitro lysis assay with splenocytes of 
vaccinated mice [135]. Huck et al. and Okada et al. demonstrated that the route of DC 
administration affects site of DC accumulation, time of DC persistence and relating efficacy of 
vaccination in vivo [129, 135]. It was shown that after s.c./i.d. injection DCs accumulate in draining 
lymph nodes for a much longer time than DCs accumulate in the spleen after i.v. injection resulting 
in a better outcome for s.c./i.d. administration of peptide-loaded DCs. These results are reflecting 
the findings in the present study. 
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Applying DNA injection with following in vivo electroporation as vaccination (see chapter 8.3.2), 
vectors encoding for the antigen are brought into murine cells. Genes of plasmid DNA are 
expressed and a xenogeneic protein is produced, which is processed inside cells. As a result 
immunogenic peptides of the protein are presented on MHC class I complexes on the cell surface. 
DCs presentig an immunogenic peptide prime naïve CD8+ T cells and a primary response of antigen-
specific effector CD8+ T cells is induced. In the present experiment the DNA vector injected into 
mice encoded for the whole OVA-protein to ensure correct processing and MHC class I-
presentation of the OVA-derived ”SIINFEKL”-peptide. Two administration routes, i.d. and i.m. 
injection of DNA vectors, were tested. Crucial factors for success of DNA vaccination is a high level 
of antigen expression at the site of application [137] and the initiation of a T cell response by DCs 
[138]. After intramuscular injection of DNA myocytes and kerationcytes express the antigen, but 
also DCs, the professional APCs, can be directly transfected or take up antigen that is secreted by 
other cell types or released by apoptotic cells [138, 139]. Electroporation may contribute to this 
process, as death of some transfected cells after electroporation could supply danger signals, which 
activate DCs [139]. For a long time it was suggested that striated muscle is the only tissue to be 
capable of taking up and expressing genes that are transferred in the form of plasmid DNA [140]. 
However, it was found that also DCs located in the skin can be successfully transfected with plasmid 
DNA [141, 142]. After transfection they migrate to draining lymph nodes and prime naïve T cells 
[142].  
In the present study vaccination via DNA injection with following electroporation elicited only low 
numbers of specific CD8+ T cells in general. In addition the number of non-responders and 
heterogenicity of specific CD8+ T cell levels was very high, making the method not applicable for 
studies requiring high animal numbers with relatively homogenous distributions of specific CD8+ T 
cell levels. Comparing the application routes, the i.d. administration of DNA vectors was marked 
superior to i.m. injection of plasmids, which was also found by Raz et al. [141]. Condon et al. could 
establish a protective tumor immunity by cutaneous genetic immunization with naked DNA [142], 
implicating the generation of a potent, antigen-specific, cytotoxic T cell response. In most cases i.m. 
injection of DNA with following electroporation was used for immunization [137-139, 143-147]. 
Paster et al. and Peng et al. could generate specific CD8+ T cell frequencies of 10 % to 25 % [139, 
147]. A result, which could not be achieved in the present experiments. Paster et al. engineered the 
vaccination-epitope in-frame into the human HLA-Cw3 molecule [139], an antigen, which is 
exceptional in provoking immunogenicity [148]. This modification of the vector led to increased 
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frequencies of epitope-specific CD8+ T cells, which could mediate delayed tumor outgrowth in 
experiments of Kalat et al. [143]. Other groups also tested i.m. injection of DNA with subsequent 
electroporation and evaluated efficacy of vaccination only with indirect parameters like tumor 
growth. In several studies i.m. application of DNA vectors with following electroporation could 
mediate protection of mice from tumor outgrowth or reduction of tumors [139, 143, 145-147]. 
Electric pulses delivered for electroporation were different to the ones delivered in the present 
experiment, which can alter permeabilization of cells during electroporation. Also diverse vectors 
were used for DNA delivery, whereby most of the time a CMV promotor was included, but 
nevertheless this can also influence antigen expression. This alterations could explain reduced 
specific CD8+ T cell frequencies in the present experiment compared to others.  
As a third immunization method the XCR1-targeted vaccination was tested (see chapter 8.3.3). 
XCR1 is exclusively expressed on cross-presenting DCs and no other tissues in mice and humans 
[121] and therefore optimal for specific targeting of cross-presenting DCs. In this experiment the 
OVA-protein and later the MCMV m38 peptide were targeted to the XCR1 receptor with the 
antibody MARX10. This antibody specifically binds to murine XCR1 [121] without altering the 
activation status of XCR1+ DCs [107]. Applying this method a large number of DCs is presenting the 
antigen in the secondary lymphoid organs, resulting in a high amount of antigen at first contact 
with precursor cells and a strong TCR stimulus during initial antigen encounter, which are 
prerequisites for a strong primary CD8+ T cell response [125, 126]. Hartung et al. showed that in an 
in vivo cytotoxicity assay and in an in vivo tumor protection experiment vaccination with the 
MARX10-OVA antibody could induce “SIINFEKL”-specific CD8+ T cells, which eliminate target cells in 
vivo [107]. After immunization with the MARX10-OVA antibody low frequencies of “SIINFEKL”-
specific CD8+ T cells could be detected in the present study. The laboratory of R. Kroczek developed 
further amplification steps to enhance antigen-specific CD8+ T cell response after injection of the 
targeting antibody coupled to the antigen. By addition of a boost step, constituted of an i.v.-
injection of antigen-loaded cells, and an amplification step with administration of half-life extended 
IL-2, high frequencies with up to 50 % “SIINFEKL”-specific CD8+ T cells could be generated. 
Corresponding levels of MCMV m38-specific CD8+ T cells could not achieve such high frequencies, 
but keeping in mind that for MCMV 38 immunization only the peptide and not the whole protein, 
as applied for “SIINFEKL”-vaccination, was fused to the targeting antibody (see chapter 7.1.12) 
MCMV m38-specific CD8+ T cell response was still very high with up to 20 % specific CD8+ T cells. 
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Another contributing factor for the varying CD8+ T cell responses for the epitopes is the high 
immunogenicity of ovalbumin.  
As mentioned before a reproducable immunization method, which is tunable, predictable and also 
flexible regarding level of effector cells, should be established for efficacy evaluation of pMHCI-IgG 
molecules. Obviously targeting of antigen to the XCR1-receptor of cross-presenting DCs combined 
with further amplification steps generated the most potent CD8+ T cell response in our hands. By 
addition or omission of amplification steps the intended percentage of specific CD8+ T cells was 
reasonably well steerable, so that this was the method of choice for generating effector cells in 
further efficacy studies. The amplification steps could have also been combined with DNA 
vaccination or immunization with peptide-loaded DCs, but as the XCR1 targeting vaccination was 
the best established one the choice finally was in favor of this immunization method. Keeping in 
mind that large numbers of animals had to be vaccinated for efficacy studies with pMHCI-IgG 
molecules, this method was also the most feasible one regarding effort. 
 
9.2 COMPARISON OF PEPTIDE-MHC CLASS I-ANTIBODY FUSION MOLECULES 
WITH OTHER PEPTIDE- MHC CLASS I-RETARGETING MOLECULES 
Several studies focused on the recruitment of CTL with antibody-targeted peptide-MHC class I 
complexes for elimination of tumor cells in recent years [1, 2, 93-105, 149-151]. None of the 
molecules were developed for clinical testing up to now because the antibody-MHC fusion proteins 
are technically difficult to produce and in vivo potency of these molecules is difficult to prove. 
Basically the molecules consist of two parts, the peptide-MHC class I part, binding to CD8+ T cells, 
and the targeting moiety, a monoclonal antibody or antibody-derived fragment, which binds to the 
tumor cells. For the targeting part, single chain variable fragments (scFvs) [99, 100, 102, 103] or 
fragment antigen binding portions (Fab´) [98, 101, 104] of antibodies were applied. The molecule 
used in the present study contained a full monoclonal antibody in the IgG format as described and 
applied in previous research work [1, 2, 151]. The size and properties of the molecule are crucial for 
tumor penetration and half-life of the molecule. Fusion proteins containing a scFv have a molecular 
mass of about 65 to 67 kDa [99, 100, 103], molecules with a Fab´ weigh about 95 kDa [98, 101] and 
the molecular weight of fusion proteins comprising a full IgG is about 190 kDa (see chapter 8.1.4). 
With respect to tumor penetration the smaller molecules constructed with a scFv or a Fab´ may 
have an advantage over the ones containing a full IgG. However, earlier work showed that 
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microvascular permeability varied only twofold for proteins between 25 and 160 kDA [152]. 
Regarding pharmacokinetic properties full IgG-fusions with a half-life of about three to six days in 
mice (and 10 to 21 days in humans) are superior to molecules with smaller antibody fragments, 
which have only a half-life of about 24 to 48 hours [99] due to lack of FcRn binding properties and 
fast renal clearance. Zahnd et al. postulated that either very small, soluble proteins with high 
affinity or very large proteins such as full IgG antibodies achieve the best tumor accumulation, 
while intermediate size molecules like scFv fragments show lower tumor accumulation. The very 
small molecules achieve this by a significantly greater capillary extravasation and the very large 
molecules by exceeding the renal filtration cutoff resulting in long circulation. Intermediate size 
molecules lack both favorable properties and thus tumor accumulation is reduced [153]. As shown 
in chapter 8.4.2.3 the surrogate peptide-MHCI- IgG fusion molecules penetrate fairly well into the 
tumor. The early clearance from the tumor is likely owed to the special surrogate isotype used for 
the antibody (see chapter 8.1.1.4). In the surrogate model no further pharmacokinetic studies were 
carried out, but recent pharmacokinetic experiments with human peptide MHC class I-IgG fusions 
in a xenograft model showed accumulation of the molecule in the tumor for over 72 hours and a 
blood half-life of the fusion protein of three to six days [154]. Some groups promoted antibody-
streptavidin-MHC tetramers for redirection of CTL [93, 94, 97, 102, 104, 150], which imply 
advantages but also several limiting factors for the use in vivo. If applied in a two-step process with 
biotinylated peptide-MHC class I complexes and a scFv genetically fused to streptavidin [97, 102, 
104], higher flexibility for patients with different HLA types could be enabled and molecular weight 
of the two proteins would be relatively low with about 85 kDa for the SA-scFv and about 45 kDa for 
the biotinylated peptide-MHC class I part indicating an adequate penetration profile. However, 
streptavidin for in vivo use is still a matter of debate, as antibody responses could be developed 
against this immunogenic protein [155, 156]. If Ab-streptavidin-MHC tetramers would be applied as 
pre-formed complexes, molecular weight would rise to about 400 kDa predicting poor tissue 
penetrance. An additional disadvantage of tetramers is the possibility of T cell activation in the 
circulation [157, 158], as they provide four sites for peptide-MHC class I / T cell receptor 
interaction, which can lead to cross-linking and following activation of T cells in the periphery. 
Another aspect regarding the antibody part of the CTL recruiters is the number of target binding 
sites. As shown by previous research bivalent binding to tumor cells elicits a more effective tumor 
cell killing than monovalent binding [1, 2, 105]. If using a monomer with a scFv or a Fab´ fragment 
as targeting moiety [98-101, 103] only monovalent binding to target cells is possible.  
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With respect to the stability of peptide-MHC class I complexes included in the molecules, covalent 
linkage of peptides to the MHC complex is preferable to loading of peptides by refolding of MHC 
class I heavy chain and ß2M around the peptide. Loaded peptide can disassociate from the MHC 
complex, which leads to loss of recruitment function of the molecule and probably non-specific 
activation of T cells and non-specific elimination of non-targeted cells due to loading of peptide 
onto other cells expressing the appropriate MHC class I complex [96, 101, 105, 150, 159]. To 
overcome those issues covalent cross-linking of the peptide to the MHC class I complex by 
photoactivation [101] or connection of the peptide to the MHC class I complex with a flexible linker 
in various formats were promoted [95, 100, 112, 160, 161].  
Summing up all aspects regarding construction of molecules, pMHCI-IgG molecules seem to be the 
optimal format for the use in patients. Applying a full IgG enables binding to target cells via avidity 
and half-life extension of the molecule due to FcRn recycling with still good tumor penetration 
properties. Fusion of the peptide, the ß2M, the heavy chain of the MHC class I complex and the 
antibody is all recombinant (see chapter 8.1.1.1), which results in a very stable protein with 
reduced immunogenicity risk compared to approaches using a biotin-streptavidin complex for 
linkage or loading of peptide into the groove of the MHC class I complex. An alternative option is 
the chemical conjugation of the targeting moiety to the peptide-MHC class I complex [98, 101, 105, 
150], which is less preferred for large scale production as it involves significant effort for synthesis 
of the molecules. Applying pMHCI-IgG molecules involves no risk of disassociation of the peptide 
from the MHC complex, as the peptide, the ß2M and the heavy chain of the MHC class I complex 
are fused with two flexible linkers. Additional stabilization of the peptide-MHC class I complex could 
be achieved by introduction of a disulfide bond connecting the linker between peptide and ß2M 
with the α1 domain of the MHC class I complex (see chapter 8.1.1.2) [112]. It is also very unlikely 
that T cells in the periphery get activated by pMHCI-IgG molecules, as the fusion protein contains 
only one peptide-MHC class I complex and activates T cells only when cross-linking with target cells 
is taking place as shown in in vitro assays [1]. For further stabilization of the molecule and 
enhancement of production yield several modifications were induced (see chapter 8.1.1). The use 
of a full monoclonal antibody in the IgG format as targeting moiety may raise the question for FcγR 
and C1q binding. To avoid CDC and FcγR-mediated co-activation of innate immune effector cells 
such as ADCC or ADCP a silent Fc-part was introduced into the molecules (see chapter 8.1.1.4). 
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9.3 IN VITRO EVALUATION OF PEPTIDE-MHC CLASS I-ANTIBODY FUSION 
MOLECULES 
Before evaluation of the in vivo efficacy of pMHCI-IgG molecules and TCB antibody, binding of 
surrogate fusion molecules to their target on tumor cell lines was tested (see chapter 8.2.1). With 
flow cytometry analysis could be shown that the fusion molecules bind to their target and that 
binding of the antibody is not impaired by N-terminal fusion of the peptide-MHC class I complex. 
This has been shown before for N-terminal fusions [1, 2, 162]. At molecule concentrations of 5 nM 
or more saturation is reached and all FAP proteins on the surface of tumor cell lines are bound. 
With decreasing compound concentrations fewer molecules are bound to tumor cells with no more 
molecule binding detected at a concentration of 0.005 nM. This applies to both tumor cell lines 
(B16-muFAP and MC38-muFAP) and both pMHCI-IgG molecules and TCB antibody. With a 
secondary antibody detecting the murine MHC class I complex H-2Kb it could be demonstrated, that 
pMHCI-IgG molecules deliver H-2Kb complexes onto the cell surface of tumor cell lines. Also in this 
case a concentration dependent manner of molecule binding with saturation at 5 nM could be 
found. The antibody detecting the OVA257-264 peptide on the H-2K
b complex, demonstrated that the 
peptide together with the MHC class I complex could be brought onto the cell surface of tumor cell 
lines by means of pMHCI-IgG molecules. Thus all components of the fusion molecule could be 
detected on tumor cell lines with flow cytometry, which justified further testing of the molecules. 
Also internalization of molecules could be excluded, constituting another pre-requisite for 
functionality of molecules. Regarding density of native H-2Kb complexes and FAP molecules on the 
cell surface of the different tumor cell lines, it could be found that B16-muFAP cells express more 
FAP but less H-2Kb complexes on their cell surface than MC38-muFAP cells. The density of target 
molecules on the tumor cell surface plays a crucial role in tumor cell killing as shown for the TCB 
antibodies before [91], but in this case the difference in target expression between both tumor cell 
lines is very small and both tumor cell lines show a high density of target molecules, so that tumor 
cell killing should be possible in both cases. This could be also confirmed in in vitro and in vivo 
studies (see chapters 8.2.3 and 8.4.1). 
Before evaluation of the in vivo efficacy of pMHCI-IgG molecules and TCB antibodies, IFN-γ 
activation of CD8+ T cells and cytotoxicity induced by fusion proteins was analyzed in vitro (see 
chapters 8.2.2 and 8.2.3). Oved et al. measured activation of specific CD8+ T cells mediated by 
scHLA-A2/EBV tetramers by determination of IFN-γ release into the culture supernatant with an 
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ELISA (enzyme-linked immunosorbent assay) assay and could demonstrate that CD8+ T cells are 
specifically activated by scHLA-A2/EBV tetramers in a concentration dependent mode [100].         
51Cr release [93, 97, 98, 101, 102, 105, 150] or [35S]methionine release [96, 99, 100, 103] assays 
were used by several groups for cytotoxicity analyses and showed that peptide-MHCI-antibody 
conjugates could mediate in vitro tumor cell elimination in a concentration- and effector to target 
(E:T) ratio- dependent manner. In this study intracellular IFN-γ production of specific CD8+ T cells 
upon exposure to effector molecules bound to target cells was measured with flow cytometry 
analysis. For evaluation of cytotoxicity mediated by fusion molecules the xCELLigence technology 
was applied as also used by Schmittnaegel et al. to determine in vitro cytotoxicity mediated by 
human pMHCI-IgG fusions compared to BiTEs (bispecific T cell engagers) with donor-derived PBMCs 
[2]. Schmittnaegel et al. could show that CMV pp65-MHC class I-IgG fusion molecules achieved a 
comparable absolute target cell killing as the BiTEs (recruiting T cells via CD3) even at low 
frequencies of specific CD8+ T cells, whereby pMHCI-IgG molecules needed more time than BiTEs to 
complete absolute tumor cell elimination.  
The MCMV m38-MHCI-IgG fusion molecule as well as the TCB antibody used in this surrogate 
model could induce IFN-γ activation of only 10 % of CD8+ T cells available for activation. However, 
target cell elimination could be completed up to 93 % with the TCB antibody and up to 63 % with 
the MCMV m38-MHCI-IgG fusion molecules. Also the surrogate pMHCI-IgG molecules needed more 
time than the TCB antibody to complete tumor cell killing. Additionally tumor cell lysis induced by 
the TCB is more effective than the one induced by pMHCI-IgGs. This is due to the fact that          
CD3-based T cell recruiters can recruit a substantially larger number of T cells within CTL than 
pMHCI-IgG molecules, which recruit only specific CD8+ T cells via T cell receptor / peptide-MHC 
class I complex interaction. Consequently T cells redirected by pMHCI-IgG molecules have to 
eliminate more target cells per effector cell than T cells redirected by CD3-based T cell recruiters. 
This was shown by Schmittnaegel et al. before [154] and explains the longer time needed to 
complete target cell killing and the less effective tumor cell lysis mediated by pMHCI-IgG molecules. 
Nevertheless, keeping in mind that pMHCI-IgG molecules had tenfold less effector cells available for 
target cell killing than TCB antibodies they could still eliminate two-thirds of the amount of tumor 
cells lysed with TCB antibodies. PMHCI-IgG molecules containing the control peptide MCMV IE3 
showed same results as controls (tumor cells only, tumor cells with splenocytes) and induced no 
IFN-γ activation of specific CD8+ T cells or cytotoxicity. This demonstrated that IFN-γ activation of 
specific CD8+ T cells and cytotoxicity is specifically mediated by pMHCI-IgG molecules and that other 
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components of splenocytes such as NK cells or macrophages barely induce molecule independent 
and unspecific elimination of tumor cells. However, 20 % of CD8+ T cells available for activation 
were activated by peptide-loading of target cells and lysis of peptide-loaded tumor cells was 
completed by 86 %. IFN-γ activation of CD8+ T cells induced by peptide-loaded tumors cells was 
higher than the one mediated by pMHCI-IgG coated tumor cells. Additionally more tumor cells 
were killed when loaded with peptide as when coated with pMHCI-IgGs. This indicates that not all 
MCMV m38-specific CD8+ T cells detecting the natural peptide-loaded MHC class I-complex on the 
tumor cell surface recognized the recombinant MCMV m38-MHCI-complex delivered to the target 
cell surface with pMHCI-IgGs. 
With respect to the OVA257-264-MHCI-IgG fusion molecule results were comparable. However, for 
OVA257-264 nearly no IFN-γ activation of CD8
+ T cells could be induced by the pMHCI-IgG. 
Nevertheless up to 80 % of tumor cells could be lysed by means of the fusion molecule, while time 
interval needed to complete target cell killing was again very large compared to TCB or peptide-
loaded tumor cells. Also in this case peptide-loaded tumor cells induced higher IFN-γ activation of 
CD8+ T cells and more effective target cell lysis than pMHCI-IgG coated tumor cells. 
Keeping in mind that there are even less H-2Kb complexes on the tumor cell surface for peptide-
loading than FAP molecules for pMHCI-IgG binding (see chapter 8.2.1), this indicates that the less 
efficient target cell killing or IFN-γ activation of CD8+ T cells mediated by pMHCI-IgGs is caused by 
the molecule itself and not by reduced functionality of specific CD8+ T cells generated by 
vaccination. Reasons for that could be incorrect folding of peptide-MHC class I complex, impurity of 
molecules in the fashion of side products lacking the peptide-MHC class I complex, aggravated 
accessibility of the peptide-MHC class I complex for CD8+ T cells due to steric hindrance or 
suboptimal distance between target cell surface and peptide-MHC class I complex brought onto the 
cell surface by pMHCI-IgGs.  
Impurity of protein can be excluded as SDS-PAGE and western blotting were applied to prove that 
only knob-hole-products (antibody fused to one peptide-MHC class I complex) were obtained after 
the purification process (see chapter 8.1.4).  
Incorrect folding of the peptide-MHC class I complex can be partially excluded, because some 
portions of the MHC complex and the peptide could be detected in the right formation with 
secondary antibodies (see chapter 8.2.1). Still it is possible that the N-terminus or C-terminus of the 
peptide is not formatted optimally in the groove of the MHC class I complex despite the disulfide 
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bond connecting the linker between peptide and ß2M with the α1 domain of the MHC class I 
complex (see chapter 8.1.1.2), which can cause poor recognition by specific CD8+ T cells. To verify 
this, a crystal structure analysis could be carried out, but this is very time consuming and expensive, 
so that this technology was not applied here.  
The accessibility of the peptide-MHC class I complex on the target cell surface is difficult to prove, 
but could be a reason for less efficient target cell killing or IFN-γ activation of CD8+ T cells mediated 
by pMHCI-IgGs. If pMHCI-IgG molecules bind to the cell surface target in such a way that the 
peptide-MHC class I complex is not or only difficult to access for specific CD8+ T cells due to steric 
hindrance, efficacy of fusion proteins will be impaired. Thus functionality of pMHCI-IgG molecules is 
also dependent on the cell surface target chosen for the fusion protein. Schmittnaegel et al. 
showed that human pMHCI-IgG fusions delivered peptide-MHC class I complexes to the target cell 
surface, that were recognized just as well as native MHC class I complexes loaded with peptide by 
specific CD8+ T cells, resulting in equal IFN-γ activation of specific CD8+ T cells and tumor cell lysis 
[1]. According to this every newly designed pMHCI-IgG fusion protein has to be tested for those 
properties before further development. 
Another aspect is the distance between tumor cell surface and peptide-MHC class I complex. By 
means of the pMHCI-IgG molecule an artificial peptide-MHC class I complex is delivered to the 
target cell surface, which is located further away from the cell surface than a native MHC class I 
complex loaded with peptide. With 170 kDa the fibroblast activation protein (FAP) is a fairly large 
surface protein. If the antibody included in pMHCI-IgG fusions binds to a part of the protein, which 
is located at the very outer end of the surface molecule, the distance between target cell surface 
and peptide-MHC class I complex delivered to the cell surface by pMHCI-IgGs is relatively large. 
Consequently the distance between target cell and effector cell recognizing to the peptide-MHC 
class I complex is also enlarged. This can have a considerable influence on effectiveness of target 
cell killing mediated by effector cells. The larger the distance between target cell and effector cell is 
the less effective is killing activity mediated by effector cells. This issue was also described for CARs 
(T cells genetically modified to express chimeric antigen receptors) [163, 164].  
Another finding was that peptide-loading of tumor cells achieved only at higher concentrations the 
maximum of IFN-γ activation, whereas pMHCI-IgG coating of tumor cells reached maximal IFN-γ 
activation already at lower concentrations. This is likely due to the fact that the antibody constructs 
bind very fast and with high affinity (< 1 pM: see chapter 8.1.1.5) to their target on the tumor cell 
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surface, while affinity of peptides to MHC class I complexes is comparably weak (<1 nM to                     
>20 000 nM) [165]. Thus at lower concentrations more peptide-MHC class I complexes are present 
on the tumor cell surface when delivered by pMHCI-IgGs than with peptide-loading, because the 
antibody constructs bind to the tumor cell surface very fast and with high affinity, while peptides 
bind more slowly to the MHC class I complexes and disassociate again easily. 
 
9.4 IN VIVO EVALUATION OF PEPTIDE-MHC CLASS I-ANTIBODY FUSION 
MOLECULES 
In vivo studies with CTL recruiters for antibody-targeted tumor cell elimination have been carried 
out before [2, 96-99, 101, 103-105]. Many experiments were performed as pre-treatment models, 
in which tumor cells were already pre-incubated with the targeting molecule in vitro before 
injection into mice [97, 101, 104, 105]. In other low bar models tumor cells were injected 
subcutaneously together with effector cells and effector molecules [96] or systemic treatment with 
effector molecules was started at the day of tumor cell inoculation or one day later [2, 98, 101, 
103]. As effector cells genetically engineered T cell clones or expanded CTLs from patient-derived 
PBMCs were applied in immunodeficient mice [2, 96, 97, 99, 103], which lack an immune system. 
Others used vaccination strategies which mostly targeted OVA as antigen and in some cases 
included adoptive transfer of OVA-specific H-2Kb-restricted TCR transgenic T cells from OT-1 mice 
[98, 104, 105]. This approach with endogenous T cell recruitment rather meets the conditions in 
patients, but is still artificial as OVA is an exceptional antigen in provoking immunogenicity resulting 
in very high and unphysiological levels of specific CD8+ T cells. Cesson et al. used a model with 
Lymphochoriomeningitis Virus (LCMV)-infected mice [101], which reflects the situation in patients 
best. Effector cells are generated in a physiological way resulting in physiological levels of specific 
CD8+ T cells. In this study endogenous T cell recruitment after vaccination for OVA or MCMV is 
applied. 
9.4.1 Experimental lung metastasis model 
Syngeneic models comparable to the preventive setting of the experimental lung metastasis model 
carried out with pMHCI-IgGs (see chapter 8.4.1.1.1) were performed by Cesson et al., Savage et al. 
and King et al. [101, 104, 105]. They showed killing capacity of pMHCI-retargeting conjugates on 
single tumor cells in the circulation using lung metastasis models with B16 melanoma cells 
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transfected for a target surface protein and endogenous T cell recruitment. Savage et al. and King 
et al. immunized mice for OVA257-264 as also done in studies with pMHCI-IgG fusions [104, 105], 
whereas Cesson et al. used mice acutely infected with influenza [101]. Comparing studies regarding 
numbers of effector cells available at tumor challenge, animals had levels of 10 % to 15 % influenza-
specific CD8+ T cells in the bronchoalveolar lavage [101], 1 % to 2 % OVA257-264-specific CD8
+ T cells 
in the spleen [105] or 6 % OVA257-264-specific CD8
+ T cells and 3 % MCMV m38-specific CD8+ T cells, 
respectively, in the blood in the present study. Savage et al. and King et al. targeted human CD20 
on B16 melanoma cells [104, 105], whereby King et al. used tumor cells expressing very low levels 
of target antigen [105]. Cesson et al. used HER2 as target on B16 melanoma cells, which was 
expressed in high frequencies comparable to FAP expression of B16 cells used in the present study 
[101]. Different to described experiments, in which tumor cells were coated with effector 
molecules in vitro before intravenous injection into mice [101, 104, 105], in the present study mice 
were treated systemically (intravenously) with effector molecules 24 hours before tumor challenge. 
As a result of all protection assays mice treated with a pMHCI-retargeting molecule showed 
significantly fewer or no lung metastases compared to control groups. The different experiments 
with variable preconditions regarding expression of target antigen, generation, epitope and levels 
of specific CD8+ T cells, effector molecules and target cells (in vitro before injection or in vivo after 
administration) led to similar results with respect to protection from lung metastases. To prove that 
elimination of tumor cells is mediated by recruitment of specific CD8+ T cells and not by other 
effects associated with the molecules (e.g. ADCC by FcγR-mediated co-activation of innate immune 
effector cells) one group in the present study was treated with a pMHCI-IgG molecule containing 
the control peptide MCMV IE3. For this MCMV epitope mice do not have specific CD8+ T cells so no 
killing of tumor cells was observed as expected. This is in line with the results on non-immunized 
mice with pMHCI-conjugates from King et al. [105]. King et al. also compared retargeting conjugates 
with one or two binding sites for hCD20, whereby the molecule with two binding sites was the 
more effective one, indicating that avidity binding of retargeting molecules is important for a better 
outcome. Additionally this is the only previous in vivo study, which compares pMHCI-retargeting 
conjugates with bispecific molecules recruiting CTL via CD3. For this purpose heterodimers 
targeting muCD3 and hCD20 with one Fab´ each were engineered [166, 167]. In the lung 
metastases protection assay the bispecific antibody could protect naïve mice completely from lung 
metastases and also immunized mice treated with the retargeting conjugates showed almost 
complete inhibition of metastases formation, with the retargeting conjugate containing two binding 
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sites for hCD20 being more effective. This results match with the findings in the this study. King et 
al. also performed a surrogate lymphoma model with human CD20-transfected EL4 cells and 
endogenous T cell recriutment after vaccination for OVA257-264 [105], in which systemic molecule 
administration was started three days after tumor cell inoculation. In this survival experiment mice 
treated with the bispecific antibody survived as long as animals treated with the retargeting 
conjugates with one binding moiety for hCD20. Retargeting conjugates binding the target via avidity 
showed the best results regarding survival of mice and hence were prior to the bispecific antibody 
containing only one target binding site. Vaccination had a significant impact on tumor growth, as 
immunized mice showed increased survival compared to naïve mice. This finding corresponds to 
the result of the experimental lung metastasis model carried out here for evaluation of pMHCI-IgG 
fusions. Vaccinated control groups showed markedly fewer B16 colonies than not-vaccinated 
vehicle groups. Tumor growth inhibition mediated only by vaccination may be an effect of 
activation of innate immune cells due to cytokine release during primary immune reaction. In the 
present study it is probably owed to the administration of complexed IL-2 during immunization, 
whereas King et al. might elicit a weak anti-tumor response induced by the anti-CD40 antibody 
injected as part of vaccination [105]. Nevertheless in both experiments a marked tumor growth 
inhibition mediated by pMHCI-retargeting molecules could be observed beyond immunisation 
alone. 
So far no study evaluating the therapeutic treatment of already established lung metastasis with 
pMHCI-retargeting molecules was described. In the present experiment B16 melanoma cells were 
injected intravenously so that tumor cells could migrate to the lung, settle down there and cause 
lung metastases. After nine days, when lung metastases were established, mice were treated 
intravenously twice with pMHCI-IgG fusions. Effector cells in mice were generated with the XCR1-
targeted vaccination as described before (see chapter 7.3.2.3.). In this experimental setup neither 
the pMHCI-IgG nor the TCB could completely eliminate tumor cells, but a significant, delayed 
metastasis growth could be achieved with both molecules in a similar fashion. One group of 
animals vaccinated for MCMV m38 was treated with the pMHCI-IgG molecule containing the 
control peptide MCMV IE3 resulting in strong metastasis growth. This showed that elimination of 
tumor cells was specifically mediated by redirection of specific CTL with pMHCI-IgG fusions. 
Conspicuously the MCMV m38 system showed a clearly better outcome than the OVA257-264 system. 
This may be caused by impaired activation capability of the OVA257-264-MHCI-IgG fusion molecule, 
which is likely due to the fact that the recombinant pMHCI-IgG was not fully achieving the potency 
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of the peptide-loading of the endogenous MHC class I complexes already obvious from the in vitro 
assays. As part of this issue there is no significant difference in metastasis burden between control 
groups treated with the non-binding control molecule or PBS and the OVA257-264-MHCI-IgG 
treatment group. Loss of target expression of tumor cells can be excluded as reason for missing 
efficacy as stable FAP expression in metastases could be demonstrated by immunohistochemistry 
(see chapter 8.4.1.2).  
Again vaccination had marked influence on metastasis growth as already described by others 
before [98, 105]. Furthermore it is interesting to note that activation of effector cells by 
immunization also seems to support function of the TCB. Metastasis burden of the not-vaccinated, 
TCB-treated group is outstandingly reduced compared to the not-vaccinated vehicle group, but still 
comparable to the number of metastases found in the vaccinated vehicle group. TCB treatment 
combined with immunization reduces metastasis burden further more.  
Summing up the pMHCI-IgG molecule as well as the TCB antibody could protect mice from lung 
metastasis in a preventive setting and reduce metastasis burden in a therapeutic setting. Keeping in 
mind that B16 is a very aggressive growing and immune suppressive tumor a notable tumor growth 
inhibition could be induced by only two systemic treatments with the molecules. This could be 
proven by two different evaluation methods (counting of visible metastasis on the lung surface and 
quantitative PCR), whereby results correlated very well.  
 
9.4.2 Solid subcutaneous tumor model 
Donda et al., Lev et al. and Novak et al. were the first ones to treat already established 
subcutaneous tumors with peptide-MHCI-antibody conjugates [98, 99, 103].  
Yoram Reiter’s group performed xenograft models with human tumors and human CTL in Balb/C 
nude mice [99, 103]. Human tumor cell lines were injected subcutaneously into mice and after 4 to 
7 days tumor volume reached 40 to 50 mm3 and therapeutic treatment was started. Therefore 
effector molecules and CTL were injected intravenously with a time interval of about six hours. The 
injections were repeated three times every other day. With this experimental set up Lev et al. and 
Novak et al. could achieve marked tumor growth inhibition and tumor regression mediated by 
retargeting molecules, which lasted even ten days after the last treatment [99, 103].  
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A syngeneic model with endogenous T cell recruitment was performed by Donda et al. [98]. Also in 
this case ovalbumin was used as antigen for generation of specific effector cells. Mice were 
adoptively transferred with splenocytes derived from OT-1 mice, which have a transgenic T cell 
receptor that recognizes ovalbumin residues 257 to 264 (“SIINFEKL”) in the context of H-2Kb, and 
afterwards immunized by subcutaneous injection of ovalbumin emulsified in an adjuvant. This 
raised a CD8+ T cell response of 12 to 40 % OVA257-264-specific CD8
+ T cells in the blood at the peak 
and about 15 % at the time point when tumor cells were grafted subcutaneously. Eight days after 
subcutaneous inoculation of CEA-transfected MC38 colon carcinoma cells, when all mice had 
palpable nodules, systemic treatment with effector molecules was started and continued until end 
of experiment with administration of retargeting conjugates every second day. In this experiment a 
significant tumor growth inhibition under continuous treatment with retargeting molecules could 
be achieved. However, the therapeutic effect showed only a temporary nature as ultimately tumors 
developed despite treatment with effector molecules. 
In the present study a surrogate model with endogenous T cell recruitment was applied to 
scrutinize efficacy of pMHCI-IgG retargeting molecules in a solid subcutaneous tumor. For 
generation of effector cells mice were immunized. As the OVA system is artificial, the 
immunodominant epitope m38 of the murine Cytomegalovirus was chosen as antigen for 
vaccination. For generation of a solid subcutaneous tumor FAP-transfected MC38 colorectal cancer 
cells were injected subcutaneously into mice. At start of treatment with the retargeting molecules 
mice had an average blood level of about 5 % MCMV m38-specific CD8+ T cells (which equals the 
level of CMV pp65-specific CD8+ T cells in chronically CMV-infected humans) and an average tumor 
volume of 97 mm3. Effector molecules were administered systemically five times at an interval of 
three days. Afterwards tumor volume was measured twice weekly. As a result no difference 
regarding tumor growth inhibition between treatment and control groups could be found. In the 
group treated with the pMHCI-IgG three out of eight animals were tumor free and in the group 
treated with the TCB two out of eight animals had complete tumor regression, while tumor 
volumes of the other animals constantly increased. However, control groups treated with PBS or 
the pMHCI-IgG molecule containing the control peptide MCMV IE3 showed same results with two 
out of eight tumor free animals and the rest of the tumors constantly growing. Tumor free mice in 
control groups are very likely caused by immune activation during vaccination as also observed in 
the experimental lung metastasis model and by others before [98, 105]. In this case especially 
administration of complexed IL-2 during vaccination seemed to be the main driver of unspecific 
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tumor regression. With the IL-2 being half-life extended by binding to a full IgG, effects lasted for 
about one week and were able to influence tumors in such a way that they completely disappear in 
some cases. Conversely, this also reveals that tumor free animals in the treatment groups may 
potentially not be induced by treatment with the pMHCI-IgG or the TCB, but by immune activation 
during immunization. In the time-to-event analysis tumor growth is slightly retarded by treatment 
with the pMHCI-IgG fusion molecule, but overall no significant tumor growth inhibition could be 
found in treatment groups. Tumor volume of the remaining tumor bearing mice in treatment 
groups constantly increased as in the control groups without delayed tumor growth kinetics.  
This exhibits a certain resemblance to the findings made by Donda et al., where a significant tumor 
growth inhibition could be achieved in the retargeting conjugate treatment group compared to the 
control group, but finally MC38 tumors also grew despite continuous systemic treatment with 
retargeting conjugates every second day [98]. Compared to the present study minor barriers had to 
be broken down as treatment interval was closer and sustained until end of experiment and at start 
of treatment blood levels of specific CD8+ T cells were higher and volume of tumors was smaller. In 
the xenograft models performed by Lev et al. and Novak et al. significant tumor growth inhibition 
and tumor regression could be achieved with only three systemic injections of retargeting 
molecules [99, 103]. However, effector cells were not recruited endogenously, but injected 
systemically within a short time period after every administration of effector molecules. This 
provides a higher amount of specific CD8+ T cells available for retargeting after treatment and 
simplifies preconditions for effective tumor growth inhibition mediated by retareting molecules. In 
addition tumor volume at start of treatment was only half as large as in the present efficacy study. 
Considered in this context hurdles in the present experiment were quite high. 
Causes for missing tumor growth inhibition mediated by pMHCI-IgG fusion molecules can be due to 
a multifold of factors. One prerequisite for successful treatment of tumors with targeted effector 
molecules is the maintenance of stable target expression of tumor cells in vivo. Recombinant cells 
are usually kept under selection pressure to force expression of the transgene (e.g. antibiotics). In 
the absence of the selection pressure in vivo and the new cellular environment, engineered cells 
may quickly adapt and lose the expression of the transgene. This may lead to loss of transgene 
expression in some tumor cells, which generate subpopulations of cells that do no longer express 
the target protein. Elimination of those tumor cells mediated by effector molecules is not possible 
as fusion proteins are not able to bind to the tumor cell surface. As shown in chapter 8.4.2.2 target 
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expression of tumor cells was still maintained independent from treatment after several weeks of 
tumor growth in vivo. Consequently loss of target expression in the solid tumor can be excluded as 
reason for missing tumor growth inhibition mediated by pMHCI-IgG fusion molecules. 
Donda et al. mentioned poor vascularization causing low penetration of effector molecules into the 
tumor and dropping blood levels of specific CD8+ T cells at later time points as reasons for reduced 
efficacy of effector molecules [98]. Different to the MC38 tumors applied by Donda et al. the MC38 
tumors used in the present study showed good vascularization and moderate molecule penetration 
as shown in chapter 8.4.2.3. The highest amount of the labelled fusion protein could be found near 
the vessels and with rising distance to vessels quantity of the molecule in the tumor tissue 
decreased. Consequently distribution of the fusion molecule in the tumor was not even, but rather 
patchy. Also binding of pMHCI-IgG molecules to tumor cells could be proved. Clearance of the 
protein from the tumor started quite early with obvious reduction of molecule amount after 24 
hours and clearance of the bulk after 48 hours. Overall, ultramicroscopy analysis showed that 
tumors were well vascularized and that fusion molecules were able to penetrate into the tumor 
tissue and bind to their target on the tumor cells. Even though distribution pattern was spotty, 
fusion proteins covered widespread areas of the tumor, which should have been at least sufficient 
for induction of stasis of tumor growth. As the bulk of the molecule is cleared from the tumor after 
48 hours, the treatment interval with systemic injections only every third day might have been a bit 
too infrequent. Shortening of the treatment interval to molecule administrations every second day 
might improve constant penetration of the tumor with effector molecules. In summary the 
penetration profile of the pMHCI-IgGs is not optimal and leaves room for improvement, but indeed 
shows widespread molecule distribution in the tumor, so that this issue should not be the reason 
for missing tumor growth inhibition in solid tumors under pMHCI-IgG treatment. 
Decrease of specific CD8+ T cell levels in the blood at later time points as mentioned by Donda et al. 
[98] could also be observed in the present study. Looking at the vaccination experiments in chapter 
8.3.3 the peak of the MCMV m38-specific CD8+ T cell response after the XCR1-targeted vaccination 
was on day nine after start of vaccination. Afterwards levels of specific CD8+ T cells slowly 
decreased until day 25 and then started to drop more significantly. In the present study animals 
were treated five times at an interval of three days with treatment starting on day ten after start of 
vaccination (see figure 8.13 and table 8.2). Thus all treatments fell into the time frame of the CD8+ T 
cell peak or in the phase of only slowly dropping CD8+ T cell levels. In this sense MCMV m38-specific 
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CD8+ T cells should have been available as effector cells at every time point of treatment with 
fusion molecules. Still no tumor growth inhibition could be observed, as tumors in the treatment 
groups started to grow as fast as tumors in the control groups. This is different to Donda et al., 
where tumor growth could be delayed at the beginnig of treatment and only at later time points, 
when blood levels of specific CD8+ T cells dropped, no more tumor growth inhibition could be 
induced with retargeting molecules [98].  
Another aspect is the infiltration of tumors with CD8+ T cells. If effector cells found in the blood are 
not able to infiltrate the tumor, no tumor cell elimination mediated by pMHCI-IgG fusions is 
possible. As shown in chapter 8.4.2.4 CD8+ T cells could be found in the tumor during treatment. 
Compared to tumors of not-vaccinated animals tumors of vaccinated mice showed marked higher 
infiltrations of CD8+ T cells. Assuming that the portion of MCMV m38-specific CD8+ T cells out of all 
CD8+ T cells in the blood is transferrable to the portion of MCMV m38-specific CD8+ T cells in the 
tumor, effector cells for recruitment and activation by pMHCI-IgG molecules should have been 
available in the tumor during treatment.  
With flow cytometry analyses the phenotype of CD8+ T cells present in the tumor was analyzed (see 
chapter 8.4.2.5). CD44 is a cell surface protein, which participates in cell-cell interaction, cell 
adhesion and cell migration. It has several functions such as lymphocyte activation, recirculation 
and homing. Expression of CD44 is an indicative marker for effector and memory T cells [NCBI Gene 
ID: 12505 and 960]. CD62L, also known as L-selectin, is a cell adhesion molecule, which is found on 
naïve or memory T lymphocytes. As homing factor it facilitates entry of T cells into secondary 
lymphoid organs by binding to ligands on endothelial cells and thus slowing lymphocyte trafficking 
through the blood [NCBI Gene ID: 20343] [168]. CD127, also known as Interleukin-7 receptor 
subunit alpha (IL7R-α), is involved in development and activation of T lymphocytes [NCBI Gene ID: 
16197]. MCMV m38-specific CD8+ T cells as well as unspecific CD8+ T cells in the tumor could be 
characterized as effector cells (CD44+/CD62L-/CD127+). Regardless of whether they were          
MCMV m38-specific or unspecific, CD8+ T cells seemed to get a little bit more activated and 
stimulated to home into the tumor by treatment with pMHCI-IgG molecules or TCB antibody, as 
they were expressing slightly more CD44 upon treatment. The phenotype of MCMV m38-specific 
CD8+ T cells (effector cells: CD44+/CD62L-/CD127+) was mostly independent from treatment and 
localization (tumor or blood) and therefore mainly caused by vaccination. In this respect, activated 
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effector cells were present in the tumor during treatment and should have the compentence to 
eliminate tumor cells. 
CD8+ T cells were also checked for expression of PD-1, a marker for activation, but also exhaustion 
of T cells. PD-1 or CD279 is a cell surface receptor, which is expressed on T and pro-B cells and 
functions as negative regulator in the immune system [NCBI Gene ID: 18566]. It binds to the ligands 
PD-L1 (CD274: [NCBI Gene ID: 60533]) and PD-L2. PD-L1 is upregulated on T and B cells upon T or B 
cell receptor signaling. Interaction of receptor and ligand down regulates activation of T cells, 
enhances apoptosis of antigen specific T cells and reduces apoptosis of regulatory T cells. As a 
consequence the mechanism promotes self-tolerance and reduces autoimmunity [169]. PD-1 
expression could be found on MCMV m38-specific and unspecific CD8+ T cells in the tumor. In the 
blood MCMV m38-specific CD8+ T cells, but not unspecific CD8+ T cells showed PD-1 upregulation. 
As MCMV m38-specific CD8+ T cells both in the tumor and in the blood expressed PD-1, activation 
of specific CD8+ T cells is mainly caused by vaccination. With pMHCI-IgG or TCB treatment PD-1 
expression on MCMV m38-specific CD8+ T cells in the tumor was even slightly higher indicating that 
treatment with effector molecules additionally activates specific CD8+ T cells. However, PD-1 
upregulation on CTL also leads to suppression of those cells upon interaction with the ligand PD-L1 
as described above [57, 59, 72, 170, 171]. PD-L1 expression on APCs or normal tissue cells is caused 
by IFN-γ release of activated CD8+ T cells [58, 59, 72, 172-174]. Also in a vast amount of tumors   
PD-L1 is upregulated [57-59], especially when CD8+ T cells producing IFN-γ are infiltrating the 
tumor. In this way tumors escape surveillance of the immune system and prevent being eliminated 
by tumor infiltrating CTL [57-59]. In the MC38 tumor model used in this study PD-L1 expression on 
tumor cells could be detected by flow cytometry analysis (see chapter 8.4.2.6). In pMHCI-IgG and 
TCB treatment groups PD-L1 expression was considerable higher than in vehicle groups indicating 
that PD-L1 upregulation on tumor cells took place in response to IFN-γ release of CD8+ T cells 
activated by treatment. These findings demonstrate that missing tumor growth inhibition under 
pMHCI-IgG or TCB treatment could be due to inactivation and suppression of effector cells via the 
PD-1 / PD-L1 axis. 
Additionally regulatory T cells could be found in the tumor (see chapter 8.4.2.5). FoxP3 is a specific 
marker for natural, adaptive and induced Treg cells. It is an intracellular protein, which functions as 
transcriptional regulator in cell nuclei, and plays a critical role in development and function of      
Treg cells [NCBI Gene ID: 20371]. CD25 is the alpha chain of the IL-2 receptor and a less specific 
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marker for Treg cells. It is expressed on activated T lymphocytes and constitutively on Treg cells   
[NCBI Gene ID: 16184]. In the physiological iummune response Treg cells prevent an overreaction of 
the immune system by downregulation of effector T cells. IL-2 released by activated effector T cells 
induces generation and maintenance of Treg cells, which thereupon secrete IL-10 and other 
suppressive cytokines [48, 175-180]. Hence regulatory T cells play a crucial role in control of 
autoimmunity. Infiltrations of Treg cells in the tumor cause in this case an unwanted, suppressive 
influence on CD8+ T cells, which leads to inactivation and loss of effector function of those cells. As 
complexed IL-2 was administered several times during vaccination in this experiment, it is not 
surprising that Treg cells could be found in the tumor. 
In summary lack of tumor growth inhibition under pMHCI-IgG treatment in solid tumors is probably 
caused by inactivation of effector cells due to suppressive influences. Basic preconditions, like 
penetration of molecules and effector cells into the tumor and binding of effector molecules to the 
target on the tumor cell surface, were met, but effector function of CD8+ T cells seemed to be 
compromised. Inactivation of CD8+ T cells by PD-1 / PD-L1 interactions with tumor cells and by 
suppressive influences on the basis of Treg cells probably led to loss of effector function of CD8
+ T 
cells and thus to lack of tumor growth inhibition.  
To overcome these issues a combination therapy with a PD-1 or PD-L1 blocking antibody could be 
applied. The PD-1 pathway would be interrupted and CD8+ T cells would no longer be impaired in 
their effector function [58, 72, 173]. Several antibodies blocking the PD-1 / PD-L1 axis are successful 
on the market or applied in clinical trials and revealed promising results in melanoma, RCC, NSCLC, 
colorectal cancer, bladder cancer or Hodgkin´s lymphoma [72-79]. 
To remove suppressive influence on CD8+ T cells caused by Treg cells in the mouse model, Treg cells 
could be depleted by administration of diphteria toxin [181, 182] or a Treg depleting antibody 
directed against CD25 [183-188]. In patients this approach has to be handeled with care as Treg cells 
play a crucial role in the control of autoimmunity. However, in some clinical trials depletion of 
regulatory T cells was accomplished with low-dose cyclophosphamide [189] or docetaxel-based 
[190] chemotherapy, with an anti-human CCR4 (C-C chemokine receptor type 4) monoclonal 
antibody [191] or with a recombinant IL-2 diphtheria toxin conjugate [192] showing good 
tolerability regarding autoimmunne responses and an improved outcome in relation to progression 
of disease.  
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As mentioned above IL-2 administration during vaccination is most certainly also involved in                  
Treg infiltration of tumors. Reduction of IL-2 dosing, in a way that specific CD8
+ T cell level is still 
viable, would probably also contribute to reduction of Treg cells in the tumor. With this approach 
unspecific tumor regression as observed in control groups of the study might also be avoided. 
Murine models applying Treg depletion combined with immune checkpoint inhibition were 
performed before. Combination of Treg depletion accomplished with an anti-mouse CD25 antibody 
and CTLA-4 blockage could significantly increase survival in mice bearing B16 tumors [185].                     
Treg depletion by administration of diphteria toxin in combination with a PD-L1 blocking and a Tim-3 
(T-cell immunoglobulin and mucin-domain containing-3) blocking antibody led to increased virus-
specific CD8+ T cell levels in mice chronically infected with FV (Friend virus) [181]. 
For successful treatment of solid tumors with pMHCI-IgG or TCB molecules the basic requirement 
of availability of functional effector CD8+ T cells has to be met. This might be accomplished with a 
combination of reduction of IL-2 dosing during vaccination, PD-1 or PD-L1 blockage and                            
Treg depletion. 
 
9.5 COMPARISON OF PEPTIDE-MHC CLASS I-ANTIBODY FUSION MOLECULES 
WITH CD3-BASED T CELL ENGAGERS 
One main aspect of the study was to compare the anti-tumor efficacy of pMHCI-IgG fusion proteins 
with CD3-based T cell recruiters. At the moment two T cell engagers recruiting and activating T cells 
via CD3 have been approved. Catumaxomab is a TCB, that targets EpCAM for the treatment of 
malignant ascites [87, 88]. It comprises a rat/mouse hybrid monoclonal antibody with an active              
Fc-domain and is therefore highly immunogenic in humans and causes severe cytokine releases due 
to FcγR binding upon systemic administration. Thus only local, peritoneal administration is 
approved [92]. Blinatumomab overcame those issues by removal of the Fc-part and linkage of the 
targeting domain with the anti-CD3 domain via a linker. It targets CD19 and is approved for 
treatment of refractory B-cell acute lymphocytic leukemia [89, 90]. However, lack of FcRn recycling 
and small size of the molecule lead to a fast drug clearance and require continuous infusion for 
several weeks. A novel IgG-based TCB, which targets CEA-expressing solid tumors, is currently in 
phase I clinical trials [91]. It exhibits a similar structure (2+1 format) as the surrogate TCB used in 
the present study with a full human IgG comprising an engineered Fc-region to abolish FcγR and 
        Discussion 142 
 
C1q binding (see chapter 8.1.1.4). Therefore it augurs a favourable pharmacokinetic and savety 
profile compared to earlier TCB formats.  
In the present study the TCB as well as the pMHCI-IgG showed comparable outcomes. Both formats 
could protect mice from lung metastasis in a preventive treatment setting and could reduce 
metastasis burden in a therapeutic treatment setting (see chapter 8.4.1). However, both molecules 
lacked mediation of tumor growth inhibition in the solid subcutaneous tumor model probably due 
to suppression of effector cells (see chapter 8.4.2). By contrast others showed efficacious tumor 
regression mediated by the human CEA-targeting TCB format in a xenograft mouse model with 
intraperitoneal transfer of PBMCs [91]. King et al. also compared the in vivo anti-tumor efficacy of 
pan-T cell recruiters with pMHCI retargeting molecules in a surrogate lymphoma model with 
endogenous T cell recruitment, whereby all molecules were Fab´-based. It was observed that the 
CD3-based T cell recruiter and the pMHCI retargeting molecule mediated the same increase of 
survival, when containing one tumor targeting domain. The pMHCI retargeting molecule comprising 
two tumor targeting moieties showed even a better outcome [105]. In in vitro assays of the present 
study the TCB showed a better activation of effector cells and a more rapid and effective target cell 
killing than the pMHCI-IgG (see chapters 8.2.2 and 8.2.3).  
Comparing CD3-based T cell recruiters with pMHCI-IgG fusions several limitations and advantages 
emerge for each format. For the use of pMHCI-IgG molecules in patients a construct comprising the 
immunodominant peptide pp65 derived from the human Cytomegalovirus (CMV) would be applied 
[1, 2, 151]. Chronic CMV infection exists in the large majority of humans [193, 194] and CMV-
specific CD8+ T cells seem to be unique in number and functionality compared with other viral 
infections [195]. Their phenotype is mostly characterized as effector memory T cells implicating the 
capability to get rapidly activated and mediate cytotoxicity. A costimulatory signal via interaction of 
CD28 on effector cells with CD80/86 on tumor cells is not needed, because memory T cells can get 
activated directly by TCR / peptide-MHC complex interactions without a costimulatory signal via 
CD28 [196]. Thus redirection of this naturally occuring, highly effective and continuously resupplied 
subpopulation of CD8+ T cells [197] for elimination of tumor cells is expected to be very efficacious 
[1, 2, 151]. Schmittnaegel et al. performed cytotoxicity assays with PBMCs derived from CMV+ 
donors and compared human pMHCI-IgG fusion molecules with BiTEs. The CD3-based molecules 
activated T cells irrespective of their subtype and specificity and induced very rapid killing of target 
cells even at very low concentrations, whereas pMHCI-IgG fusions mediated a more graded and 
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more slowly elimination of tumor cells in a concentration-dependent manner. In this study almost 
identical results could be observed in the in vitro assays with surrogate pMHCI-IgG and TCB 
molecules (see chapter 8.2.3). The later onset and concentration dependence of target cell killing 
applying pMHCI-IgG fusions is likely due to the lower number of effector cells activated initially and 
could pose an advantage as side effects like cytokine release or tumor lysis syndrome could become 
more managable [2]. Another aspect, that would broaden the safety window, is the relatively low 
affinity of TCRs for their cognate pMHC complexes [198]. Peripherial binding to T cells in the 
cirulation is reduced and preferential binding of the molecule to the tumor cell target via avidity is 
facilitated. Thus no unspecific T cell activation in the absence of simultaneous binding to the tumor 
cell target in the periphery is expected even at high molecule concentrations [2, 151]. In the human 
CEA-targeting TCB this issue is addressed by introduction of only one CD3 targeting domain with 
low affinity [91]. Conclusively, a better safety profile for pMHCI-IgG molecules is expected, as 
nonspecific cytokine release due to polyclonal T cell activation as observed with CD3-based T cell 
recruiters is reduced as shown in vitro [2] and in vivo [105]. In addition pMHCI-IgG molecules 
should not be able to activate CD4+ T cells, especially regulatory T cells, which is another advantage 
compared to TCBs. The limiting factor of pMHCI-IgG fusion proteins for the use in patients is the 
restriction to a specific patient population. One precondition for successful treatment with pMHCI-
IgGs is the prior exposure to CMV infection [2]. As the majority of the human population is CMV-
positive and prevalence of CMV infection increases with age [193, 194] this should not represent a 
substantial hurdle. The other, more limiting, prerequisite for application of pMHCI-IgG fusions is the 
physiological occurrence of a certain HLA-allotype in patients. The immunodominant peptide pp65 
derived from CMV is presented on HLA A*0201, which can be found in 35 % to 40 % of patients 
[199]. In summary, pMHCI-IgG fusion molecules seem to constitute a good and feasible alternative 
to CD3-based T cell recruiters in patients with high risks of side effects and in tumor types 
expressing low levels of antigen. 
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11 APPENDIX 
DNA vector for production of proteins and DNA vaccination: 
 
 
Amino acid sequences of engineered antibodies and fusion molecules: 
(Mutations: EU-Index Kabat numbering scheme [114]) 
●   Peptide-MHC class I-IgG fusion molecule: 
Peptide-MHC class I fused antibody heavy chain: 
Amino acid 1 to 19: Signal peptide, 20 to 27: Peptide (specified below), 28 to 42: Linker 1 (G4S)3 
(disulfide-stabilization linker 1 / MHC class I complex: 29: G10C), 43 to 141: Murine ß2M, 142 to 
161: Linker 2 (G4S)4, 162 to 435: α1 – α3 H-2K
b (disulfide-stabilization linker 1 / MHC class I 
complex: 245: Y84C), 436 to 437: Linker 3 (GS), 438 to 553: Variable domain of the heavy chain of 
the murine FAP binder (VH), 559 to 651: CH1 IgG2c, 675 to 778: CH2 IgG2c (silent Fc-part: LALA 
mutation: 675: L234A / 676: L235A, DAPG mutation: 711: D270A / 770: P329G), 787 to 883: CH3 
IgG2c (disulfide-stabilization pMHCI-HC / HC: 790: Y349C, hole-mutation: 807: T366S / 809: M368A 
/ 848: Y407V) 
001 MGWSCIILFL VATATGVHSX XXXXXXXGCG GSGGGGSGGG GSIQKTPQIQ 
051 VYSRHPPENG KPNILNCYVT QFHPPHIEIQ MLKNGKKIPK VEMSDMSFSK 
101 DWSFYILAHT EFTPTETDTY ACRVKHASMA EPKTVYWDRD MGGGGSGGGG 
151 SGGGGSGGGG SGPHSLRYFV TAVSRPGLGE PRYMEVGYVD DTEFVRFDSD 
201 AENPRYEPRA RWMEQEGPEY WERETQKAKG NEQSFRVDLR TLLGCYNQSK 
251 GGSHTIQVIS GCEVGSDGRL LRGYQQYAYD GCDYIALNED LKTWTAADMA 
301 ALITKHKWEQ AGEAERLRAY LEGTCVEWLR RYLKNGNATL LRTDSPKAHV 
351 THHSRPEDKV TLRCWALGFY PADITLTWQL NGEELIQDME LVETRPAGDG 
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401 TFQKWASVVV PLGKEQYYTC HVYHQGLPEP LTLRWGSEVQ LLESGGGLVQ 
451 PGGSLRLSCA ASGFTFSSHA MSWVRQAPGK GLEWVSAIWA SGEQYYADSV 
501 KGRFTISRDN SKNTLYLQMN SLRAEDTAVY YCAKGWLGNF DYWGQGTLVT 
551 VSSAKTTAPS VYPLAPVCGG TTGSSVTLGC LVKGYFPEPV TLTWNSGSLS 
601 SGVHTFPALL QSGLYTLSSS VTVTSNTWPS QTITCNVAHP ASSTKVDKKI 
651 EPRVPITQNP CPPLKECPPC AAPDAAGGPS VFIFPPKIKD VLMISLSPMV 
701 TCVVVDVSED APDVQISWFV NNVEVHTAQT QTHREDYNST LRVVSALPIQ 
751 HQDWMSGKEF KCKVNNRALG SPIEKTISKP RGPVRAPQVC VLPPPAEEMT 
801 KKEFSLSCAI TGFLPAEIAV DWTSNGRTEQ NYKNTATVLD SDGSYFMVSK 
851 LRVQKSTWER GSLFACSVVH EGLHNHLTTK TISRSLGK 
 
MCMV m38 peptide: 
001 SSPPMFRV 
MCMV IE3 peptide: 
001 RALEYKNL 
OVA257-264 peptide: 
001 SIINFEKL 
 
Unfused antibody heavy chain: 
Amino acid 1 to 19: Signal peptide, 20 to 135: Variable domain of the heavy chain of the murine 
FAP binder (VH), 141 to 233: CH1 IgG2c, 257 to 360: CH2 IgG2c (silent Fc-part: LALA mutation: 257: 
L234A / 258: L235A, DAPG mutation: 293: D270A / 352: P329G), 369 to 465: CH3 IgG2c (disulfide-
stabilization pMHCI-HC / HC: 377: P354C, knob-mutation: 389: T366W, HL->RF mutation: 458: 
H435R / 459: L436F) 
001 MGWSCIILFL VATATGVHSE VQLLESGGGL VQPGGSLRLS CAASGFTFSS 
051 HAMSWVRQAP GKGLEWVSAI WASGEQYYAD SVKGRFTISR DNSKNTLYLQ 
101 MNSLRAEDTA VYYCAKGWLG NFDYWGQGTL VTVSSAKTTA PSVYPLAPVC 
151 GGTTGSSVTL GCLVKGYFPE PVTLTWNSGS LSSGVHTFPA LLQSGLYTLS 
201 SSVTVTSNTW PSQTITCNVA HPASSTKVDK KIEPRVPITQ NPCPPLKECP 
251 PCAAPDAAGG PSVFIFPPKI KDVLMISLSP MVTCVVVDVS EDAPDVQISW 
301 FVNNVEVHTA QTQTHREDYN STLRVVSALP IQHQDWMSGK EFKCKVNNRA 
351 LGSPIEKTIS KPRGPVRAPQ VYVLPPCAEE MTKKEFSLWC MITGFLPAEI 
401 AVDWTSNGRT EQNYKNTATV LDSDGSYFMY SKLRVQKSTW ERGSLFACSV 
451 VHEGLHNRFT TKTISRSLGK 
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Antibody light chain: 
Amino acid 1 to 19: Signal peptide, 20 to 127: Variable domain of the light chain of the murine FAP 
binder (VL), 131 to 230: Constant domain of the light chain (Cκ) 
001 MGWSCIILFL VATATGVHSE IVLTQSPGTL SLSPGERATL SCRASQSVSR 
051 SYLAWYQQKP GQAPRLLIIG ASTRATGIPD RFSGSGSGTD FTLTISRLEP 
101 EDFAVYYCQQ GQVIPPTFGQ GTKVEIKRAD AAPTVSIFPP SSEQLTSGGA 
151 SVVCFLNNFY PKDINVKWKI DGSERQNGVL NSWTDQDSKD STYSMSSTLT 
201 LTKDEYERHN SYTCEATHKT STSPIVKSFN RNEC 
 
Non-binding control antibody (DP47): 
Variable domain of the heavy chain (VH): 
 
001 EVQLLESGGG LVQPGGSLRL SCAASGFTFS SYAMSWVRQA PGKGLEWVSA 
051 ISGSGGSTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKGS 
101 GFDYWGQGTL VTVSS 
Variable domain of the light chain (VL): 
 
001 EIVLTQSPGT LSLSPGERAT LSCRASQSVS SSYLAWYQQK PGQAPRLLIY 
051 GASSRATGIP DRFSGSGSGT DFTLTISRLE PEDFAVYYCQ QYGSSPLTFG 
101 QGTKVEIK 
 
●   T cell bispecific antibody: 
Antibody light chain with CD3ε binding domain (CrossMAb format): 
Amino acid 1 to 19: Signal peptide, 20 to 126: Variable domain of the light chain of the murine 
CD3ε binder (VL), 129 to 225: CH1 IgG1 
001 MGWSCIILFL VATATGVHSD IQMTQSPSSL PASLGDRVTI NCQASQDISN 
051 YLNWYQQKPG KAPKLLIYYT NKLADGVPSR FSGSGSGRDS SFTISSLESE 
101 DIGSYYCQQY YNYPWTFGPG TKLEIKSSAK TTPPSVYPLA PGSAAQTNSM 
151 VTLGCLVKGY FPEPVTVTWN SGSLSSGVHT FPAVLQSDLY TLSSSVTVPS 
201 SPRPSETVTC NVAHPASSTK VDKKIVPRDC 
 
Antibody heavy chain with CD3ε binding domain (CrossMAb format) and FAP binding domain: 
Amino acid 1 to 19: Signal peptide, 20 to 135: Variable domain of the heavy chain of the murine 
CD3ε binder (VH), 139 to 238: Constant domain of the light chain (Cκ), 143 to 252: Linker (G4S)2, 
253 to 368: Variable domain of the heavy chain of the murine FAP binder (VH), 269 to 465: CH1 
IgG1, 479 to 585: CH2 IgG1 (silent Fc-part: DAPG mutation: 510: D270A / 574: P329G), 586 to 692: 
CH3 IgG1 (mutations for heterodimerization not shown) 
001 MGWSCIILFL VATATGVHSE VQLVESGGGL VQPGKSLKLS CEASGFTFSG 
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051 YGMHWVRQAP GRGLESVAYI TSSSINIKYA DAVKGRFTVS RDNAKNLLFL 
101 QMNILKSEDT AMYYCARFDW DKNYWGQGTM VTVSSASDAA PTVSIFPPSS 
151 EQLTSGGASV VCFLNNFYPK DINVKWKIDG SERQNGVLNS WTDQDSKDST 
201 YSMSSTLTLT KDEYERHNSY TCEATHKTST SPIVKSFNRN ECGGGGSGGG 
251 GSEVQLLESG GGLVQPGGSL RLSCAASGFT FSSHAMSWVR QAPGKGLEWV 
301 SAIWASGEQY YADSVKGRFT ISRDNSKNTL YLQMNSLRAE DTAVYYCAKG 
351 WLGNFDYWGQ GTLVTVSSAK TTPPSVYPLA PGSAAQTNSM VTLGCLVKGY 
401 FPEPVTVTWN SGSLSSGVHT FPAVLQSDLY TLSSSVTVPS SPRPSETVTC 
451 NVAHPASSTK VDKKIVPRDC GCKPCICTVP EVSSVFIFPP KPKDVLTITL 
501 TPKVTCVVVA ISKDDPEVQF SWFVDDVEVH TAQTQPREEQ FNSTFRSVSE 
551 LPIMHQDWLN GKEFKCRVNS AAFGAPIEKT ISKTKGRPKA PQVYTIPPPK 
601 EQMAKDKVSL TCMITDFFPE DITVEWQWNG QPAENYKNTQ PIMNTNGSYF 
651 VYSKLNVQKS NWEAGNTFTC SVLHEGLHNH HTEKSLSHSP GK 
 
Antibody heavy chain with FAP binding domain: 
Amino acid 1 to 19: Signal peptide, 20 to 135: Variable domain of the heavy chain of the murine 
FAP binder (VH), 136 to 232: CH1 IgG1, 246 to 352: CH2 IgG1 (silent Fc-part: DAPG mutation: 277: 
D270A / 341: P329G), 353 to 459: CH3 IgG1 (mutations for heterodimerization not shown) 
001 MGWSCIILFL VATATGVHSE VQLLESGGGL VQPGGSLRLS CAASGFTFSS 
051 HAMSWVRQAP GKGLEWVSAI WASGEQYYAD SVKGRFTISR DNSKNTLYLQ 
101 MNSLRAEDTA VYYCAKGWLG NFDYWGQGTL VTVSSAKTTP PSVYPLAPGS 
151 AAQTNSMVTL GCLVKGYFPE PVTVTWNSGS LSSGVHTFPA VLQSDLYTLS 
201 SSVTVPSSPR PSETVTCNVA HPASSTKVDK KIVPRDCGCK PCICTVPEVS 
251 SVFIFPPKPK DVLTITLTPK VTCVVVAISK DDPEVQFSWF VDDVEVHTAQ 
301 TQPREEQFNS TFRSVSELPI MHQDWLNGKE FKCRVNSAAF GAPIEKTISK 
351 TKGRPKAPQV YTIPPPKEQM AKDKVSLTCM ITDFFPEDIT VEWQWNGQPA 
401 ENYKNTQPIM NTNGSYFVYS KLNVQKSNWE AGNTFTCSVL HEGLHNHHTE 
451 KSLSHSPGK 
 
Antibody light chain with FAP binding domain: 
Amino acid 1 to 19: Signal peptide, 20 to 127: Variable domain of the light chain of the murine FAP 
binder (VL), 131 to 230: Constant domain of the light chain (Cκ) 
001 MGWSCIILFL VATATGVHSE IVLTQSPGTL SLSPGERATL SCRASQSVSR 
051 SYLAWYQQKP GQAPRLLIIG ASTRATGIPD RFSGSGSGTD FTLTISRLEP 
101 EDFAVYYCQQ GQVIPPTFGQ GTKVEIKRAD AAPTVSIFPP SSEQLTSGGA 
151 SVVCFLNNFY PKDINVKWKI DGSERQNGVL NSWTDQDSKD STYSMSSTLT 
201 LTKDEYERHN SYTCEATHKT STSPIVKSFN RNEC 
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●   Anti-XCR1 antibody: 
Antibody heavy chain: 
Amino acid 1 to 19: Signal peptide, 20 to 135: Variable domain of the heavy chain of the murine 
XCR1 binder (VH), 141 to 233: CH1 IgG2c, 257 to 360: CH2 IgG2c (silent Fc-part: LALA mutation: 
257: L234A / 258: L235A, DAPG mutation: 293: D270A / 352: P329G), 369 to 465: CH3 IgG2c, 470 to 
479: Sortase-tag, 480 to 489: Poly-histidine-tag 
001 MGWSCIILFL VATATGVHSQ VQLQQPGAEL VKPGASVKLS CKASGYTFTN 
051 YWIHWMKQRP GQGLEWIGMI HPNSDNTKYN EKFKAKAILT VDKSSSTAYM 
101 QLSSLTSEDS AVYYCARFAN DGAYWGQGTL VTVSAAKTTA PSVYPLAPVC 
151 GGTTGSSVTL GCLVKGYFPE PVTLTWNSGS LSSGVHTFPA LLQSGLYTLS 
201 SSVTVTSNTW PSQTITCNVA HPASSTKVDK KIEPRVPITQ NPCPPLKECP 
251 PCAAPDAAGG PSVFIFPPKI KDVLMISLSP MVTCVVVDVS EDAPDVQISW 
301 FVNNVEVHTA QTQTHREDYN STLRVVSALP IQHQDWMSGK EFKCKVNNRA 
351 LGSPIEKTIS KPRGPVRAPQ VYVLPPPAEE MTKKEFSLTC MITGFLPAEI 
401 AVDWTSNGRT EQNYKNTATV LDSDGSYFMY SKLRVQKSTW ERGSLFACSV 
451 VHEGLHNHLT TKTISRSLGG GGGSLPETGG SGSHHHHHH 
 
Antibody light chain: 
Amino acid 1 to 19: Signal peptide, 20 to 131: Variable domain of the light chain of the murine 
XCR1 binder (VL), 135 to 234: Constant domain of the light chain (Cκ) 
001 MGWSCIILFL VATATGVHSD VVVTQTPLSL PVSLGDPASI SCKSSQSLVH 
051 SNGNTYLHWY LQKPGQSPKL LIYKISNRFS GVPDRFSGSG SGTDFTLKIS 
101 RVEAEDLGVY FCSQNTHVPY TFGGGTKLEI KRADAAPTVS IFPPSSEQLT 
151 SGGASVVCFL NNFYPKDINV KWKIDGSERQ NGVLNSWTDQ DSKDSTYSMS 
201 STLTLTKDEY ERHNSYTCEA THKTSTSPIV KSFNRNEC 
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